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 i 
Résumé 
Les nanoparticules (NPs) de polymère ont montré des résultats prometteurs pour leur 
utilisation comme système de transport de médicaments pour une libération contrôlée 
du médicament, ainsi que pour du ciblage. La biodisponibilité des médicaments 
administrés oralement pourrait être limitée par un processus de sécrétion intestinale, 
qui pourrait par la suite être concilié par la glycoprotéine P (P-gp). La dispersion de la 
Famotidine (modèle de médicament) à l’intérieur des nanoparticules (NPs) pegylées a 
été évaluée afin d’augmenter la biodisponibilité avec du polyéthylène glycol (PEG), 
qui est connu comme un inhibiteur de P-gp. L’hypothèse de cette étude est que 
l’encapsulation de la Famotidine (un substrat de P-gp) à l’intérieur des NPs préparées à 
partir de PEG-g-PLA pourrait inhiber la fonction P-gp. La première partie de cette 
étude avait pour but de synthétiser quatre copolymères de PEG greffés sur un acide 
polylactide (PLA) et sur un squelette de polymère  (PLA-g-PEG), avec des ratios de 
1% et 5% (ratio molaire de PEG vs acide lactique monomère) de soit 750, soit 2000 Da 
de masse moléculaire. Ces polymères ont été employés afin de préparer des NPs 
chargés de Famotidine qui possède une faible perméabilité et une solubilité aqueuse 
relativement basse. Les NPs préparées ont été analysées pour leur principaux 
paramètres physicochimiques tels que la taille et la distribution de la taille, la charge de 
surface (Potentiel Zeta), la morphologie, l’efficacité d’encapsulation, le pourcentage 
résiduel en alcool polyvinylique (PVA) adsorbé à la surface des NPs, les propriétés 
thermiques,  la structure cristalline et la libération du médicament. De même, les 
formules de NPs ont été testées in vitro sur des cellules CaCo-2 afin dʼévaluer la 
perméabilité bidirectionnelle de la Famotidine. Généralement, les NPs préparées à 
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partir de polymères greffés PLA-g-5%PEG ont montré une augmentation de la 
perméabilité du médicament, ce par l’inhibition de l’efflux de P-gp de la Famotidine 
dans le modèle CaCo-2 in vitro. Les résultats ont montré une baisse significative de la 
sécrétion de la Famotidine de la membrane basolatéral à apical lorsque la Famotidine 
était encapsulée dans des NPs préparées à partir de greffes de 5% PEG de 750 ou 2000 
Da, de même que pour d’autres combinaisons de mélanges physiques contenant du 
PEG5%. La deuxième partie de cette étude est à propos de ces NPs chargées qui 
démontrent des résultats prometteurs en termes de perméabilité et d’inhibition d’efflux 
de P-gp, et qui ont été choises pour développer une forme orale solide. La granulation 
sèche a été employée pour densifier les NPs, afin de développer des comprimés des 
deux formules sélectionnées de NPs. Les comprimés à base de NPs ont démontré un 
temps de désintégration rapide (moins d’une minute) et une libération similaire à la 
Famotidine trouvée sur le marché. Les résultats de l’étude du transport de comprimés à 
base de NPs étaient cohérents avec les résultats des formules de NPs en termes 
d’inhibition de P-gp, ce qui explique pourquoi le processus de fabrication du comprimé 
n’a pas eu d’effet sur les NPs. Mis ensemble, ces résultats montrent que 
l’encapsulation dans une NP de polymère pegylé pourrait être une stratégie 
prometteuse pour l’amélioration de la biodisponibilité des substrats de P-gp. 
 
Mots-clés : Poly(ethylene glycol), P-glycoprotéine, Nanoparticules, Perméabilité, 
CaCo-2, Acide polylactique. 
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Abstract 
Polymeric nanoparticles (NPs) have shown promising results to be used as drug 
delivery carriers for controlled drug release and for targeting. The bioavailability of 
orally administrated drugs might be limited by an intestinal absorbed secretion process, 
which could in turn be mediated by P-glycoprotein (P-gp). The dispersion of 
Famotidine (drug model) within PEGylated nanoparticles (NPs) was evaluated in order 
to enhance the bioavailability using polyethylene glycol (PEG), which is known as a P-
gp inhibitor. The hypothesis of this study is that the encapsulation of Famotidine into 
NPs prepared from PEG-g-PLA could inhibit the P-gp function. The first part of the 
study aimed to synthesize four copolymers of PEG grafted on a polylactide acid (PLA) 
polymer backbone (PLA-g-PEG) with ratios of 1 % and 5 % (molar ratio of PEG vs 
lactic acid monomer) of either 750 or 2000 Da molecular weights. These polymers 
have been used to prepare NPs loaded with Famotidine, which has low permeability 
and relatively low aqueous solubility. Prepared NPs were analyzed for their main 
physicochemical parameters such as size and size distribution, surface charge, 
morphology, encapsulation efficiency, percentage of residual poly(vinyl alcohol) 
(PVA) adsorbed at the surface of the NPs, thermal properties, crystalline structure and 
drug release. Also, NP formulations were tested in vitro on CaCo-2 monolayer cells in 
order to assess the bidirectional permeability of Famotidine. Generally speaking, NPs 
prepared from PLA-g-5%PEG grafted polymers showed improved drug permeability 
by inhibiting the P-gp efflux of Famotidine in the CaCo-2 in vitro model. Results 
showed a very significant decrease in the secretion of Famotidine from basolateral to 
apical when Famotidine was encapsulated in NPs prepared from 5 % grafting of either 
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750 or 2000 Da PEG, as well as in other combinations of physical mixtures containing 
PEG5%. The second part of the study is about those loaded NPs which showed 
promising results in terms of permeability and inhibition of P-gp efflux and which 
were selected to develop a solid oral dosage form. Dry granulation was used to densify 
NPs in order to develop tablets of the two selected NP formulations. NP based tablets 
showed a fast disintegration time (less than one minute) and a similar release profile as 
marketed Famotidine. The transport study of NP based tablets showed consistent 
results with NP formulations in terms of P-gp inhibition, which explains why the 
tablet’s manufacturing process had no effect on NPs. Our results demonstrated that the 
presence of hydrophilic polymers (PEG) on the surface of NPs grafted at 5 % PEG, 
irrespective to molecular weights, provides an effective way to control the interface 
between NPs and the biological systems (P-gp in this case) as they are designed to 
interact with. Taken together, these results show that encapsulation in a PEGylated 
polymeric NP could be a promising strategy to improve the oral bioavailability of P-gp 
substrates. 
 
Keywords : Poly(ethylene glycol), P-glycoprotein, Nanoparticles, Permeability, CaCo-
2, Poly(lactic) acid. 
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1. Introduction 
The majority of drugs on the market are formulated for the oral route, most of them 
aimed at the blood circulation for the systemic action. It is the most convenient and 
safe administration route, particularly for chronic delivery, but it poses a number of 
challenges for formulators in terms of bioavailability (fraction of drug actually 
reaching the circulation) due to degradation by enzymes and harsh pH conditions, low 
solubility of some drugs and limited absorption by the gastro intestinal tract (GIT) 
epithelium(1). The GIT (Figure 1.1) is approximately 6 m in length with varying 
diameters. It consists of the oesophagus, the stomach, the small intestine (the major 
digestive organ) and large intestine or colon. The luminal surface is not smooth, with 
deep, circular fold about 1 cm high, villi, mucosal projections about 1 mm long, and 
microvilli (plasma membrane microprojections), increasing the surface area of 
absorption to about 200 cm2. Orally administrated drug molecules must stay for 
enough time in intestinal lumen and resist harsh gastric and intestinal environments to 
be efficiently absorbed by intestinal cells via different mechanisms(1-3). 
 
Figure 1.1 Scheme of Gastro-Intestinal-Tract. Adapted from(1). 
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1.1. Structure and Physiology of GIT 
The structure of GIT wall (at the small intestinal level) is comprised of four main 
histological layers. The first layer, the serosa, is the outer layer of epithelial and 
supporting connective tissue. The second layer contains two layers of smooth muscle, a 
thinner outer layer, with longitudinally orientated muscle fibers and a thicker inner 
layer, with fibers orientated in a circular pattern. The third layer, submucosa is a 
connective tissue layer consisting of some secretory tissues richly supplied with blood 
and lymphatic vessels, including the lacteal, a wide lymph capillary at the centre of the 
villi. The fourth layer, the mucosa, is composed of: the muscularis mucosa, the 
mucosa, connective tissue and epithelium(1). The intestinal epithelium acts as a 
physical and physiological barrier to drug absorption. It mainly consists of absorptive 
enterocytes and mucus producing Goblet cells, endocrine and Paneth cells spread along 
the epithelium. The GIT epithelium is covered by a layer of mucus. Immuno-
competent cells, such as B and T lymphocytes and dendritic cells are located beneath 
the epithelium(2, 4). The small intestine wall possesses a rich blood network and the 
GIT blood circulation is nearly a third of cardiac output flow, underlining the 
importance of exchanges between the GIT lumen and blood circulation. The lymphatic 
system plays an important part in fat absorption from GIT. The areas of lymphoid 
tissue close to the epithelial surface called Peyer's patches or follicle-association 
epithelium (FAE) and serve as immune sampling ports in the intestine. The FAE, 
separating organized, mucosa associated tissue from the lumen, is composed of 
enterocytes and M cells. M-cells are found in the follicle-epithelium of Peyer's patches. 
Microflod M-cells are important in local immune response to pathogens(5) and could 
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be harness to deliver macromolecules and oral vaccines(6). M cells disorganized brush 
border at the apical membrane have reduced microvilli and thinner surface mucus. 
Moreover, M cells have specific surface-adhesion molecules which might be important 
features for active targeting(1, 2, 4-7).  
 
1.2. Route and Barrier to Drug Absorption 
Drugs molecules encounter many barriers in GIT (Figure 1.2) once released from their 
dosage forms after they have dissolved in the gastrointestinal fluids. Drug molecules 
must be in solution and not bound to food or other material within GIT, chemically 
stable to withstand the GIT pH and resist to enzymatic degradation in the lumen. 
Finally drug molecules need to diffuse across the mucus (unstirred water layer) and 
across the gastrointestinal membrane, the main cellular barrier in order to reach blood 
circulation(3). The main drug absorption pathways from the GIT include carrier-
mediated transcellular transport, vesicular transport, passive paracellular transport 
through entrocytes, and lymphatic uptake by M-cells. 
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Figure 1.2 Structure of GIT barrier: drug and NC transportation pathways. 
on the left,enterocytes, on the right M-cell. A mucus layer is found on the apical side of 
enterocytes and M-cell.(1) Paracelluar route. (2) Transcelluar route. (3) M-cell 
phagocytosis. With a permission from (8) 
 
1.2.1. GIT Environment  
The GIT environment is characterized by peristalsis, variable pH, and the presence of 
surfactants (bile salts), enzymes, bacteria, food, and different types of secretions. GIT 
pH affects the dissolution rate and absorption of drug molecules. The GIT has a wide 
range of pH values in empty stomach (pH 1.2-3), small intestine (pH 5-7) and colon 
(pH 6 to 7.5)(9). Moreover, pH depends of some variables such as time of the day, 
meal volume and volume of secretions. To provide effective treatment, the delivery 
system should offer a good protection against these enzymes(2, 10).  
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1.2.2. Mucus Layer (unstirred water layer) 
Mucus is a viscoelastic, translucent, aqueous, protective gel that is secreted throughout 
GIT and different mucosal surfaces ( pulmonary, nasal, etc.)(1). Its thickness varies 
from 50 to 150 μm in the stomach to 15-150 μm in intestine. It has a large water 
component (≈ 95%) and other constituents, which are responsible for its physical and 
functional properties, are largely glycoproteins called mucins(11). Mucus acts as a 
protective layer and a mechanical barrier. It is continually replaced from beneath as it 
is being removed from GIT surface through acidic, enzymatic breakdown and abrasion 
(peristaltic movement of food towards the colon). GIT mucus is comprised of two 
layers, a firmly adherent layer, slowly cleared of an unstirred layer close to the 
epithelium surface, and luminal mucus layer, a stirred layer, a more rapidly cleared 
layer(12). It is secreted continuously and digested, so for drugs to be delivered to 
mucosal surfaces, they need to diffuse through the unstirred mucus layers adhering to 
cells(1, 12, 13). Below the mucus layer, the cells present a dense of highly diverse 
glycoproteins and glycolipids, which form the glycocalyx. A glycocalyx (Figure 1.3) 
found on the apical portion of microvilli within the GIT, especially within the small 
intestine(3, 5, 7, 13, 14). Mucin glycoproteins are secreted in large quantities by 
mucosal epithelia, and cell surface mucins are a prominent feature of the apical 
glycocalyx of all mucosal epithelia. It provides additional surface for adsorption and 
includes enzymes secreted by the absorptive cells that are essential for the final steps of 
digestion of proteins and sugars(3, 13, 14). The glycocalyx is highly variable from 
tissue to tissue; for example, the glycocalyx of human intestinal microvilli tips is thick 
(100–500 nm) in comparison with the glycocalyx of the lateral microvilli surface (30–
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60 nm)(5). Both the secreted and adherent mucosal barriers are constantly renewed and 
could potentially be rapidly adjusted to changes in the environment, for example, in 
response to microbial infection(5, 13, 14). 
 
Figure 1.3 Schematic representation of some elements of epithelial cells of GIT: 
 (A)Glycocalyx, (B)Mucus layer, (C)Transcellular Route, (D)Enerocytes, (E)Tigh 
junction and (F)Paracellular Route. Adapted from(5). 
 
 
1.2.3. Tight Junctions and Paracellular Route 
In the paracellular space, the presence of junctions restricts the passage of large 
molecules. These include the tight junction, a protein complex that establishes links 
between adjacent cells through the intercellular space . Two other protein complexes, 
namely the adherens junctions and desmosomes further tighten cell association, 
without fusing cell membranes. The apical compartment of the lateral membrane 
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consists of 3 components: tight junctions, adherent junctions, and desmosomes(9). For 
desmosomes and adherent junction the adjacent cell membranes are 15 – 20 nm apart, 
but are in contact at tight junctions, with the intercellular spaces being completely 
absent. Tight junctions act as gatekeeper paracellular route, regulating drug molecule 
flux and prevent free movement of molecules in paracellular space. Understanding the 
barrier function of tight junctions is necessary for developing absorption enhancers to 
deliver drugs via the paracellular route. Diffusion is regulated by concentration 
differences and by hydrostatic pressure gradient between the two sides of the 
epithelium. Tight junctions are main barriers to this type of absorption(15-18).  
 
1.2.4. M-cells 
Finally, transportation by Peyer's patches, which contain M-cells found in the Follicle-
association epithelium (FAE) at the base of villi, is important in the phagocytosis and 
endocytosis of NPs and microparticles(5). Peyer's patches  are aggregations of 
lymphoid tissue that are widespread along the intestine and tend to increase in number 
in the ileum. The physiological role of M-cells is to sample antigens present in the 
lumen to transport them to immune cells on their basal side. They have high 
transcytosis activity, but represent less than 1 % of the intestinal mucosa surface. 
Particles could be taken up by M-cells via specific (active endocytosis) or non-specific 
(adsorption endocytosis) mechanism(19).  
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1.2.5. Transcellular Route and Membrane Transporter (Permeability-
glycoprotein) 
1.2.5.1. Transcellular Route 
The transcellular route comprises passive and active transport. For carrier-mediated 
transcellular transport (active transcellular transport), drugs are moved across 
membranes by protein transporters present on the apical membrane of enterocytes 
(generally energy-dependent). The vesicular transport route consists of fluid-phase 
endocytosis and receptor-mediated endocytosis (caveolae-dependent, clathrin-
dependent, caveolae-calthrin-independent, etc.). Vesicular transport could lead to the 
degradative pathway (via lysosomes), or to exocytosis, transport across the epithelium 
(transcytosis) to the basolateral side of enterocytes near capillaries(8, 20). For passive 
transcellular transport, drugs should be able to diffuse across the apical membrane, 
cytoplasm, and basal membrane. The surface area available for passive transcellular 
transport makes up 99.9% vs. 0.01 % for the passive paracellular pathway(8).   
 
1.2.5.2. Membrane Transporter P-gp  
Recently research has been focus in understanding the role of membrane transporters in 
drug safety and efficacy. In particular, more than 400 membrane transporters in two 
major super families ATP-binding cassette (ABC) and solute carrier (SLC) have been 
characterized and localized to tissues and cellular membrane domains in the human 
body(21, 22). Membrane transporters are controlling uptake and efflux of crucial 
compounds such as sugars, amino acids, nucleotides, inorganic ions and drugs(23). 
Permeability glycoprotein (P-gp) is a plasma membrane glycoprotein of about 170 kDa 
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that belongs to the superfamily of ATP- binding cassette (ABC) transporters expressed 
in cancer cells and responsible for chemotherapy resistance(23). P-gp protects cells 
from cytotoxic compounds and relatively lipophilic substrates by actively transporting 
them out of the cell against a concentration gradient, thus decreasing intracellular 
levels below their effective and/or toxic concentrations(23, 24). It is expressed in the 
apical membrane of many normal tissues such as luminal small intestine, colon, kidney 
proximal tubules, liver and capillary endothelial cells of the blood brain barrier(23, 24). 
Membrane transporter expression in the two major sites (the intestine and/or liver) can 
influence how much of a drug reach the systemic circulation after an oral dose, 
suggests that factors affecting their function will be determinants of oral drug 
pharmacokinetics(22-24). It has been demonstrated that the intestinal P-gp localized in 
the enterocytes, an ATP dependent multidrug efflux pump, can be an active secretion 
system or an absorption barrier by pumping drugs from the intestinal cells into the 
lumen(24-27). Numerous studies have demonstrated that P-gp possesses broad 
substrate specificity and it is involved in the transport of neutral compounds such as 
digoxin and cyclosporine, negatively charged carboxyl groups such as those found in 
atorvastatin and fexofenadine, and hydrophilic drugs such as methotrexate(28). The 
degree of hydrogen bonding and partitioning into the lipid membrane has been 
determined to be a rate-limiting step for substrate interactions with P-gp(23). There is 
strong evidence in the literature that P-gp obtains the energy required for transport of 
drug substrates across the membrane via the hydrolysis of ATP. The mechanistic basis 
of the transport of substrates by ABC transport proteins has been studied and  focused 
on the characterization of the ATP hydrolysis and transport of a variety of drug-
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substrates and understanding how these two activities are coupled(28). A number of 
innovative approaches have been used to identify the causal events at the nucleotide 
binding domains (NBDs) that drive conformational changes at the transport-substrate 
site. It has been proposed by Loo and Clarke that P-gp binding site (Figure 1.4a) to be 
funnel shaped and narrow at the cytoplasmic side and the central, putative drug-
substrate binding region has a diameter of 9–25 Å (also designated as the high affinity 
site) and approximately 50 A˚ at its widest (low affinity site)(29). Biochemical data 
and the structures of ABC transporters suggest the presence of a large hydrophobic 
cavity with remarkable plasticity of this cavity and provide insights into the 
conformational changes that accompany drug binding(28).  It has been proposed that 
P-gp is composed of two symmetrical halves joined by a linker region and each half 
with six  putative trans-membrane segments and one cytoplasmic nucleotide-binding 
site (NBD)(30, 31). The cytoplasmic terminus, of each half, contains the sequences for 
a nucleotide-binding site, responsible for ATP binding and hydrolysis. Both nucleotide 
binding sites of P-gp are necessary for transport of substrates out of the cell(30).  
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Figure 1.4 Different mechanism involved in P-gp inhibition and Drug-substrate binding pocket 
of P-gp. Adapted from(25, 28). 
 
 
1.3. P-gp Inhibitors 
Manipulating membrane transporters level leading to increase or reduce their functions 
and co-administration with inhibitors are all important tools to alter the ability of 
membrane transporter to transport substrates (23). Therefore, intestinal absorption of 
drugs that are secreted by a P-gp-mediated efflux system can be improved by inhibiting 
the function of P-gp in the intestinal membrane and the oral bioavailability of a wide 
range of drugs can be increased. NPs have the ability to inhibit the effect of P-gp by 
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limiting the presence of free drugs in cell cytosol (drugs confined inside NPs) and/or 
by including P-gp inhibitors, such as PEG, on their surface. Moreover, inhibition of P-
gp activity may be an effective way to enhance oral bioavailability and increase 
anticancer agent efficacy in multi-drug resistant tumors. P-gp inhibitors based on their 
development duration are classified in three generations. The first generation inhibitors 
were pharmacological actives such as verapamil, cyclosporin A, quinidine, reserpine 
and tamoxifen but were of limited use due to their high toxicity profile. Second 
generation of P-gp inhibitors came into existence to overcome toxicity problem of the 
first generation. D-isomer of verapamil, that is, dexverapamil, which is less cardiotoxic 
than verapamil and they were more potent than their parent compounds and also shown 
less toxicity. Development of third generation of P-gp inhibitors are superior and 
balanced in performance in relation to activity and toxicity with regard to their earlier 
counterparts. Third generation P-gp inhibitor are effective at the nanomolar 
concentration range for example, elacridar, tariquidar and zosuquidar and they are 
currently being tested(24). Various pharmaceutical excipients both from synthetic and 
natural sources, belonging to the categories such as surfactants, polymers and lipid 
excipients have demonstrated ability to inhibit the transport activity of P-gp resulting in 
enhanced intracellular drug accumulation (24, 28). Directed transport and the 
mechanisms by which excipients inhibit P-gp activity varies with the excipients types 
and are currently under investigation. Different mechanisms (Figure 1.4b) are said to 
be involved in P-gp inhibition for various class of inhibitors. P-gp can be inhibited by: 
i) blocking drug-binding site(s) either competitively, non-competitively or 
allosterically; ii) interfering ATP hydrolysis and iii) altering integrity of cell membrane 
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lipids(24, 28, 32). It was proposed that changes in cellular membrane fluidity may be 
associated with alterations in P-gp activity and the lipid phase of the membrane plays a 
crucial role in the multidrug resistance of P-gp(25). Moreover, P-gp drug-binding 
domains are present in the transmembrane segments of P-gp and P-gp is highly 
sensitive to the lipid environment(25). Some excipients such PEG, Cremophor El and 
Tween80 increase cell membrane fluidity, whereas others decrease the fluidity of the 
cell membrane(33, 34).  
 
1.4. Nanoparticles as Effective Oral Drug Carrier 
A significant challenge that most drugs face is their inability to be delivered 
effectively. Nanotechnology offers a solution to allow for safe, high-dose, specific 
delivery of pharmaceuticals. Nanotechnology has the potential to transform the 
pharmaceutical field by offering the ability to encapsulate and strategically deliver 
drugs while improving their therapeutic index(35, 36). It is becoming evident that 
nanotechnology prove to b effective in creating new therapies but also in giving old 
therapies new life. NCs have attracted significant attention due to their promising 
applications in the fields of drug transport. A major issue in drug delivery is 
maintaining the stability of nanoparticles in the human body for the effective delivery 
of a drug to the site of action without clearance by reticuloendothelial (RES). Indeed, 
significant progress has already been achieved by introducing hydrophilic moieties to 
the nanoparticle surface, which can inhibit the adsorption of serum proteins and 
hemocytes, therefore maintaining stable nanoparticle circulation in the blood(35, 36). 
The following examples (Figure 1.5) have been selected to illustrate the challenge of 
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drug delivery with different types of NCs. They do not represent an exhaustive 
compilation of studies produced in this field.  
 
 
 
 
Figure 1.5 Different Types of NCs (A) Micelles, (B) Liposomes, (C) Dendrimers, Poymeric 
nanoparticles and Nanocapsules With a permission from (8). 
1.4.1. Polymeric Nanoparticles 
Polymeric NPs are among the most promising strategies to improve oral delivery, 
because of their stability in the GIT, protection of encapsulated actives and the relative 
ease with which their physiochemical and drug release characteristics can be 
modulated(37). A variety of biodegradable and nonbiodegradable polymers have been 
employed for fabrication of polymeric NPs for oral drug delivery. A large variety of 
materials can be used to prepare NPs (matrix-structure nanospheres or capsules) and to 
modify their surfaces. Nanospheres are matrix systems in which the drug is physically 
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and uniformly dispersed, while nanocapsules are vesicular systems in which the drug is 
confined to a cavity surrounded by a polymer membrane(11, 38). Synthetic (polyester, 
acrylates, etc.) and natural materials, such as chitosan, dextran, gelatin, etc., are being 
used to prepare these NCs. Polymeric NPs are more stable in GIT than other NCs such 
as liposomes and they can protect encapsulated drug from GIT environment(37, 39, 
40). Various polymeric materials enable to modulate the physicochemical 
characteristics (e.g. zeta potential, hydrophobicity), drug release properties (e.g. 
delayed, prolonged), and biological behavior (e.g. targeting, bioadhesion, improved 
cellular uptake) of nanoparticles(37). Nanoparticle surface can be modified by 
adsorption or chemical grafting of certain molecules such as poloxamers and 
poly(ethylene glycol) (PEG)(37). Polymeric NPs are distributed more uniformly in the 
GIT therefore the drug is released and absorbed more uniformly and the risk of local 
irritation reduced, compared to unique dosage forms(39-41). Insulin has been the focus 
of research for formulation in effective NCs for oral delivery. Insulin loaded 
poly(isobutylcyanoacrylate) nanocapsules manifest improved effects on glycemia in a 
diabetic rat model over oral free Insulin(37, 42). It is noteworthy that the percentage of 
Insulin dose actually crossing the GIT mucosa is increased but stay low (a few % of 
bioavailability), requiring higher insulin doses increasing potential toxic effects and 
underlining the limitations of these approaches(37).  
 
1.4.2. Liposomes and Lipid-Based Nanocarriers 
Liposomes are aqueous compartments enclosed by lipid bilayer membranes. 
Liposomes are concentric bilayered vesicles in which an aqueous volume is entirely 
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enclosed by a membranous lipid bilayer mainly composed of natural or synthetic 
phospholipids. Liposomes are formed when thin lipid films or lipid cakes are hydrated 
and stacks of liquid(39, 40). Liposomes can serve as efficient drug carrier to improve 
drug bioavailability because of their ability to pass through lipid bilayers and interact 
with cell membrane(43, 44). Because of liposomes structure, liposomes can be 
designed for water- and lipid-soluble drugs. Unfortunately, for oral drug delivery, they 
have limited application because of their instability in the GIT environment(43). Their 
recent role seems confined to increasing the bioavailability of low-solubility drugs. 
They appear to accumulate in mucus, prolonging their residence time but limiting their 
diffusion(43). They have been proposed as vaccination adjuvants and as antigen 
presentation to M-cells(45). Lipids and phsopholipids in the form of solid lipid 
nanoparticles (SLN) are an interesting alternative to polymeric matrix NCs for 
hydrophobic drug and protein encapsulation(43). For instance, camptothecin-loaded 
SLN coated with poloxamer 188 (200 nm sized particles with zeta potential around -70 
mV) display increased bioavailability compared to the oral, soluble drug form(46). 
Similarly, insulin encapsulated in lectin-modified SLN presents increased 
bioavailability(47).  
 
1.4.3. Micelles 
In an aqueous medium, above a given concentration termed the critical micellar 
concentration (CMC), surfactants self-assemble into a colloidal dispersion of 
molecular aggregates called micelles (<50–100 nm)(48). Micelles are composed of a 
hydrophilic shell (usually PEG) and hydrophobic core(48). Micelles have been studied 
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as drug delivery systems to improve solubility, absorption and protect drugs 
molecules(9, 49). Although polymeric micelles have a longer life span than surfactant 
micelles, there are still some challenges facing their preparation, such as stability, 
increased drug loading, resistance to dilution in the GIT, and narrow size distribution 
required(50-53). Micelles have been mainly studied to improve the drug solubilisation 
of highly hydrophobic drugs, such as taxanes, for oral chemotherapy(49, 54). There are 
no clear indication that they can cross the mucosal epithelium other than in the form of 
isolated copolymers(9, 48). 
 
1.4.4. Hydrogel Nanocarrier 
 
Hydrogels are polymeric networks with three-dimensional configuration capable of 
absorbing high amounts of water or biological fluids(55). Hydrogel nanoparticles have 
gained considerable attention as one of the most promising NC owing to their unique 
potentials via combining the characteristics of a hydrogel system with a 
nanoparticle(55, 56). NC delivery systems, hydrogel nanospheres, fabricated from 
poly(methacrylic acid) (PMAA) and PEG, and loaded with the chemotherapeutic agent 
bleomycin, have disclosed an improved effect because of their mucoadhesive 
properties and P-gp inhibition(57). Negatively-charged, 700nm sized NCs of alginate 
and chitosan encapsulating insulin were prepared and results indicate a decrease of 
glycemia about 40 % in diabetic rats(56, 58). 400nm sized alginate and dextran 
sulphate NCs encapsulating insulin increased GIT uptake (13 % bioavailability) and 
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decreased glycemia in a diabetic rat model. This superior uptake comparison to free 
insulin seems to be linked to uptake of NCs by small intestine epithelial cells(58).   
1.4.5. Dendrimers 
A dendrimer is generally described as a macromolecule, which is characterized by its 
highly branched 3D structure that provides a high degree of surface functionality and 
versatility. Due to their multivalent and monodisperse character, dendrimers have 
attracted wide interest in the field of chemistry and biology, especially in applications 
like drug delivery, gene therapy and chemotherapy(59, 60). Dendrimers have 
hydrophilic exteriors and hydrophilic interiors, which are responsible for its 
unimolecular micellar nature. They form covalent as well as non-covalent complexes 
with drug molecules and hydrophobes, which are responsible for its solubilisation 
behaviour(59-61). Dendrimers have a distinctive small size and could serve as 
solubilizing agents for hydrophobic drugs(59). Poly(amido amino) (PAMAM) 
dendrimers have been reported to improve the intestinal absorption of poorly soluble 
drugs (propranolol) but appeared less efficient with macromolecular drugs (insulin)(60, 
62). Moreover, the dendrimer dose should be kept low to reduce toxicity(62, 63). In 
vitro, PAMAM toxicity was diminished by surface modification with lauroyl chloride 
while their permeation through CaCo-2 cell monolayer was increased(62).  
  
1.5. NanoCarrier Translocation and Drug Bioavailability 
A nanocarrier (NC) is nanomaterial being used as a transport module for another 
substance, such as a drug. Nanocarriers for drug delivery have become key vehicles for 
 21 
the storage and delivery of drugs. Various nanocarriers including liposomes, polymers, 
micelles and dendrimers have been developed and explored for drug delivery(64). 
Drug bioavailability refers to the rate and extent at which the active drug reaches the 
systemic circulation. For most drugs, their pharmacological activity can be directly 
related to bioavailability(65). As consequence of GIT morphology and physiology, 
drugs must overcome GIT barriers to be absorbed efficaciously: conditions prevailing 
in GIT lumen favoring degradation, the barrier mucus layer and, finally, transport 
across the epithelium themselves toward the blood or lymphatic circulation. NC role 
could be limited to protection against degradation and/or enhancing drug solubilisation. 
In this scenario, intact NCs are confined to the GIT lumen, but contribute to increased 
bioavailability by releasing drugs near the epithelium, acting as permeability enhancer, 
favoring adhesion and penetration of mucus layer, and/or contributing to the opening 
of tight junctions. On the other hand, drug encapsulation could involve NCs 
translocation, along with the drug load, across the epithelium(66). It could even 
involve a role for the orally administrated NCs in drug distribution in the systemic 
circulation. Indeed intact NCs introduced in the blood circulation could provide the 
advantages of protection from metabolism, long circulation (if PEGylated), targeting 
and improved pharmacokinetic. While most studies have focused on blood drug levels 
or pharmacodynamic effects, few have followed the fate of NCs(51). However, in 
animal experiments, several types of NCs, administrated  by oral route, have been 
found in blood or organs, but in general, they are poorly taken up, the order of 
magnitude being a few percentage of the initial dose (67). There are also stability 
issues, as polymeric NPs are more likely to be discerned in blood compared to 
 22 
liposomes or micelles that are most likely to undergo dissociation and degradation in 
the GIT lumen or during translocation across the epithelium. For most of the drugs 
administered as oral solid dosage forms, except in case of controlled release 
formulations and disintegration occur rapidly. In these cases, the rate limiting 
processes in the absorption of dosage forms are (a) dissolution rate and (b) rate of drug 
permeation through the biological membrane(65). Dissolution is the rate determining 
step for hydrophobic, poorly water soluble drugs. In case of hydrophilic drugs with 
high aqueous solubilities, dissolution is rapid and the rate determining step in the 
absorption is often the rate of permeation through the biological membrane. Drug 
instability during absorption can affect its bioavailability(65). Two major stability 
problems resulting in poor bioavailability of an orally administered drug are 
degradation of the drug into inactive form, and interaction with one or more 
components of the dosage form or those present in the GIT to form a complex that is 
poorly soluble or is unabsorbable.(65)  
 
 
1.6. Optimizing Nanocarrier Physiochemical Properties for 
Oral Delivery 
1.6.1. Increased Drug Dissolution, Absorption, and Protection from 
Degradation 
NCs could offer protection to drug molecules, and could also decrease the amount of 
drug needed for therapeutic action, thus reducing drug side effects. This could be 
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particularly significant for peptide and protein delivery, such as insulin for instance. 
Unprotected drugs, when introduced into the GIT, might not achieve the expected 
pharmacological effect because of many factors, such as drug stability in GIT fluid, 
incomplete absorption and permeability issues. Particles in nano-scale could improve 
bioavailability by increasing drug absorption by augmenting dissolution rate, due to 
favorable surface/volume ratios and favorable physical drug states (crystalline, 
amorphous or dispersed molecularly) in NCs for release dissolution(10, 19, 68-70). 
Lastly, NCs stability is variable, and some are more sensitive than others (micelles, 
liposomes) to the GIT environment ( acidity, bile salts, lipids, etc.).  
1.6.2. Mucus Adhesion and Penetrating Properties 
1.6.2.1. Mucoadhesive Nanocarrier 
Increasing the residence time of drug loaded NCs in small intestine might result in 
greater absorption of the drug and/or of the carrier itself. Adhesion to mucus has been 
proposed to extent NC residence time. For instance, mucoadhesion has been 
documented for NC surface modification with chitosan, the cationic charges of the 
polymer interacting with the negatively charged mucus(71). The creation of disulphate 
bonds on mucus glycoproteins with NC surface derived from thiols have been 
proposed as a mucoadhesion strategy(72). Broomberg et al. studied mucoadhesive 
ionic micelles, composed of the copolymer Pluronic® poly(acrylic acid), for oral 
delivery(73). The mucoadhesive properties of the copolymer linked to ionic interaction 
between mucin and carboxyl groups on the polymer, and the entanglement of Pluronic 
(PPG-PEG-PPG block) with the mucin network. Mucoadhesion is size dependent, with 
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maximum adhesion at around 100 nm(74). Examination of the behavior of NCs with 
different surfaces, i.e., PLA-PEG NPs (200 nm, zeta potential -24 mV), PS NPs (200 
nm, +1 mV), and chitosan NPs (30 nm, +17 mV) revealed the effects of mucus 
adhesion (via interactions of hydrophobic surface with hydrophilic domains of mucus 
gylcoproteins) on NC uptake in vitro(75). pH-responsive NPs (250 nm diameter) of 
chitosan and poly(glutamic acid) encapsulating a modified insulin were prepared. It 
was found that the drug carrier was retained in the GIT, while modified insulin showed 
an increase in absorption into systemic circulation, a result consistent with the 
mucoadhesion properties of chitosan NCs(76). Mucoadhesion increases the residence 
time. On the other hand, bounding to mucin fibers are subjected to natural and 
continuous clearance of the mucus layer (stirred layer) with as a consequence a 
maximum residence of about 4-6 h(12).  
 
1.6.2.2. Mucus-Penetrating Nanocarriers 
Penetration of mucus is limited by gel porosity and interactions between NC surfaces 
and gel components. Conflicting data on charges  required to avoid ionic interactions 
with mucus resulted in an attempt to develop neutral hydrophilic surface 
modifications(12). PEG a hydrophilic polymer, has been used to coat NPs. PEG 
(2kDa) minimizes interactions with anionic-charged hydrogel, allowing faster 
transport(77). PEGylated 100 nm sized particles show slower transport and diffusion 
than 200 or 500 nm sized particles through the mucus layer. This could be explained by 
the existence of large pores in gel, allowing large NPs to be transported, while smaller 
ones enter the more densely packed gel (a process similar to size exclusion 
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chromatography). It could also be explained by differences in the PEG layer structure 
in smaller NCs, with a higher radius of curvature, permitting direct interaction between 
the NC surface and mucus compare to larger NC(78). Indeed lowering PEG coverage 
to 40 % and increasing PEG length to 10 KDa, decrease NC diffusion in the mucus 
layer(12). PEG effect on further translocation across the epithelium by different 
pathways remains to be clarified(67, 75, 79). 
 
 
1.6.3. Translocation Across Tight Junctions  
In normal physiological conditions, translocation of NCs through tight junctions is 
severely limited by their relative small surface area and tightness. In fact, NC passage 
is dependent on junction opening. NCs made of chitosan or with chitosan on surface 
(and also co-administration with free chitosan) have displayed the ability to transiently 
open tight junctions between epithelial cells, facilitating the transport of drug 
molecules(16, 18). Other permeability enhancers such as synthetic peptides (Occludin) 
and fatty acids (Tween) have been proposed, but all of them have intrinsic toxicity and 
indiscriminately open the junctions to all kinds of GIT contents(15, 37). 
 
1.6.4. Translocation Across Enterocytes 
NC translocation across enterocytes can occur by transcytosis, consisting of three 
steps, i.e., uptake of the NC at the apical side, intracellular trafficking toward the 
basolateral side and exocytosis (67). Size and surface properties are the main 
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determinants of transport efficacy and pathway chosen by NCs. Particle size, a critical 
characteristic of NCs, has a direct effect on cellular uptake. It has been well-accepted 
in research that small sized particles could be taken up by enterocytes and M-cells, 
enterocytes having a maximum uptake of 50-100 nm sized particles, while M-cells can 
engulf particles up to the mcirometer range(5, 67, 80). Peyer's patches have up to 200-
fold higher uptake of PLGA NCs than non-patch tissues(68, 81). 100 nm sized NCs 
diffuse in the submucosal layers while large size particles (micrometer range) are 
predominantly localized in epithelial lining of tissue(80). Moreover, Peyer's patch 
uptake predominates over enterocytes uptake, even if the former represents only about 
1 % of the intestinal mucosal surface(80). The presence of hydrophilic polymers on the 
surface of NPs might increase transport through mucosal surface, although conflicting 
results have been reported(82). The adsorption of hydrophilic block-co-polymers 
(poloxamer) onto polystyrene NCs markedly reduces uptake in the small intestine(67). 
For instance, 300-nm sized PLGA particles were found to migrate from the GIT into 
different tissues and organs, especially the liver(83). When modified on the surface 
with PEG and chitosan, they migrated from the GIT into peritoneal macrophage(84). 
These results are consistent with the importance of polymeric NC stability as well as 
surface modification to cross the GIT epithelium. Endocytosis pathways depend on 
surface properties. PLGA particles, or chitosan NCs, for instance, are predominantly 
endocytosed via clathrin-dependent pathways(51). In contrast, it has been 
demonstrated that the bioavailability of paclitaxel loaded in lipid nanocapsules (from 
25 to 135 nm) is improved across CaCo-2 cell monolayers because of this type of NC 
capacity to improve transport, predominantly via caveolae-dependent pathways(85, 
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86). Non-specific adhesion properties might improve NC localization and transport. 
Lectins are saccharide-binding membrane glycoproteins, which can bind reversibly to 
sugars either in free form or supported on other membranes. They might adhere to the 
GIT surface to improve absorption and permeability(87). Lectin binding was found to 
be favored at neutral pH and reduced under acidic pH. Tomato lectin has been reported 
to increase bioadhesive and conjugate with mucus gel. Surface modification with 
covalent attachment of tomato lectin molecules indicated widespread uptake of PS NP 
by enterocytes rather than by Peyer's patchs(67). Lectin conjugation with the NP 
surface improved NP transport across the intestinal mucosa by increasing interaction 
with mucus or epithelial cells(87, 88). Gliadin, another mucoadhesive agent, was 
conjugated with NPs carrying amoxicillin. These NPs were more effective for local 
treatment of Helicobacter pylori than conventional GIT therapy(89).   
 
1.6.5. Translocation Across M-cells 
The ability of M-cells to transport different materials by transcytosis (either 
phagocytosis or endocytosis) have made them a good target to deliver vaccines and 
drugs(90). Moreover, steric hindrance by mucus layer is lowered as the layer over M-
cells is thinner than over enterocytes. M-cells in the intestine might be targeted for 
mucosal vaccination to transport antigens to induce mucosal immunity(6). PLA 
particles (in the 200 nm range), traced by fluorescence, showed initial accumulation in 
mucus and then moved to M-cells (in 15 min). Further examination disclosed NPs in 
immune cells in sub epithelial tissue, confirming barrier crossing(91). In summary, 
 28 
optimal NC size seems to be below 1 μm with maximal uptake between 100 nm and 
200 nm.  
 
1.7. Poly (Ethylene Glycol) (PEG) Used as P-gp Inhibitor 
 
Poly(ethylene glycol) (PEG) is water soluble, uncharged, having very low order of 
toxicity (up to 10 mg/kg body-weight), and non-immunogenic(92). It is a commonly 
used pharmaceutical excipient as coating agent, plasticizing agent, stabilizer for 
emulsion and to enhance the solubility of drugs(92). Presently PEG is one of the most 
popular material to modify particulate surfaces in order to avoid recognition by cells of 
the mononuclear phagocyte system (MPS) and inhibit P-gp efflux(8, 35, 93). The 
incorporation of PEG onto the NC surface (absorbed or covalently linked) increases the 
NC half life in the systemic circulation and this effect is related to decrease 
opsonization(94, 95). PEG decreases protein interaction with NC surfaces, modifies 
PK and biodistribution(96), and decrease NC cellular uptake(97). Hydrophilic and 
flexible PEG chains act via a steric repulsion effect, rendering protein binding 
unfavorable and that repulsion effect depends on chain length, optimal surface density, 
and optimal chain configuration(96). 2 to 5 kDa seems to be the minimum length for 
the stealth effect and are able to reduce the absorption of opsonins and other serum 
proteins(8, 93, 95). Optimal protein resistance has been reported in PLA polymeric 
NPs with 5% w/w PEG content and PEG density for optimal conformation and 
efficacy translates into an inter-chain distance of around 1.5 nm on polyester NP 
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surfaces(93). PEG layer density which cover NCs should reach a density where PEG 
chains are forced to configure a mushroom/brush configuration (Figure 1.6), however 
without leaving uncovered hydrophobic or charged surface where opsonins can 
bind(35, 44). The efficacy result of PEG ‘brush’ to alter the biodistribution of 
biodegradable nanoparticles was composed of poly (lactic-co-glycolic acid) (PLGA) or 
of poly (lactic acid) (PLA) as core was demonstrated(10, 12, 93). However other 
configurations have been tested, the linear PEG (usually methoxy-PEG) is the standard 
to be used. Generally, linear PEGs are more effective than branched PEGs of 
equivalent size, as shown by a decrease in opsonization and macrophage uptake(98). A 
complex relationship of PEG chain length, carrier size (determining surface availability 
for PEG anchorage), and weight ratio between PEG and hydrophobic component of the 
carrier (e.g, PLA-PEG particles) influences the final surface properties of NCs. It was 
demonstrated that a free PEG, a pharmaceutical excipients, is capable of inhibiting 
efflux transporter (e.g., P-gp and/or MRP activity) activity in Caco-2 cell monolayer 
and such PEG-induced inhibition of efflux transporter activity is most likely related to 
changes in the microenvironment of P-gp in Caco-2 cell membranes(99). It was 
reported that PEG capability to inhibit the P-gp transporter function in CaCo-2 
monolayer cells and in vitro model of intestinal mucosa might likely be due to changes 
in membrane fluidity of P-gp in CaCo-2 monolayer cells(25, 33, 100). Although the 
mechanism of PEG for P-gp inhibition is unclear, direct interactions of the PEG chain 
with substrate binding site of P-gp pump and alter phospholipids membrane fluidity 
have been also proposed (22, 23, 100-103). Some concerns about the importance of the 
microenvironment of P-gp expressed in CaCo-2 model were raised. For instance, 
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would it be the same environment as intestinal mucosal cells in vivo and whether P-gp 
in these cells react in similar way to PEG? In the case where the lipid composition of 
membrane in the human intestinal mucosa differs from CaCo-2 cells, it is possible that 
the effects of PEG on P-gp activity in vitro may be different from those observed in 
vivo in animal and/or human(100). Therefore, further studies (e.g., gut perfusion 
studies, pharmacokinetic studies in animal models) should be conducted to establish a 
possible in vitro/in vivo correlation. Besides mucus penetration, PEG addition to the 
PLA NP surface has been reported to enhance particle stability in biological fluids, 
preventing protein and enzymes absorption(104). 
 
Figure 1.6 PEG NCs coverage. (A) Brush configuration and (B) Mushroom configuration. 
With a permission from (8). 
 
1.8. Targeting 
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The main purpose in the development of nanocarriers for drug delivery application is 
certainly drug targeting to the desired site of action and controllable biodistribution 
into the body. Orally administered targeted nanoparticles have a large number of 
potential biomedical applications and display several putative advantages for oral drug 
delivery, such as the protection of fragile drugs or modification of drug 
pharmacokinetics. Nanoparticles have advantages, such as small size, high surface 
area, and modification using functional groups for high capacity or selectivity. 
Nanoparticles have emerged as potential drug delivery systems and are used for 
targeting drug to particular organs/tissues via the peroral route of administration(105-
107). It could be drug or drug carrier targeting and the ability of the drug to accumulate 
in the organ or tissue selectively and quantitatively, independent of the site and method 
of its administration. Therefore, drug concentration at the site(s) of action should be 
high, while its concentration in other non-targeted organs and tissues should be below 
certain minimal levels thus minimizing any negative side-reactions and maximizing 
therapeutic index(19, 105, 106). Some ligand such as lectin and proteins that bind 
sugars reversibly and are involved in many cell recognition and adhesion processes. 
Nanoparticles with peptidic ligands are especially worthy of notice because they can be 
used for specific targeting in the gastrointestinal (GI) tract. The optimization of particle 
size and surface properties and targeting by ligand grafting have been shown to 
enhance nanoparticle transport across the intestinal epithelium. Different grafting 
strategies for non-peptidic ligands, e.g., peptidomimetics, lectin mimetics, sugars and 
vitamins, that are stable in the gastrointestinal tract. Some ligand such as lectin and 
proteins that bind sugars reversibly and are involved in many cell recognition and 
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adhesion processes. Tomato lectin-conjugated NP resist the digestion process and 
increase the bioadhesive and endocytic potential of latex particles. Ligand density on 
the particle surface is somehow difficult to reproduce and must be optimized to allow 
cellular uptake in order to achieve optimal therapeutic efficacy. Lectin insulin 
liposomes (190 nm) modified with a hydrophobic anchor, N-glut-PE, promoted the 
oral absorption of insulin due to the site-specific combination of the GI cell membrane 
and vitamin B12-coated dextran NP (150-300 nm) improved the cellular uptake of 
absorptive enterocytes. Despite promising results with agents that increase specific 
receptor-mediated endocytosis, insufficient quantities of insulin loaded particles are 
absorbed through the intestinal epithelium. Therefore, targeted drug has advantages 
over conventional drug delivery system such as the drug quantity required to achieve a 
therapeutic effect may be greatly reduced, as well as the cost of therapy. This 
challenging goal can be obtained exploiting natural passive targeting that always 
occurs into the body or altering this process by a modification of the nanocarriers in 
order to achieve the so-called active targeting(105, 106). 
 
 
1.8.1. Passive Targeting 
 
Passive targeting refers to the accumulation of drug or drug carrier system at a 
particular site whose explanation may be attributed to physicochemical or 
pharmacological factors of disease. Passive targeting is based on NCs size and surface 
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properties, namely, surface charge, degree of hydrophobicity and non-specific 
adhesion, which direct them towards particular organs, across biological barrier, such 
as specialized epithelia, or enter the cell cytoplasm(8, 106). For GIT intestinal mucosa, 
passive targeting could be done through enterocytes to deliver proteins and peptides or 
through M-cells to delivery vaccine and it generally depends on the type approach that 
determined the specific parameters required to design NC delivery system(19, 50, 69, 
108). M-cells have been targeted to deliver vaccine or drugs due to M-cell ability to 
transcytosis and transport of different materials. NCs and a ligand such as cholera toxin 
B (CTB) could be used in vaccine targeting to M-cells membrane and PEGylated 
PLGA nanoparticles displaying RGD-peptide also was used to target M cells for oral 
vaccination(6, 7, 90). NCs functionalized with lectins have been used to target possibly 
over expressed sugar residues on the surface of some cells  such as epithelial improve 
NPs transport across intestinal mucosa by increasing interaction with mucus or 
epithelial cells(87, 88, 90). Gladin nanoparticles, muco-adhesive agent, were found 
more effective to use for local treatment of H.pylori by carrying amoxicillin than 
conventional therapy(109). It is reported that bioavailability of paclitaxel loaded in 
lipid nanocapsules was improved across CaCo-2 cell monolayer because of NC 
capacity to improve paclitaxel transport across intestinal barrier(85, 86, 110). 
 
1.8.2. Active Targeting  
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Active targeting includes specific modification of drug or drug carrier systems with 
active agents having selective affinity to recognize and interact with specific cell, 
tissue or organ in the body(105, 106). A number of possibilities to obtain the 
decoration and the most commons are alteration of the surface charge, adsorption to the 
ligands on the surface or direct attachment of a specific biomolecules(105, 106). 
Grafting ligands (biorecognition molecules) onto the nanoparticles refers to active 
targeting and aims to increase specific cell uptake. The ligands must be linked on the 
surface in the form of decorating moieties and this ligands may be active molecules 
(proteins, peptides, monoclonal antibody, or any other moiety)(111). Nanoparticles 
bearing these ligands are recognised by cell surface receptors and this leads to 
receptor-mediated endocytosis(105, 106). Doxorubicin-loaded PLGA-b-PEG 
nanocarriers targeted with folate were used as folate receptor is over expressed in a 
wide variety of human tumors(112). 
 
1.9. Oral Dosage Form  
 
The oral route of drug administration is the most convenient for patients. Solid oral 
dosage forms are the preferred route for many drugs and are still the most widely used 
formulations for new and existing formulations(1). The tablet one of the many forms 
that an oral drug can take such as syrups, elixirs, suspensions and emulsions(1). Of all 
pharmaceutical preparations, tablet is one of the most commonly used oral solid dosage 
forms to deliver the drug for therapy, because of its convenience in terms of self 
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administration, compactness and ease in manufacturing(113). A wide range and 
diversity of ingredients are often included in tablet formulations.  A tablet comprises a 
mixture of active substances and excipients, usually in powder form, pressed or 
compacted from a powder into a solid dose. A pharmaceutical dosage form typically 
consists of active pharmaceutical ingredient and excipients(113). The excipients 
usually play an important role in manufacturing, stability and performance(92). The 
excipients are added to aid the formulation stability, manufacture, facilitate the 
preparation, patient acceptability and drug delivery. Some properties of final dosage 
form, such as bioavailability and stability, are dependent on the excipients chosen, 
concentrations and interactions with each other and the active ingredients (65). The 
commonly used excipients such as diluents, binders, glidants (flow aids) and lubricants 
to ensure efficient tabletting. A binder is added to help hold the tablet together and give 
it strength. A wide variety of binders may be used such as lactose, dibasic calcium 
phosphate and corn (maize) starch. Some binders, such as starch and cellulose, are also 
excellent disintegrants. Diluents are used to increase dosage form volume or weight, 
and as such they can also be referred to as fillers. Some diluents, such as 
microcrystalline cellulose (MCC), can also be considered as dry binders since they 
improve the compactibility or tabletability of the compression mix. Tablets need to be 
strong enough to resist the stresses of packaging, shipping and handling. The hardness 
of tablets is the principle measure of mechanical strength. A disintegrate is also 
needed to aid tablet dispersion once swallowed, releasing the drug for absorption. 
Lubricants prevent ingredients from clumping together and from sticking to the tablet 
punches filling machine. Lubricants also ensure that tablet formation and ejection can 
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occur with low friction between the solid and die wall, as well as between granules, 
which helps in uniform filling of the die. Common minerals like talc or silica, and fats, 
e.g. vegetable stearin, magnesium stearate or stearic acid are the most frequently used 
lubricants in tablets. In the tablet manufacturing process, it is important that all 
ingredients be fairly dry, powdered or granular, uniform in particle size, and freely 
flowing. Mixed particle sized powders segregate during manufacturing operations due 
to different densities, which can result in tablets with poor drug content uniformity but 
granulation should prevent this.  
 
1.9.1. Direct Compression  
 
Direct compression (DC) is the tableting of a blend of ingredients without a 
preliminary granulation or agglomeration process as shown in Figure 1.7(1, 114-117). 
To perform DC, powder blend can be mixed well, do not require granulation and can 
be compressed into tablets through DC. The powder blend has to flow to ensure a 
consistent tablet weight, it has to compress and compact into tablets and the resulting 
tablets have to stay stable over time to maintain safety and efficacy(114). When a 
adequately homogenous mix of the components cannot be obtained with simple 
blending processes, the ingredients must be granulated prior to compression to assure 
an even distribution of the active compound in the final tablet. Figure 1.7 showed 
whether wet granulation and dry granulation, two basic techniques are used to 
granulate powders for compression into a tablet(1, 118).  
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1.9.2. Wet Granulation 
 
Wet granulation is a process for size enlargement, where small primary particles are 
joined together using agitation and a liquid binder(119). Wet granulation is a process of 
using a liquid binder to lightly agglomerate the powder mixture(1, 120). The amount of 
liquid has to be properly controlled, as over-wetting will cause the granules to be too 
hard and under-wetting will cause them to be too soft and friable. Aqueous solutions 
have the advantage of being safer to deal with than solvent-based systems but may not 
be suitable for drugs which are degraded by hydrolysis(118). Low shear wet 
granulation processes use very simple mixing equipment, and can take a considerable 
time to achieve a uniformly mixed state. High shear wet granulation processes use 
equipment that mixes the powder and liquid at a very fast rate, and thus speeds up the 
manufacturing process. Fluid bed granulation is a multiple-step wet granulation 
process performed in the same vessel to pre-heat, granulate, and dry the powders(1, 
118-120).  
 
1.9.3. Dry Granulation 
 
Generally, for thermal or moisture sensitive substance, dry granulation process is 
preferably used to prepare granules and to densify the powder blend, for proper flow 
and compressibility properties(118). The dry granulation process involves the 
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compaction and densification of powders, using a roller compactor or tablet press that 
is employed as a slugging tool for powders that may not have a sufficiently uniform 
stream in the die cavity(118). Dry granulation consists in compacting powder to form a 
slug with a heavy duty, rotary tablet press or a solid strip, using a roller compactor and 
then reducing its size by milling or screening to achieve a desired granule(116, 117, 
121). Dry granulation requires drugs or excipients with cohesive properties, and a dry 
binder may need to be added to the formulation to facilitate the formation of granules. 
Dry granulation does not require solvents, which is advantage over wet granulation and 
would be preferable especially for drugs, which are moisture or heat sensitive(25, 99, 
100, 122).  
 
Figure 1.7 Powder blend flow properties and different techniques for compression into 
tablet. Adapted from(113). 
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2. Hypothesis and Objectives of the study 
2.1. Hypothesis 
Generally the objective of drug delivery is to design a sophisticated system that could 
deliver the drug molecules at the desired site of action and minimize the side 
effects(35, 123). Degradable polymers such as Poly(lactic acid) (PLA),  Poly(amido 
amine) (PAMAM) and Poly(ε-caprolactone) (PCL) have been used to design and 
develop microcarriers and nanocarriers(11, 38, 124, 125). Bioavailability of oral drugs 
can be influenced by many factors such as solubility, permeability, metabolism and 
transporter glycoprotein (P-gp). Famotidine is a hydrophilic since the octanol/water 
coefficient is log P = -0.64. Moreover, Famotidine has a ionisable quanidin basic group 
pKa = 8.44 (Figure 2.1)and it has log D (-3.4) which is very hydrophilic at working pH 
(7.4). Famotidine water solubility is 1g/l and this solubility and ionisable properties are 
part of poor bioavailability. Famotidine was selected as drug model for this study 
because of Famotidine is P-gp substrate and its bioavailability is influenced by P-gp 
efflux(23, 126, 127). Some studies recently demonstrated that PEG, a pharmaceutical 
excipient, is capable to inhibit P-gp efflux and there is close association between P-gp 
and cell membrane(24, 33, 100, 122, 128). A relation between PEG and P-gp inhibition 
has been shown by Ashiru-Oredope et.al, and Huger et.al  (24, 128). Indeed, because 
PEG contains many oxyethylene groups, it is reasonable to believe that PEG might 
alter the activity of P-gp by a nonspecific mechanism involving changes in membrane 
fluidity(100). The proposed mechanism of PEG assumes that it  has the ability to alter 
the membrane fluidity of polar head group regions due to interruption of hydrophobic 
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environment in which P-gp acts(129). Moreover it is suggested by Hugger et al (2002) 
that increasing the concentration of PEG could cause a significant decrease in fluidity 
of polar head group regions of membrane(130). It has also been proposed that PEG-
induced P-gp inhibition by the steric hindrance effect of PEG chains that may interfere 
with interaction of P-gp substrate and P-gp binding site(130). The hypothesis of this 
study is based on using NPs prepared from grafted PLA-g-PEG polymer could improve 
oral permeability of drugs via P-gp inhibition(130-132). This grafted polymer is 
composed of hydrophilic segment PEG grafted on PLA hydrophobic backbone and 
both parts are FDA approved polymers.  
 
Figure 2.1 Famotidine Structure 
 
 
2.2. The objectives of the study 
The general objective of this research is to design a nanocarrier from PLA-g-PEG 
copolymer capable to inhibit P-gp efflux of drugs across CaCo-2 cell monolayers 
(pump drug back from basolateral side to apical side).  
Therefore, the specific objectives of this research are that: 
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1) PLA-g-PEG will be synthesized with two PEG molecular weights and two 
grafting ratios. 
2) NPs will be prepared from PLA-g-PEG polymers. Beside the inhibition 
function of PEG on P-gp, drugs which are P-gp substrate will be encapsulated 
in NPs to protect from harsh environment as the model drugs chosen will be 
given orally.  
3) Loaded NPs prepared from different PLA-g-PEG polymers will be tested for 
their bidirectional permeability across CaCo-2 cell monolayers in order to 
evaluate the effect of PEG on P-gp efflux.  
4) Loaded NPs with promising CaCo-2 results will be selected to develop an oral 
dosage formulation (tablet).  
5) Tablets prepared from selected NPs formulations will be tested for their 
bidirectional permeability across CaCo-2 cell monolayers in order to evaluate 
whether the effect of PEG on P-gp efflux influenced by tablet compressing.   
In order to meet those objectives, the following experiments were performed: 
i. Polymer synthesis based on two PEG molecular weights (750 Da and 
2000 Da )and grafting ratios (1% and 5%) based on the method used in 
our lab(133) :- 
1.  PLA-g-1%PEG750Da 
2. PLA-g-1%PEG2000Da 
3. PLA-g-5%PEG750Da 
4. PLA-g-5%PEG2000Da 
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ii. Characterization of synthesized polymers by GPC, NMR, FTIR, 
grafting efficiency calculation and DSC. 
iii. NP preparation by emulsion-solvent evaporation method (high pressure 
homogenizer) from four grafted polymers to encapsulate Famotidine as 
a model drug.   
iv. Characterization of prepared nanoparticles for particle size and size 
distribution, PVA, surface charge, morphology, efficiency 
encapsulation, FTIR, DSC, XRPD, drug release and cytotoxicity.    
v. CaCo-2 cell monolayers in vitro model bidirectional permeability 
evaluation of prepared NPs loaded with Famotidine 
vi. NPs powder characterization as per bulk and tapped density, powder 
flow and compressibility.  
vii. Formulation and process development of selected NPs with promising 
results from CaCo-2 oral solid tablet.  
1. F1 NPs PLA-g-5%PEG2000Da  
2. F2 NPs PLA-g-5%PEG750Da  
viii. Tablet physical characterization such as DSC, XRPD, particle size and 
size distribution tablet weight, thickness, hardness, disintegration, drug 
stability and drug release carried out for:-  
1. PLA-g-5%PEG750Da NPs based formulation 
2. PLA-g-5%PEG2000Da NPs based formulation 
3. Commercial Famotidine formulation (Control) 
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ix. In vitro permeability evaluation of NPs based and commercial tablet 
formulations across CaCo-2 cell monolayers in bidirectional sides 
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Résumé : 
La biodisponibilité des médicaments administrés par voie orale peut être limitée par les 
processus intestinaux  médiés par les glycoprotéines-P (P-gp). Le polyéthylène glycol 
(PEG) est connu comme étant un inhibiteur des P-gp. La dispersion de famotidine 
(substrat des P-gp) encapsulée dans des nanoparticules pegylées (NPs) a été utilisée 
afin d’augmenter sa biodisponibilité. Le but de ce projet est d’évaluer l’utilisation 
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potentielle des NPs préparées à partir des fonctions PLA-g-PEG en étudiant la 
perméabilité in vitro avec le test cellulaire Caco-2. Des PLA-g-PEG qui sont des PEG 
greffés sur l’acide polylactique de 750 et 2000 Da (PLA) ont été synthétisés avec 1% et 
5% (ratio molaire de PEG vs monomère d’acide lactique). Ces polymères ont été 
utilisés pour préparer des nanoparticules de famotidine et testées in vitro avec le test 
Caco-2. Une baisse significative de la sécrétion de famotidine a été observée du côté 
basolatéral vers l’apical lorsque des nanoparticules de famotidine de PEG5%-g-PLA 
ont été utilisées. Ces nanoparticules semblent être une alternative promettante pour 
améliorer la biodisponibilité orale des substrats de P-gp.
  
 
 
3.1. Abstract 
Bioavailability of oral drugs may be limited by an intestinal secretion process mediated 
by P-glycoprotein (P-gp). Polyethylene glycol (PEG) is known as P-gp inhibitor. 
Dispersion of Famotidine (P-gp substrate) within pegylated nanoparticles (NPs) was 
used to enhance its bioavailability. In this work, our goal was to evaluate the potential 
use of NPs prepared from PLA-g-PEG on P-gp function by studying in vitro 
permeability across CaCo-2 cells. PEG grafted on a polylactide acid (PLA) backbone 
(PLA-g-PEG) were synthesized with 1 % and 5 % (molar ratio of PEG vs lactic acid 
monomer) of 750 and 2000 Da. These polymers were used to prepare Famotidine 
loaded NPs and tested in vitro on CaCo-2 cells. Significant decrease in secretion of 
Famotidine from Basolateral-to-Apical was observed when Famotidine was 
encapsulated in NPs prepared from PLA-g-5%PEG. NPs prepared from PLA-g-
5%PEG could be a promising strategy to improve oral bioavailability of P-gp substrate. 
Keywords: Caco-2, Famotidine, Nanoparticles,  Permeability,  P-gp , PLA, PEG 
 
3.2. Introduction 
 
In order to be absorbed via the oral route, drug molecules must dissolve into 
gastrointestinal fluids, resist to enzymatic degradation and not bind to food. 
Moreover, drug molecules need to diffuse across the gastrointestinal membrane to 
reach the systemic circulation, either by entering epithelial cells from the apical 
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(luminal) side and exiting from the basolateral side (transcellular transport) or by 
passing through the intercellular space (paracellular transport). Small molecule 
transporters act as biochemical barriers to transcellular transport while the tight 
junctions of the epithelium act as a physical barriers to paracellular transport (Aulton, 
2007). Amongst transport proteins is P-glycoprotein (P-gp), a glycoprotein of about 
170 kDa also called apical efflux transporter (Akhtar, et al., 2011, Estudante, et al., 
2013).  P-gp is part of the super family of ATP-binding cassette (ABC) transporters 
involved in the transport of various substrates across extra- and intracellular 
membranes.  P-gp is expressed in various normal tissues including liver, kidney, 
adrenal glands, brain, testis and the intestinal brush border membranes (Akhtar, et al., 
2011, Estudante, et al., 2013). P-gp is also expressed in tumor cells and responsible 
for the efflux of chemotherapeutic agents from multidrug-resistant (MDR) cancer 
cells. In the GI tract, P-gp acts as absorption barrier by lowering intracellular drug 
concentration, by secreting drugs from the cytosol of intestinal cells to the intestinal 
lumen and by reducing permeability and bioavailability, thus having a profound 
impact on the pharmacokinetics of several drugs (Akhtar, et al., 2011). Therefore the 
oral bioavailability of drugs that are P-gp substrates could be improved by inhibiting 
the P-gp efflux function within the intestinal membrane (Dahan, et al., 2008, Shen, et 
al., 2006). 
 
Some pharmaceutical excipients can inhibit the secreting function of P-gp in the 
intestinal membrane and therefore improve the oral bioavailability of P-gp substrate 
drugs (Ashiru-Oredope, et al., 2011, Hugger, et al., 2002). Polyethylene glycol (PEG) 
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is uncharged, hydrophilic and soluble in many organic solvents. PEG is commonly 
used as an excipient in pharmaceutical formulations and available commercially in 
molecular weights ranging from 200 to 8000 Da (Rowe, et al., 2009). For instance, 
PEG 6000 Da has been used to increase aqueous solubility or dissolution of some 
drugs by solid dispersion technique (Essa, et al., 2010). Moreover, PEG has been 
shown to enhance bioavailability of some drugs by inhibiting P-gp efflux (Hugger, et 
al., 2002). Indeed, PEGs within a range of 300 to 4000 Da have been used to improve 
oral permeability of P-gp substrate drugs (M. Rabanel, et al., 2012). Some studies 
showed that P-gp is highly sensitive to the lipid environment of cell membranes and 
that increased concentrations of PEG alter membrane fluidity probably through 
interactions between oxyethylene groups and the phospholipid polar headgroups 
(Ashiru-Oredope, et al., 2011, Collnot, 2007, Hugger, et al., 2002, Hugger, et al., 
2002, Iqbal, et al., 2010).  
Nanosized formulations have been shown efficient at enhancing drug absorption and 
bioavailability of several drugs (Hunter, et al., 2012, Lenhardt, et al., 2008, Mittal, et 
al., 2007, Sepassi, et al., 2007). Nanoparticles (NPs) are drug carriers with a size 
varying from 10 to 1000 nm in which the drug is either physically or molecularly 
uniformly dispersed. Nanocapsules are vesicular systems in which the drug is 
confined to a cavity surrounded by a unique polymer membrane (Merisko-Liversidge, 
et al., 2003, Panoyan, et al., 2003). In recent years, biodegradable NPs have been 
increasingly tested in pharmaceutical research as promising drug delivery systems 
(Li, et al., 2008). Nanoformulation may contribute to improving drug adsorption in 
several ways such as preventing premature degradation of the drug in hostile 
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gastrointestinal environment, contributing to target drugs to specific parts of the 
gastrointestinal tract and allowing the delivery of poorly soluble drugs (Bala, et al., 
2004, Bhardwaj, et al., 2005, Mittal, et al., 2007). Indeed, improvement of passage 
through biological barriers by nanocarriers administered orally has been reported for 
several encapsulated drugs (M. Rabanel, et al., 2012). PEGylated drug carriers have 
initially been developed to prevent rapid elimination by mononuclear phagocyte 
system and increase systemic circulation time to optimise drug delivery (Owens , et 
al., 2006). However, PEGylated drug carriers can also be of benefit to oral delivery 
by improving penetration through the mucus barrier covering the epithelium, 
favouring interaction with epithelial cell membranes, decreasing interaction with food 
and, as discussed earlier, decreasing P-gp activity (Mert, et al., 2012). Famotidine, a 
H2-receptor antagonist, inhibits gastric acid secretion and heals gastric and duodenal 
ulcers. After oral administration, the onset of the antisecretory effect occurred within 
one hour; the maximum effect was dose-dependent, occurring within one to three 
hours. Famotidine has been chosen as model drug because of its relatively low and 
variable oral bioavailability apparently due to its relatively low aqueous solubility 
and efflux transport by P-gp (Kiho Lee, 2002). Encapsulation of this drug in 
PEGylated nanocarriers could therefore be a promising approach. The objective of 
this paper is thus to develop and evaluate the effect of nano-encapsulation of 
Famotidine in PEG-grafted poly(lactic acid) (PLA-g-PEG) NPs on P-gp efflux and 
permeability through Caco-2 cell monolayers.  
3.3. Materials and methods 
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3.3.1. Materials 
 
Pharmaceutical grade famotidine was obtained from Corealis Pharma Inc, (Laval, 
QC, Canada). Organic solvents were purchased from Laboratoire MAT (Montréal, 
QC, Canada) while other chemicals were from Sigma-Aldrich (St-Louis, MI, USA). 
All solvents were HPLC grade and used without further purification. All materials for 
cell culture were purchased from Invitrogen (Burlington, ON, Canada).  
 
 
3.3.2. Polymer synthesis 
 
Polymers of PEG randomly grafted on poly(D,L-lactide) were synthesised as 
previously (Essa, et al., 2010, Nadeau, et al., 2005, Shilpa, et al., 2005). PEG grafting 
was performed at density ratios of 1% and 5% (mol/mol of lactic acid). In brief, a 
polyester-co-ether copolymer of D, L-lactide (21.5 g, 99 mmol or 95 mmol) and allyl 
glycidyl ether (AGE) (0.343 g, 2 mmol or 10 mmol) was first synthesised by ring-
opening polymerisation using tetraphenyl tin as catalyst (1:10 000 molar ratio with 
regard to lactide) under argon. The reaction was maintained at 180 °C for 6 h. The 
copolymer thus obtained was dissolved in acetone and precipitated in water. After 
polymer drying under vacuum, the allyl pendant groups were oxidised to hydroxyl 
groups by hydroboration with an equimolar quantity of borane in tetrahydrofuran. 
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The reaction was carried out for 2 h at 0 °C followed by oxidation in presence of 
hydrogen peroxide under alkaline condition (1 N NaOH). The pendant hydroxyl 
groups were further oxidised to carboxylic acid groups by Jones reagent under 
stirring for 3 h at 0°C, then converted to acyl chloride by adding thionyl chloride 
(1:1000 molar equivalents) under stirring at ambient temperature for 2 h. Methoxy 
poly(ethylene glycol) (mPEG) (2000 or 750 g/mol) was grafted onto the PLA 
copolymer backbone by reacting the hydroxyl groups of MPEG with the pendant acyl 
chlorides in presence of pyridine and 4-dimethylaminopyridine (DMAP). 
Subsequently, the polymer was purified by successive washings with 1 N HCl and 
precipitation in water from acetone. The final polymer was dried under vacuum (900 
mbar) before storage at -20 °C. 
 
 
3.3.3. Polymer characterisation 
 
 
3.3.3.1. Nuclear magnetic resonance (NMR) 
 
Samples of each polymer (10 to 20 mg) were dissolved in CDCl3 and 1H-NMR 
spectra were recorded using a Brucker ARX 400 spectrometer (Bruker, Germany). 
Chemical shift (d) was measured in ppm using tetramethylsilane (TMS) as internal 
reference.  
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3.3.3.2. Gel permeation chromatography (GPC) 
 
The number average (Mn) and the weight average (Mw) molecular weights of the 
synthesised polymers were determined by GPC. GPC was performed using a Waters 
chromatography system (Waters, USA) equipped with a refractive index detector and 
a Phenogel 5-µm column (Phenomenex). Polystyrene standards (400, 200, 90, 50, 30, 
20, 4, and 2 kDa) were used for calibration with chloroform as mobile phase at a flow 
rate of 0.6 mL/min. Polymer was dissolved in of chloroform at 2.5 mg/mL. 
Polydispersity index (PDI) was calculated using the Mw/Mn ratio from GPC data. 
 
 
3.3.3.3. Grafting efficiency 
 
The number and weight percentages (w/w %) of PEG units present in a copolymer 
chain were calculated based on 1H NMR spectra, GPC data, lactic acid molecular 
weight and PEG molecular weight. Poly(D,L-lactide)-graft-PEG (PLA-g-PEG) is a 
random branched copolymer with a structure shown in Figure 3.1, where x is the 
number of lactic acid moieties and y  the number of grafted PEG chains. Equation 1 
describes the calculation of the molar fraction of PEG (p) from the x and y values 
obtained by 1H NMR.  
݌ = ௬௫ା௬     (Equation 1) 
The molecular weight of the graft copolymer (mp) is the sum of all lactic acid units 
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and grafted PEG branches (Equation 2) 
݉௣ = 72ݔ +݉௚ ∙ ݕ   (Equation 2) 
Where 72 is the molecular weight of a lactic acid monomer and mg the molecular 
weight of a grafted PEG moiety. 
Extracting x from Equation 1 yields: (Equation 3) 
Substituting x in (Equation 2) and expressing for y yields: 
ݕ = ௠௣∙௣଻ଶ(ଵି௣)ା௣∙௠೒       (Equation 4) 
ݕ = ݉௣
72 ቀ1 − ݌݌ ቁ +݉௚
 
Where p is obtained by 1H-NMR, mp is measured by GPC (J-M. Rabanel1, 2012) and 
mg  is approximated to the Mn of a PEG chain considering that the grafting connecting 
group (AGE) has a minor impact on Mn of PEG. 
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3.3.3.4. Fourier transform infrared spectroscopy 
 
Fourier transform infrared (FTIR) spectroscopy was used to characterise the 
functional groups of PLA and PEG from PLA-g-PEG polymers and NPs. The spectra 
of PLA-g-PEG polymers with four different compositions, of PEG and of PLA were 
recorded using a Nicolet spectrometer (Nicolet iS10, Madison, WI). All spectra were 
recorded at ambient temperature at a resolution of 2 cm−1 and 64 scans per 
measurement to obtain an adequate signal-to-noise ratio. The IR spectra were 
recorded in transmission mode from dry powders of the polymers, which were spread 
on a sample holder stage and scanned from 4000 cm-1 to 400 cm-1.  
 
 
3.3.3.5. Differential scanning calorimetry (DSC) 
 
Thermal characterisation was carried out using a TA Universal Analysis Q20 
instrument (TA instruments, DE, USA). Polymers, NPs, physical mixtures of 
Famotidine and blank NPs as well as two polymorphs of Famotidine were 
characterised. Physical mixtures were prepared by triturating Famotidine and blank 
NPs at a similar weight ratio as for Famotidine-loaded NPs. Samples of 
approximately 5 mg were sealed in flat bottom aluminium pans with lids. Samples 
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were analysed in triplicate from -35 to 200 °C at a heating rate of 10 °C/min under 
nitrogen flow (50 mL/min). Indium was used as the calibration standard.   
 
3.3.4. NP preparation 
 
 
3.3.4.1. Emulsion-solvent evaporation  
 
 NPs were prepared by an (oil/water) emulsion-solvent evaporation method. 
Famotidine (110 mg) and the polymer (1090 mg) were dissolved in 12 mL of a 1:1 
mixture of dichloromethane (DCM) and dimethylformamide (DMF) and emulsified 
in 100 mL of a 0.5% (w/v) polyvinyl alcohol (PVA) solution using a high-pressure 
homogeniser Emulsiflex C30 (Avestin, ON, Canada) at a pressure of 10,000 psi for 3 
min. DCM and DMF were then evaporated under reduced pressure with constant 
stirring for 3 h. NP suspensions were centrifuged at 18,500 g (Sorval Evolution RC, 
USA) for 1 h, the NPs collected and reprocessed four times. The NPs were then 
lyophilised (Lyph-Lock 4.5, Labconco, USA) to obtain dry NPs and stored at -20 °C 
until further use. Blank NPs were prepared in a similar manner.  
 
 
3.3.4.2. Nanoprecipitation 
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The nanoprecipitation technique was used to prepare PLA-g-PEG and PLA blank 
NPs. The resulting NPs are PVA-free and were prepared for size and zeta potential 
comparison purposes. An organic phase was prepared by dissolving 200 mg of 
polymer in 10 mL of acetone. The polymeric solution was added dropwise to 20 mL 
of milliQ water with magnetic stirring at room temperature. The dispersing phase, 
water, was chosen as a liquid in which the polymer is insoluble (the non-solvent, NS). 
The freshly formed NPs were stirred overnight in order to let the solvent diffuse out 
of the NPs. The NPs were then lyophilised to obtain dry NPs and stored at -20 °C 
until further use.  
 
3.3.5. NPs characterisation 
 
3.3.5.1. Particle size  
 
Freeze-dried NPs were resuspended in Milli-Q water (0.01% w/v) and sonicated for 3 
min prior to measurement so as to break aggregates. The size and size distribution of 
blank, Famotidine-loaded as well as PLA NPs were measured by dynamic light 
scattering (DLS) using a ZetaSizer Nanoseries ZS instrument (Malvern instrument, 
Worcester, UK). Mean particle diameter was calculated by differential size 
distribution processor (SDP) intensity analysis. Three measurements consisting each 
of three runs particle size analysis were performed at 25 °C.  
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3.3.5.2. Surface charge (zeta potential) 
 
Surface charge of blank and Famotidine-loaded NPs was measured in triplicate using 
a Zeta Sizer Nanoseries ZS instrument (Malvern instrument, Worcester, UK). NPs 
were suspended in 10 mM aqueous sodium chloride and measurements were carried 
out at 25 °C. The mean value and standard deviation were calculated from the 
triplicates.  
 
3.3.5.3. Determination of residual PVA 
 
The amount of residual PVA was determined using a colorimetric method based on 
the formation of a complex between two adjacent hydroxyl groups of PVA and an 
iodine molecule (Sahoo, et al., 2002). Briefly, 2 mg of lyophilised NPs were treated 
with 2 mL of 0.5 M NaOH for 15 min at 60 °C. Each sample was neutralised with 
900 µL of 1 N HCl and the volume was adjusted to 5 mL with distilled water. To 
each sample, 3 mL of a 0.65 M solution of boric acid, 0.5 mL of a solution of I2/KI 
(0.05 M/0.15 M) and 1.5 mL of distilled water were added. The samples were 
incubated for 15 min at room temperature and absorbance was measured at 690 nm 
using a Biochrom Ltd spectrophotometer (Cambridge, UK). The amount of PVA was 
calculated using calibration curve of PVA prepared under the same conditions. 
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3.3.5.4. Particle morphology 
 
Size, shape and surface morphology of NPs were studied using a Nanoscope IIIa 
Dimension 3100 atomic force microscope (Digital Instruments, CA, USA). NP 
suspensions in Milli-Q water (0.01% w/v) were deposited on freshly cleaved mica, air 
dried and analysed. Images were obtained in tapping mode using an etched silicon 
probe (TESP7) with tip radius of 5 to 10 nm, spring constant of 20-100 N/m and 
resonance frequency of 200-500 kHz. Cantilever length was 125 µm. A set-point ratio 
(-i.e., ratio of oscillation amplitude after engagement to oscillation amplitude in free 
air) between 0.5 and 0.7 (moderate tapping mode) was used for all topographic and 
phase images unless otherwise stated. 
 
 
3.3.5.5. Encapsulation efficiency and drug loading  
 
Encapsulation efficiency of Famotidine in NPs was determined by high-performance 
liquid chromatogrphy (HPLC). Briefly, 10 mL of 1N aqueous NaOH was added to 10 
mg of NPs and stirred for 30 min. The samples were analysed using a Shimadzu 
HPLC system (Kyoto, Japan) with SPD-20A UV/vis detector and a Hyperclone 5 µm 
packing 130 Å pore size BDS C18 column (Phenomenex, CA, USA). A mixture of 
phosphate buffered solution at pH 6.0 and methanol (10/90 v/v) was used as the 
mobile phase at a flow rate of 1 mL/min. Famotidine was detected at 267 nm at a 
retention time of 7.5 min. Analyses were performed in triplicate. Encapsulation 
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efficiency (EE) was calculated as the percentage of drug entrapped in NPs compared 
to the initial amount of drug added to the solvent during NP preparation using 
Equation 5: 
Equation 5 
ܧܧ% = Amount	of	drug	entrapped	in	NPsInitial	amount	of	drug	added x100 
Drug loading (DL) of NPs was calculated as the percentage of drug entrapped in NPs 
compared to the total weight of NPs using Equation 6: 
Equation 6 
ܦܮ% = ܣ݉݋ݑ݊ݐ	݋݂	݀ݎݑ݃	݁݊ݐݎܽ݌݌݁݀	݅݊	ܰܲݏܶ݋ݐ݈ܽ	ܽ݉݋ݑ݊ݐ	݋݂	ܰܲݏ 	ܺ	100 
 
 
3.3.5.6. X-Ray powder diffraction (XRPD) 
  
The crystal structure of the NPs was studied by XRPD using a Bruker X-ray 
diffractometer model D2 phaser (Karlsrushe, Germany) with a CuKα radiation source 
(ɧλ=1.59 A°) operating at 30 kV and 10 mA and with a LynxEye detector with 
2.49239° angular opening. The opening slit, scatter plate and detector windows were 
0.6 mm, 1.0 mm and 3 mm, respectively. The measurements were made over a range 
from 4 to 40° 2θ with increments of 0.02° at a scanning speed of 3.4o per min. The 
samples were analysed using a low volume sample holder. Famotidine forms (A and 
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B), Famotidine-loaded NPs and physical mixtures of Famotidine and blank NPs were 
analysed.  
 
 
3.3.5.7. Drug release 
 
The dialysis diffusion technique was used to evaluate in vitro Famotidine release 
from different NPs formulations. Briefly, known amounts of NPs were suspended in 
3 mL of buffered saline medium at pH 7.4 and placed into cellulose ester dialysis 
bags (6-8 kDa cut-off, Spectra-Por 1 membrane, Spectrum laboratories, USA). The 
dialysis bags were placed in 50-mL screw cap tubes containing 10 mL of phosphate 
buffered saline (PBS) medium at pH 7.4 (external volume) and incubated at 37 °C  
with shaking at 150 rpm using a horizontal water bath shaker (Orbit Shaker Bath, 
Labline, USA). The medium (10 mL) was sampled at predetermined time intervals to 
quantify Famotidine and replaced with 10 mL of fresh buffered saline medium. The 
HPLC method described earlier (see encapsulation efficiency and drug loading 
section) was used to quantify Famotidine released from the NPs. 
 
 
3.3.5.8. Cytotoxicity 
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Caco-2 cells were seeded in 96well microplates (100 µL of a 500,000 cells/mL 
suspension in culture medium) and incubated at 37 °C with 5% CO2 for 24 h. The 
Caco-2 cells were added to each well except for one control row containing medium 
only. Suspensions of pure Famotidine, Famotidine-loaded NPs and blank NPs were 
prepared at concentrations ranging from 0.04 to 10 mg/mL prepared under sterile 
environment. A fixed amount of test solutions (10 μL) was added to cells (n=4 per 
test solution). One row of cells was not treated and served as control. The microplate 
was centrifuged at 600 rpm for 30 seconds to ensure bring the liquid phase at the 
bottom of the wells. The medium was removed and the cells washed with 150 μL 
cold PBS (4°C). The cold PBS was then replaced with 100 μL of fresh medium. A 
colorimetric assay was used for the assessment of cell proliferation. Briefly, 10 μL of 
MTT solution (5 mg/mL thiazolyl blue tetrazolium in PBS pH 7.4) was added to each 
wells and the plate incubated for 4 h at 37 °C. An acidic isopropanol solution (40 mL 
of Isopropanol, 5 mL 1N HCL and 5 mL Triton X-100, 50 μL) was then added to 
each well. The plate was covered with aluminium foil and slowly agitated for 12 h. 
The microplates were read using the Magellan 4 software at a wavelength of 570 nm 
and reference wavelength of 690 nm. Calculation of cell viability was done according 
to Equation 7: 
Equation 7 
Cell proliferation (%) =     ۯ܊ܛܗܚ܊܉ܖ܋܍	ܗ܎	ܕ܍܌ܑܝܕ	ܟܑܜܐ	ܛ܉ܕܘܔ܍ି	ۯ܊ܛܗܚ܊܉ܖ܋܍	ܗ܎	ܕ܍܌ܑܝܕ	ܟܑܜܐܗܝܜ	܋܍ܔܔܛۯ܊ܛܗܚ܊܉ܖ܋܍	ܗ܎	ܕ܍܌ܑܝܕ	ܟܑܜܐ	܋܍ܔܔܛ	–	ۯ܊ܛܗܚ܊܉ܖ܋܍	ܗ܎	ܕ܍܌ܑܝܕ	ܟܑܜܐܗܝܜ	܋܍ܔܔܛ  
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3.3.5.9. In vitro permeability evaluation by bidirectional Caco-2 cells 
monolayer  
 
3.3.5.9.1. Culture of Caco-2 cells  
 
The Caco-2 ATCC cell line (American Type Culture Collection, Manassas, VA, 
USA) was cultured in Dulbecco’s modified eagle’s medium (DMEM) supplemented 
with 10% Fetal Bovine Serum, 1% non-essential amino acids, 0.25 µg/mL 
Amphotericin B and 100 U/mL Penicillin/Streptomycin (Gibco, USA). The cells 
were grown and maintained in tissue culture flasks and incubated at 37 °C under a 5 
% CO2 and 90 % relative humidity atmosphere (Sanyo CO2 incubator, USA).  
 
 
3.3.5.9.2. Caco-2 cells monolayer 
 
The Caco-2 cells were grown until reaching 90% confluence. Using trypsin-EDTA 
(Ethylene Diamine Tetra acetic Acid), the cells were detached from the culture flask 
and seeded at a density of 60,000 cells/cm2 on Transwells™ (Costar, NY, USA) with 
polycarbonate membranes (12 mm i.d., 3.0 µm pore size). Culture medium (DMEM) 
was changed in both the apical and basolateral  compartments on the day after 
seeding and every successive day (Apical volume: 0.5 mL, Basolateral volume: 1.5 
mL). Caco-2 cells monolayer were used 21-28 days post-seeding. The integrity of the 
cell monolayer during the growth phase was monitored by taking trans epithelial 
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electrical resistance (TEER) readings using an EVOM™ epithelial tissue volt-ohm-
meter with an Endohm-12 electrode (Millipore Corp. USA). The resistance of the 
monolayer was determined by subtracting the total resistance (membrane support and 
cell monolayer) from the membrane support resistance. Cells monolayers with TEER 
values greater than 300 W/cm2 were used in transport experiments.  
 
 
3.3.5.9.3. Transport experiments 
 
Cells monolayers were pre-incubated for 30 min at 37 ºC in Hank's balanced salt 
solution (HBSS). Basolateral-to-apical and apical-to-basolateral transport 
experiments were performed by respectively adding 1.5 and 0.4 mL of solutions 
containing 80 μg/mL Famotidine. Transport studies were carried out for five test 
groups, namely pure Famotidine, Famotidine-loaded PLA-g-PEG NPs (four 
formulations were tested), physical mixtures of Famotidine and blank NPs, physical 
mixtures of Famotidine and PEG (two molecular weights were tested, PEG750Da and 
PEG2000Da) and Famotidine-loaded PLA NPs. Transport studies were carried out in 
triplicate for each formulation. The HPLC method described in the section entitled 
“encapsulation efficiency and drug loading” was used to quantify Famotidine in the 
basolateral and apical compartments over 4 h. From the results, the apparent 
permeability coefficients in both directions as well as the asymmetry index of the 
transport were calculated. The apparent permeability coefficient is determined from 
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the amount of Famotidine diffused with time. Papp is calculated according to Equation 
(8):  
Equation 8 
௔ܲ௣௣	(ܿ݉	ݏିଵ) = (݀ܳ ݀ݐ)	(1 (ܣܥ଴⁄⁄ )) 
Where dQ/dt is the rate of permeation in centimetre per second, C0 is the initial 
concentration of Famotidine in the donor cell (either the basal or apical compartment) 
and A is the area of the monolayer. The asymmetry index allows identifying potential 
P-gp substrates. This efflux ratio was obtained by dividing Papp value in the 
basolateral-to-apical direction by the corresponding value in the apical-to-basolateral 
direction. A ratio greater than 1.0 indicates the predominance of secretory transport 
and suggests the presence of an efflux transporter such as P-gp.   
 
 
3.3.6. Data analysis 
 
All experiments were conducted at least in triplicate (n=3) and results were expressed 
as mean ± standard deviation unless otherwise noted. Statistical significance was 
evaluated by one-way analysis of variance (ANOVA) using SigmaStat software 
version 3.1. The effect of PEG on the P-gp efflux of Famotidine compared to pure 
Famotidine was evaluated from the transport study data using ANOVA followed by 
the Holm-Sidak test. The statistical significance was set as p < 0.05, with a 
confidence level of 95%.  
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3.4. Results and discussion 
 
3.4.1. Polymer synthesis and characterisation 
 
3.4.1.1. NMR 
 
A typical 1H NMR spectrum was obtained for the PLA homopolymer, with a 
characteristic peak at 5.2 ppm corresponding to the tertiary PLA proton (m, –CH) and 
another peak at 1.5 ppm corresponding to the pendant methyl group of the PLA chain 
(m, –CH3). Moreover, the integration ratio of both peaks was 3:1, which is also 
characteristic of the PLA homopolymer (Nadeau, et al., 2005, Shilpa, et al., 2005). 
Likewise, typical spectra were obtained the for PLA-g-PEG polymers with a peak at 
5.2 ppm for the tertiary PLA proton (m, –CH), a peak at 3.6 ppm for the protons of the 
repeating units of the PEG chain (m, OCH2–CH2O), a minor peak at 4.3 ppm for the 
protons connecting the PEG graft to the PLA backbone (m, CH2–OCO) and a peak at 
1.5 ppm for the pendant methyl group of the PLA chain (m, –CH3).  
 
 
3.4.1.2. GPC 
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PLA-g-PEG graft polymers were synthesised by ring-opening polymerisation. Gel 
permeation chromatography was used to measure the Mw and Mn of the graft 
polymers. In this study, two types of PEG (750 and 2000 Da) were grafted at two PEG 
vs. lactic acid ratios (1 and 5%)  in order to evaluate the impact of PEG on the P-gp 
efflux. PEG molecular weight of 750Da or 2000Da were chosen for optimal 
biocompatibility. PEG with high molecular weight become too big to be eliminated. 
PEG with lower molecular weight than 750Da is not enough to increase the 
hydrophilicity of the NPs surface.  Table 3.1 shows GPC results for the different PLA-
g-PEG polymer compositions as well as for the PLA polymer used in this study. The 
Mw of the grafted PLA-g-PEG polymers varies from 6000 to 21 137 Da while Mn is 
from 3100 to 17 330 Da. PLA-1%PEG750 is the shortest polymer while PLA-g-
5%PEG2000 is the largest, in agreement with the PEG molecular weights and grafting 
ratios used.  Polydispersity index (PDI) values were calculated by dividing Mw by Mn. 
PDI was higher for graft polymers with 1% PEG compared to polymers with 5% PEG. 
PLA-g-5%PEG2000 had the smallest PDI value at 1.22 while PLA-g-1%PEG750 had 
the highest at 1.93.  The presence of unreacted mPEG or PLA species may explain the 
large PDI in case of PLA-g-1%PEG750.  
 
3.4.1.3. Grafting efficiency 
 
Grafting efficiency of PEG to PLA backbone was calculated by comparing the 
intensity ratio of the 1H-NMR PEG peak at 4.3 ppm to that of the PLA peak at 5.16 
ppm (% mol PEG to mol of lactic acid monomer). Comparison of the expected grafting 
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percentage of PEG to the actual grafting percentage (Table 3.1) shows that PEG2000 
grafting was complete at both percentages while PEG750 grafting was incomplete 
(0.4% and 1% instead of the theoretical 1% and 5.7% values, respectively). It is 
remarkable that PEG 750 Da grafting was lower than theoretical one, whereas PEG Da 
2000 grafting higher than the expected. The best results obtained of PEG 2000 Da 
compare to PEG 750 Da, it may be explained by the reactivity of different PEG 
(2000Da and 750 Da) with pendant carboxylic compare to ended carboxylic group. 
Mechanistic study could demonstrate the following hypothesis, PEG750Da reacts with 
lactic carboxylic group at the end of polymer backbone while PEG 2000 Da reacts 
more with pendant group. Based on the results, the actual grafting of PLA-g-
5%PEG750 is close to 1% and the polymer will therefore be compared to PLA-g-
1%PEG2000 in studies examining the effect of the PEG molecular weight on 
properties of the NPs. Moreover, Table 3.1 also indicates the PEG content of the graft 
polymers on a weight basis. Generally, the PLA-g-PEG2000 polymers had higher PEG 
content than the PLA-g-PEG750. For instance, PLA-g-5%PEG2000 contains 66% w/w 
PEG per polymer chains compared to 8.6% for PLA-g-5%PEG750 (J-M. Rabanel1, 
2012). 
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Polymer Composition Mw (Da) 
Mn 
(Da) PDI 
Actual 
grafting 
(%) 
PEG per 
polymer 
chain 
(%) 
PEG 
melting 
point (oC) 
PLA Glass 
transition 
temperature 
(oC) 
PLA 46 400 32 040 1.44 N/D N/D N/D 50.24 ± 0.73 
PLA-g-1%PEG750Da 6000 3100 1.93 0.4 4.4 N/D -- 
PLA-g-1%PEG2000Da 17 697 11 340 1.56 1.1 24.1 50.68 ± 0.13 * 
PLA-g-5%PEG750Da 16 621 12 905 1.29 0.9 8.6 N/D 29.68 ± 1.87 
PLA-g-5%PEG2000Da 21 137 17 330 1.22 5.7 66.2 53.42 ± 0.39 * 
*  Tg and PEG melting point at same temperature, -- Tg not detected , N/D  Not detected  , n=(3) 
 
 
Table 3.1 Molecular weight, PDI, grafting percentage and thermal properties (n=3) of 
polymers evaluated during this study. 
 
3.4.1.4. Fourier transform infrared FTIR 
 
FTIR scans were done for pure PLA, pure PEG and the four graft polymers. The FTIR 
scan of pure PLA (Figure3. 2) exhibits characteristic absorption bands corresponding 
to asymmetric and symmetric stretching of C-H at 2998 and 2944 cm-1 and of CH3 at 
1451 cm-1, respectively. The PLA C-O stretching bands from -CH-O- and -O-C=O also 
appeared at 1182 cm-1, 1083 cm-1 and 1747 cm-1 (Choi, et al., 2013, Elmowafy, et al., 
2008). The FTIR scan of pure PEG 2000 (Figure 3.2) showed an absorption band at 
2883 cm-1 which is attributed to the aliphatic C-H stretching band of PEG (Choi, et al., 
2013, Elmowafy, et al., 2008). The characteristic and major stretch bands of PLA and 
PEG at 1747 cm-1 and at 2880 cm-1, respectively, were used as reference when 
comparing to the spectra of PLA-g-PEG polymers. FTIR scans of the four synthesised 
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polymers (Figure3. 2) showed that both characteristic PLA and PEG peaks were 
detected. Moreover, Figure 3. 2 presents an absorption band at 3300 cm-1 in case of 
PLA-g-5%PEG, which is attributed to the O-H stretching band of PEG. The FTIR 
results confirmed the presence of both PEG and PLA in the graft polymers, which is in 
agreement with the 1H NMR results. 
 
 
Figure 3.2 FTIR Spectra of PLA, PEG and different PLA-g-PEG polymers 
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3.4.1.5. DSC 
 
In case of PLA-g-5%PEG750, the PLA glass transition temperature (Tg) can be 
detected at 29.68°C while for PLA-g-1%PEG750 no Tg was detected (Table 1). For 
both PLA-g-PEG2000 polymers, the PLA Tg could not be measured due to the 
interference with PEG melting. The reported melting point of PEG 2000 at 52°C 
(Rowe, et al., 2009) was used to characterise the PLA-g-PEG2000 polymers. Table 3.1 
shows presence of the PEG peak at 50.68°C for PLA-g-1%PEG2000 and at 53.42°C 
for PLA-g-5%PEG2000. Unassigned transitions at -1.77°C and -0.09°C were observed 
for the first and second heating runs of PLA-g-1%PEG750 and PLA-g-1%PEG2000, 
respectively. Since the signals are not attributable to the Tg of PLA or PEG, they might 
be due to dimer of end PLA grafted PEG yield synthesis.  
 
 
3.4.2. NPs characterisation 
 
3.4.2.1. Particle size 
 
Famotidine-loaded and blank NPs were prepared from four PLA-g-PEG polymers by 
the emulsion solvent evaporation method. For comparison purposes, Famotidine-
loaded and blank NPs were also prepared from PLA polymer. The mean size of NPs 
can be influenced by parameters such as surfactant concentration (PVA in this case), 
polymer molecular weight and homogenisation pressure (Lamprecht, et al., 2000, 
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Sahoo, et al., 2002). DLS, also called photon correlation spectroscopy PCS, is a rapid 
and accurate method often used to determine the mean size, the size distribution and 
the polydispersity index (PI) of NPs (Gaumet, et al., 2008). The diameter obtained by 
DLS is a value that pertains to how particles diffuse within a fluid and corresponds to 
a hydrodynamic diameter. The diameter obtained by this technique is the diameter of 
a sphere having the same translational diffusion coefficient as the measured particle 
Particle size and size distribution obtained by DLS for different NP formulations are 
shown in Table 3.2. Drug-loaded PLA-g-1%PEG750 NPs were the smallest with a 
mean particle size of 156 nm, followed by PLA-g-1%PEG2000 NPs at 180 nm.  
PLA-g-5%PEG750 NPs had a mean particle size of 192 nm while PLA-g-
5%PEG2000 were the largest with a mean size of 211 nm. Even though drug-loaded 
NPs were prepared under similar conditions, a significant difference in particle size 
(p=0.004) was observed among the different formulations. The differences in size 
may be due to the varying PEG grafting densities and molecular weights of the 
polymers used to prepare the NPs. Indeed, NPs prepared from PLA-g-5%PEG2000 
had the largest diameter, which might be a consequence of the highest PEG grafting 
density affecting the surface of the NPs surface, the higher molecular weight, and an 
increased polymeric solution viscosity, as previously reported (Gorner, et al., 1999, 
Lamprecht, et al., 2000). Table 3.2 shows that the particle size of blank NPs prepared 
from PLA-g-5%PEG were significantly smaller (p≤0.001) than their drug-loaded 
counterparts, probably due to volume occupied by the drug (Lamprecht, et al., 2000). 
NPs presented a unimodal and homogeneous size distribution with relatively low PI 
values ranging from 0.026 to 0.139 (Table 3.2) (Patravale, et al., 2004). NPs prepared 
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from PLA-g-1%PEG750 were the most polydisperse  due to the fact that the PLA-g-
1%PEG750 polymer had lowest molecular weight, lowest grafting efficiency and 
itself had the largest polymer PDI. Furthermore, the presence of NPs consisting of 
ungrafted and grafted polymers might have also contributed to dispersity. Drug-
loaded NPs prepared from PLA had a mean particle size of 166 nm and PI of 0.135. 
The difference in polymer composition between PLA and the graft polymers (PLA-g-
PEG) brought about  differences in the resulting NPs.    
Composition 
Average 
Particle 
size (nm) 
±SD 
PI ±SD D L (%) Tg (°C) 
Famotidine 
melting point 
(°C) 
Blank NPs PEG750Da1%-g-PLA 154 ± 1.21   41.80 ± 0.37 
 
Loaded NPs  156 ± 2.75 0.139 ± 0.02 2.8 ± 0.08 47.00 ± 0.00 186.32 ± 0.45 
Blank NPs PEG2000Da1%-g-PLA 174 ± 0.66   40.70 ± 2.90 
 
Loaded NPs  180 ± 6.09 0.095 ±0.01 0.8 ± 0.06 45.00 ± 0.13 190.11 ± 0.24 
Blank NPs PEG750Da5%-g-PLA 149 ± 2.26  41.93 ± 0.12  
Loaded NPs  192 ± 0.58 0.026 ±0.09 2.2 ± 0.03 43.00 ± 0.61 183.67 ± 5.06 
Blank NPs PEG2000Da5%-g-PLA 161 ± 1.6  47.30 ± 0.60  
Loaded NPs  211 ± 2.44 0.056 ± 0.02 1.5 ± 0.04 48.02 ± 2.00 184.73 ± 6.99 
Blank NPs PLA 140 ± 1.2    
Loaded NPs PLA 166 ± 0.5 0.5 ± 0.01 50.00±0.13 185.19 ± 0.17 
SD=Standard Deviation, PI=Polydispersity, DL= Drug Loading, Tg = Glass transition temperature 
 
Table 3.2 Particle size, PI, drug loading, and thermal properties Famotidine and different NPs 
(n=3) 
 
 
3.4.2.2. Surface charge 
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The surface charge is an important indicator of NPs’ stability and predictor of in vivo 
fate (Mittal, et al., 2007). A method widely used to measure surface charge is zeta 
potential (Soppimath, et al., 2001). The zeta potential of NPs can take positive or 
negative values depending on the composition of NPs. Both PVA used as surfactant 
and the PEG grafts of the PLA-g-PEG polymers could have an impact on the zeta 
potential of the present NPs. PVA was used during NP preparation to prevent 
coalescence of emulsion droplets. In order to examine the distinct contributions of 
PVA and PEG to zeta potential, PLA-g-PEG and PLA NPs were prepared from two 
methods (either emulsion evaporation in presence of PVA or nanoprecipitation in 
absence of PVA) and studied. Drug-loaded NPs prepared by emulsion solvent 
evaporation method were also studied. Drug-loaded NPs could not be prepared by 
nanoprecipitation because Famotidine was insoluble in the solvent used to prepare the 
NPs (acetone).  As shown in Table 3.3, PLA-g-PEG NPs prepared by nanoprecipitation 
(without PVA) had zeta potential values ranging from -24.4 to -46.7 mV compared to -
45.2 mV for PLA NPs, consistent with results from others (Gref, et al., 1999, Tobio, et 
al., 1998). The presence PEG at the surface of the NPs significantly brought the zeta 
potential of the NPs prepared from PLA-g-PEG polymers closer to neutrality compared 
to NPs. The effect is attributed to PEG shifting the shear plane away from the NP 
surface. Similar observations were previously reported (Hawley, et al., 1997). The 
results in Table 3 show that the highest zeta potential value was obtained for the PLA-
g-5%PEG2000 NPs (highest PEG content) while the lowest value was obtained for 
PLA-g-1%PEG750 (lowest PEG content), further suggesting a correlation between 
zeta potential and PEG-to-PLA ratio. The zeta potential results obtained for drug-
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loaded and blank NPs prepared by the emulsion evaporation method in presence of 
0.5% PVA are reported in Table 3. The zeta potential values ranged from -4.6 to -9.9 
mV for the drug-loaded NPs and were between -4.2 to -6.3 mV for the corresponding 
blank NPs, in agreement with the results reported for similar polymers (Sant, et al., 
2008). The drug-loaded PLA-g-1%PEG750 NPs had a low PVA residual content 
(8.4% w/w) and presented the lowest zeta potential value at -9.9mV while the drug-
loaded PLA-g-5%PEG750 NPs had the highest PVA residual content (15.3% w/w) and 
presented the highest zeta potential value at -4.6 mV, suggesting a correlation between 
zeta potential PVA association to NPs (Vila, et al., 2004, Yoncheva, et al., 2005). In 
case of the blank NPs, no clear relationship between residual PVA content and zeta 
potential value could be seen. The presence of residual PVA at the surface of PLA NPs 
prepared by emulsion evaporation brought the zeta potential of the NPs closer to 
neutrality (-5.4 mV) compared to PLA NPs prepared by nanoprecipitation in absence 
of PVA (-45.2 mV). Overall, the zeta potential results obtained for NPs prepared by the 
two methods indicate an important contribution of PVA to zeta potential. 
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 PVA Zeta potential (mV) 
Composition (w/w %) 
emulsion solvent 
evaporation 
method 
Nanoprecipitation 
method 
 Average ± SD Average ± SD Average ± SD 
Blank NPs PLA-g-1%PEG750Da 10.13 ± 0.33 -6.3 ± 0.5 -46.7 ± 0.8 
Loaded NPs 8.4 ± 0.13 -9.9 ± 1.4 
Blank NPs PLA-g-1%PEG2000Da 9.05 ± 0.47 -4.2 ± 0.0 -30 ± 1.0 
Loaded NPs 12.3 ± 1.13 -4.8 ± 0.2 
Blank NPs PLA-g-5%PEG750Da 11.18 ± 1.39 -5.1 ± 0.2 -30.2 ± 1.4 
Loaded NPs 15.3 ± 2.23 -4.6 ± 0.4 
Blank NPs PLA-g-5%PEG2000Da 15.51 ± 2.89 -4.5 ± 0.2 -24.5 ± 0.2 
Loaded NPs 14.6 ± 1.34 -7.7 ± 1.0 
Blank NPs PLA 10.01 ± 0.92 -5.4 ± 0.1 -45.3 ± 0.8 
Loaded NPs PLA 9.07 ± 1.83 -15.2 ± 1.1 
 
Table 3.3 Residual PVA content of NPs prepared by emulsion evaporation as well as 
zeta potential of blank and drug-loaded NPs prepared by emulsion evaporation or 
nanoprecipitation  Methods (n=3) 
 
 
 
 
3.4.2.3. Residual PVA determination 
 
PVA was used as emulsifier during NP preparation as it forms an interconnected 
network on the PLA polymer surface capable of stabilizing the emulsion. However, 
PVA remains associated with the NPs despite repeated washings (Sahoo, et al., 2002), 
thus potentially affecting properties such as particle size, zeta potential, release 
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kinetics, etc. (Sahoo, et al., 2002). As reported in Table 3.3, 8.4 to 15.3% w/w residual 
PVA remained at the surface of all drug-loaded formulations, despite four washings. It 
has been reported that the solvents used during NP preparation influence the quantity 
of PVA adsorbed at the polymer-organic solvent/water interface. The amount of 
residual PVA associated to NPs increases with increased miscibility between the 
organic solvent and water since partitioning of PVA into the polymeric phase is then 
favoured (Sahoo, et al., 2002). Such phenomenon could explain the relatively higher 
residual PVA content associated to our NPs  compared to other NPs previously 
prepared in our lab using DCM only (Shilpa, et al., 2005). DMF is more miscible in 
water than DCM and could indeed bring higher amounts of residual PVA to associate 
with NPs (Sahoo, et al., 2002).  
 
 
3.4.2.4. Particle morphology 
 
The NPs were studied by Atomic Force Microscope (AFM). Tapping mode AFM is a 
versatile technique to study sample surface at the nanoscale (phase image) as well as 
topography (height image) of soft materials such as polymers. The AFM images 
revealed that the NPs were spherical in shape and agglomerated. AFM also served as a 
second method to confirm the NP sizes obtained by DLS. The height image reproduced 
in Figure 3.3 shows a representative population of NPs with spherical shape and sizes 
ranging from 120 nm to 130 nm at the resolution of 5 nm to 10 nm.  
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Figure 3.3 Tapping mode AFM image (topography) of NPs (PLA-g-5%PEG2000Da), 
scan size 1µmx1µm  
 
3.4.2.5. Encapsulation efficiency and drug loading 
 
Encapsulation efficiency and drug loading of Famotidine varied for the four NP 
batches produced and were fairly low at 7 to 22% and 0.8 to 2.8%, respectively (Table 
3.2). Encapsulation efficiency was found to be in the following order for the four 
polymers: PLA-g-1%PEG750 > PLA-g-5%PEG750 > PLA-g-5%PEG2000 > PLA-g-
1%PEG2000. In general, NPs prepared with PEG2000 had a lower drug loading 
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compared to NPs prepared from PEG750 (p≤0.001). Many factors can influence 
encapsulation efficiency and drug loading such as the nature of drug to be encapsulated 
and the size of the particles. Famotidine is rather hydrophilic and may have rapidly 
partitioned into the external aqueous phase during NP preparation, thereby decreasing 
its entrapment into the NPs during polymer deposition (Govender, et al., 1999). 
Encapsulation efficiencies of NPs prepared using an o/w method have previously been 
shown to depend on the partition of the drug between the internal and external phases 
as well as on the nature of the entrapping material (Mittal, et al., 2007, Redhead, et al., 
2001). In addition, drug loading may be influenced by the size of the NPs, as NPs have 
a high surface area compared to their volume. Because of the small volume of NPs, a 
high proportion of drug molecules will be incorporated near or at the surface of NPs 
and readily released during NPs preparation and washing steps (Mittal, et al., 2007, 
Redhead, et al., 2001). Furthermore, it has been suggested that the PEG chains of graft 
polymers such as PLA-g-PEG are located toward the NPs’ surface, which also might 
not favour high Famotidine loading (J-M. Rabanel1, 2012). 
 
 
3.4.2.6. FTIR 
 
Several characteristic absorption bands of Famotidine form B (3504, 3398, 1530, 1275 
and 1142 cm-1) were previously observed in NPs by FTIR spectroscopy(Elmowafy, et 
al., 2008, Lin, et al., 2006, Ramachandran, et al., 2011). Here, the characteristic peak at 
3504 cm-1 for the amino group of Famotidine was used as a reference to follow 
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Famotidine loaded in NPs. The amine (NH) band at 3504 cm-1 was not detected in the 
four Famotidine-loaded NP formulations produced.  
 
 
3.4.2.7. DSC 
 
The crystal state of Famotidine was characterised by DSC during and after NP 
preparation. Famotidine has two polymorphic crystal forms (A and B) with melting 
points at 171.43 and 164.4 °C, respectively. Form B is the metastable, kinetically-
favoured form and was used as starting material for this study (Hassouna, et al., 2011)., 
In a control experiment, Famotidine was crystallised from a mixture of DCM and DMF 
and analysed by DSC. The melting peak at 163.13 °C corresponded to Famotidine 
form B and indicated that no change due to the DCM:DMF solvent couple used was to 
be expected during the process of the NPs. The DSC results obtained for the 
Famotidine-loaded NPs prepared from PLA-g-1%PEG750 and PLA-g-1%PEG2000 
indicate sharp melting of Famotidine with peaks at 186.32 and 190.11 °C, respectively 
(Table 3.2 and Figure 3.4). Similar results were obtained for Famotidine-loaded NPs 
prepared from both PLA-g-5%PEG polymers as well as PLA (Table 3.2). After 
encapsulation a shift of melting point to higher temperature was observed in 
accordance to the presence of a crystalline form however no polymorphic form at this 
temperature has been described in the literature. A possible explanation is an 
interaction between the drug molecules and the polymer yielding a complex. The Tgs 
detected for blank NP formulations of PLA-g-1%PEG750, PLA-g-1%PEG2000 and 
 100 
PLA-g-5%PEG750 were 41.8, 40.7 and 41.93 °C, respectively (Table 3.2). The Tg of 
PLA-g-5%PEG2000 NPs was higher at 48.02 °C. The DSC scans obtained for 
Famotidine-loaded NP formulations were comparable to those of the blank NPs, except 
for NPs prepared from PLA-g-1%PEG750. In the later case, a 6-°C Tg shift to higher 
temperatures (p≤0.001) was observed in presence of Famotidine. The Tg shift to higher 
temperature might be due to Famotidine restricting the mobility of the polymer 
molecules. Indeed, NPs prepared from PLA-g-1%PEG750 had the highest drug 
loading (2.8% w/w) amongst all four NP formulations.  
 
 
Figure 3.4 Thermogram of Famotidine and four loaded NPs formulations 
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3.4.2.8. XRPD 
 
XRPD was used to identify the crystal structure of materials, notably to detect 
Famotidine crystal peaks after encapsulation in NPs. The starting material Famotidine 
form B possesses distinct major characteristic peaks at 5.96, 11.5, 15.7, 17.5, 19.5, 
20.5, 22.5 and 24.5° 2Ɵ (Ferenczy, et al., 2000). Figure 3.5 showed the characteristic 
diffractogram of Famotidine crystal B. XRPD confirmed that the pure Famotidine used 
in this study was crystalline, since it showed sharp, distinct peaks. Famotidine 
crystallised from a 1:1 mixture of DCM and DMF was again used as control to 
evaluate the potential impact of the NP formation process on Famotidine crystallinity. 
Compared to the starting material, the major peaks of Famotidine crystallised from 
DCM and DMF were preserved, with some peak inversions at lower intensities. The 
XRPD scans of Famotidine-loaded NPs showed two pattern types that varied with 
grafting ratio more than with PEG length. In case of NPs prepared from PLA grafted at 
1% PEG, a peak at 8.50° 2Ɵ was detected (Figure 5) instead of 5.94° for Famotidine 
form B. Moreover, other peaks at 11.5, 15.7, 19.5, 20.5, 22.5 and 24.5° corresponding 
to Famotidine (B) were detected. In case of NPs prepared from PLA grafted at 5% 
PEG, Famotidine exhibited two minor peaks at 21.50° and 23.50° 2Ɵ (Figure 5), 
suggesting a change in Famotidine’s state from crystal to amorphous or to nanocrystal 
below the XRPD limit of detection (Jiang, et al., 2012, Liu, et al., 2011, Morakul, et 
al., , Sahoo, et al., 2011). Such absence and/or reduction of Famotidine peaks for NPs 
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with 5% grafting density could indicate the presence of PEG at high density at the 
NPs’ surface(Yu, 2001). 
 
Figure 3.5 X- Ray diffractograms of Famotidine and four loaded NPs formulations 
    
 
3.4.3. Drug release 
 
The purpose of studying release kinetics from different NPs formulations is to observe 
the effect of polymer composition (PEG molecular weight, grafting density, residual 
PVA) and particle size on Famotidine release profiles. Figure 3.6 shows the percentage 
of Famotidine released in vitro from NPs prepared from the different PLA-g-PEG 
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polymers as well as from PLA. In all cases, nearly all Famotidine was released within 
four hours. The release profiles of Famotidine were comparable among all NP 
formulations, except for PLA-g-1%PEG750 NPs at the 5 min sampling time when a 
significantly higher release of Famotidine was observed (p=0.034). The higher initial 
release compared to other NP formulations may be attributed to the higher drug 
loading of this formulation. All release profile of Famotidine from NPs showed a 
biphasic release behaviour, as reported by others (Avgoustakis, et al., 2002). The first 
phase lasted up to 30 min and accounted for the release of 50 to 60 % of Famotidine. It 
was followed by a slower release phase from 30 min to 4 h.  
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Figure 3.6 Percentage of Released Famotidine from different loaded NPs formulations 
(n=3) 
 
The release of Famotidine from all NP formulations was fast, which might be due to 
the hydrophilic nature of Famotidine (Baseer, et al., 2013, Shoaib, et al., 2010). 
Famotidine release profiles showed no significant influence of graft polymer molecular 
weight, PEG molecular weight, PEG grafting ratios particle size and PVA.   
 
 
 
 
3.4.4. Cytotoxicity  
 
Cell growth is determined by counting viable cells after staining with a vital dye. 
Trypan blue staining is a simple way to evaluate cell membrane integrity (and thus 
infer on cell proliferation or death). PLA is a well-known biodegradable and 
biocompatible polymer and PEG is regarded as having a very low order of toxicity; 
toxicity of the graft polymers was therefore expected to be low (Rowe, et al., 2009). 
Results showed that, after 24 h of contact with the NPs, cell viability ranged from 
100% to 60%at the concentrations tested (0.31, 0.63, 1.25, 2.5, 5 and 10 mg/mL). 
When in contact with pure Famotidine for 24 h, cell viability ranged from 100% to 
80% at the various concentrations tested (0.04, 0.08, 0.17, 0.34, 3.5 and 7.6 mg/mL). 
As its concentration encapsulated in NPs, Famotidine exhibited no toxic effect during 
the transport studies. 
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3.4.5. Transport experiments 
  
Caco-2 cells (a human adenocarcinoma cell line) were used as a well-established and 
reliable model to evaluate intestinal drug absorption, drug permeability and substrate 
activity on efflux transport proteins such as P-gp (Artursson, et al., 2012, Pranav Shah, 
2006). The transport experiments were conducted to evaluate permeability of 
Famotidine and to examine the potential effects of polymer composition (PEG 
molecular weight, grafting density, residual PVA) and NP size on P-gp efflux of 
encapsulated Famotidine across Caco-2 cells in vitro. Different Famotidine-loaded NP 
formulations, physical mixtures (PMs) of Famotidine and blank NPs (at concentrations 
corresponding to drug-loaded NP formulations) as well as PMs of Famotidine with 
PEG 2000 Da and PEG 750 Da were tested. Pure Famotidine and drug-loaded PLA 
NPs (no PEG) were used as control to evaluate the effect of PEG on P-gp efflux of 
Famotidine. Transport experiments were performed in triplicate using Famotidine at 80 
ug/mL applied either on the apical or basal side of the model. In the model, the upper 
surface of the cells represents the apical (mucosal) side while the lower surface 
represents the basolateral (serosal) side. P-gp inhibitors such as PEG act on the 
mucosal side and their in vitro effect will be seen in the upper part of the Caco-2 
model. The formulations most effective at inhibiting P-gp efflux of Famotidine will 
decrease or inhibit the basolateral-to-apical Famotidine transport. The asymmetry 
index, namely the ratio of secretory (basolateral-to-apical) to absorptive (apical-to-
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basolateral) transport, reflects the overall effect of P-gp. Figure 3.7 and Table3.4 show 
that pure Famotidine had an asymmetric index value of 1.01 which means the secretory 
action of P-gp (basolateral-to-apical) compensates for the absorption of Famotidine 
(apical-to-basal) (Rozehnal, et al., 2012). As indicated in Table 3.4, NPs of PLA-g-
5%PEG2000 had the lowest asymmetry index (0.007), followed by NPs prepared from 
PLA-g-5%PEG750 (0.01) and PLA-g-1%PEG750 (0.58), suggesting that P-gp efflux 
inhibition of Famotidine can be attributed to PEG content. Asymmetry index results 
were related more to actually grafting, in case of PLA-g-5%PEG2000 which had 5% 
actually grafting compared with PLA-g-5%PEG750 which had 1% actual grafting. 
Indeed, as PEG content increased the inhibition effect increased, which is consistent 
with the general hypothesis of the study (Hugger, et al., 2003, Iqbal, et al., 2010, Kin-
Kai, et al., 2002, Shen, et al., 2006). 
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Formulations & Combinations AP-BL Papp (cm/s x10-06) ± SD 
BL-AP 
Papp (cm/s x10-06) ± SD AI ± SD
Pure Famotidine 10.45 ± 0.62 10.51 ± 0.9 1.01± 0.11
PLA-g-1%PEG750Da+2.8%FMT 55.34 ± 13.69 30.93 ± 2.26 0.58±0.11
PLA-g-5%PEG750Da+2.2%FMT 45.12 ±  12.9 0.67 ± 0.16 0.01±0.00
PLA-g-1%PEG2000Da+0.8%FMT N/D 0.77 ± 0.29 ***
PLA-g-5%PEG2000Da+1.5%FMT 19.10 ±  8.38 0.13 ± 0.01 0.007±0.0
PM (Blank NPs PLA-g-1%PEG750Da&FMT) N/D 0.30 ± 0.08 ***
PM (Blank NPs PLA-g-5%PEG750Da&FMT) 38.76 ±  31.7 6.23 ± 5.43 0.16±0.01
PM (Blank NPS PLA-g-1%PEG2000Da&FMT) 11.75 ± 6.79 0.3 ± 0.08 0.025±00
PM (Blank NPs PLA-g-5%PEG2000Da&FMT) 84.43 ± 6.8 22.51 ± 1.82 0.27±00
PM(PEG750Da&FMT) 53.25 ± 11.02 5.48 ± 0.1 0.11±0.02
PM(PEG2000Da&FMT) 40.02 ± 21.08 0 ***
*** (AI) was not calculated, N/D: Not detected 
Table 3.4 Results of bidirectional transport of different NP formulations and PMs of 
Famotidine across Caco-2 cell monolayer (n=3) 
 
No results were obtained from bidirectional experiments in case of Famotidine-loaded 
PLA NPs. It can be noticed from the asymmetry index results that increased P-gp 
inhibition is obtained for formulations and mixtures containing 5 mol% PEG, resulting 
in good absorptive transport. This is consistent with other findings (Hugger, et al., 
2002, Hugger, et al., 2003). It has been reported by some authors that NPs absorbed via 
transcellular transport enter  cells by endocytic processes at the cell apical side and, 
after intracellular trafficking, exit by exocytic processes at the basolateral side (M. 
Rabanel, et al., 2012, Monjed, et al., 2004, Rieux, et al., 2006). Surface properties, 
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hydrophobicity and surface charge dictate the behaviour of NPs in vitro and in vivo. In 
this study, the presence of the hydrophilic polymer PEG at the surface of the NPs 
provides an effective way of controlling the interface between NPs and biological 
systems (P-gp in this case) which they are designed to interact with. 
 
 
Figure 3.7 Bidirectional transport study of Famotidine across Caco-2 from different 
NPs formulations and (PM) combinations (n=3) 
 
 
 
3.5. Conclusion 
PLA-g-PEG polymers with different grafting ratios were synthesised and PEG 
molecular weights. The final molecular weight of the graft polymers was consistent 
with the PEG length and grafting ratio used. PLA-g-1%PEG1 polymers were more 
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polydisperse than PLA-g-5%PEG polymers, which might be due to the presence of 
ungrafted PEG in the former case. The grafting of PEG to PLA was confirmed by 1H 
NMR and FTIR. The PLA Tg was detected only for PLA-g-5%PEG750while PEG 
melting was detected for both PLA-g-PEG2000 polymers, confirming the grafting of 
PEG. Together, the 1H-NMR, GPC, FTIR and DSC results indicate that PLA-g-PEG 
polymers with different PEG molecular weights and grafting ratios were successively 
synthesised. Different NP formulations were thus prepared from those polymers. The 
NPs were prepared with mean particle sizes ranging between 156 and 211nm, as 
confirmed by DLS and AFM. The NPs had a unimodal size distribution with PI values 
ranging from 0.026 to 0.139. The zeta potential of the NPs ranged between -4.6 and -
9.9 mV. Based on FTIR, DSC and XRPD results, Famotidine exists in crystal form 
when loaded in PLA-g-1%PEG NPs while they are in amorphous state when loaded in 
PLA-g-5%PEG NPs. Famotidine release from NPs showed a biphasic release 
behaviour. Similar Famotidine release kinetics were obtained for all NP formulations, 
except for PLA-g-1%PEG750 for which a burst was observed. Transport studies across 
Caco-2 membranes showed that Famotidine-loaded NPs prepared from both PLA-g-
5%PEG polymers were able to inhibit the P-gp efflux of Famotidine. Therefore, NPs 
prepared from PLA-g-5%PEG are proposed as promising solid oral formulations to 
improve oral bioavailability of P-gp substrate drugs. 
 
 
 
 
 110 
 
 
 
 
 
3.6. References 
 
N. Akhtar, A. Ahad, R. K. Khar, M. Jaggi, M. Aqil, Z. Iqbal, F. J. Ahmad and S. 
Talegaonkar. The emerging role of P-glycoprotein inhibitors in drug delivery: a patent 
review. Expert Opinion on Therapeutic Patents, 2011;21:561-576 
P. Artursson, K. Palm and K. Luthman. Caco-2 monolayers in experimental and 
theoretical predictions of drug transport. Advanced Drug Delivery Review, 2012;64, 
Supplement:280-289 
D. A. I. Ashiru-Oredope, N. Patel, B. Forbes, R. Patel and A. W. Basit. The effect of 
polyoxyethylene polymers on the transport of ranitidine in Caco-2 cell monolayers. 
International Journal of Pharmaceutics, 2011;409:164-168 
K. Avgoustakis, A. Beletsi, Z. Panagi, P. Klepetsanis, A. G. Karydas and D. S. 
Ithakissios. PLGA-mPEG nanoparticles of cisplatin: in vitro nanoparticle degradation, 
in vitro drug release and in vivo drug residence in blood properties. Journal of 
Controlled Release, 2002;79:123-135 
I. Bala, S. Hariharan and M. Kumar. PLGA nanoparticles in drug delivery: The state of 
the art. Critical Reviews in Therapeutic Drug Carrier Systems, 2004;21:387-422 
 111 
A. B. Baseer, Abdul), F. H. Hassan, Fouzia), S. H. Hassan, Syed Muhammad Fareed), 
S. J. Jabeen, Sabahat), F. I. Israr, Fozia), G. M. Murtaza, Ghulam) and N. H. Haque, 
Naheed). Physico-chemical comparison of famotidine tablets prepared via dry 
granulation and direct compression techniques. Pakistan Journal of  Pharmaceutical 
Sciences, 2013;26:439-443 
V. Bhardwaj, S. Hariharan, I. Bala, A. Lamprecht, N. Kumar, R. Panchagnula and M. 
Kumar. Pharmaceutical Aspects of Polymeric Nanoparticles for Oral Drug Delivery. 
Journal of Biomedical Nanotechnology, 2005;1:235-258 
K.-m. Choi, M.-C. Choi, D.-H. Han, T.-S. Park and C.-S. Ha. Plasticization of 
poly(lactic acid) (PLA) through chemical grafting of poly(ethylene glycol) (PEG) via 
in situ reactive blending. European Polymer Journal, 2013;49:2356-2364 
E.-M. e. a. Collnot. Mechanism of Inhibition of P-Glycoprotein Mediated Efflux by 
Vitamin E TPGS: Influence on ATPase Activity and Membrane Fluidity. Molecular 
Pharmaceutics 
Mol. Pharmaceutics, 2007;4:465-474 
A. Dahan and G. L. Amidon. Segmental Dependent Transport of Low Permeability 
Compounds along the Small Intestine Due to P-Glycoprotein: The Role of Efflux 
Transport in the Oral Absorption of BCS Class III Drugs. Molecular Pharmaceutics, 
2008;6:19-28 
E. Elmowafy, G. Awad, S. Mansour and A. El-Shamy. Release Mechanisms Behind 
Polysaccharides-Based Famotidine Controlled Release Matrix Tablets. Aaps 
Pharmscitech, 2008;9:1230-1239 
 112 
S. Essa, J. M. Rabanel and P. Hildgen. Effect of polyethylene glycol (PEG) chain 
organization on the physicochemical properties of poly(d, l-lactide) (PLA) based 
nanoparticles. European Journal of Pharmaceutics and Biopharmaceutics, 2010;75:96-
106 
M. Estudante, J. G. Morais, G. a. Soveral and L. Z. Benet. Intestinal drug transporters: 
An overview. Advanced Drug Delivery Reviews, 2013;65:1340-1356 
G. G. Ferenczy, L. Parkanyi, J. G. Angyan, A. Kalman and B. Hegedus. Crystal and 
electronic structure of two polymorphic modifications of famotidine. An experimental 
and theoretical study. Journal of Molecular Structure: (Theochem), 2000;503:73-79 
M. Gaumet, A. Vargas, R. Gurny and F. Delie. Nanoparticles for drug delivery: The 
need for precision in reporting particle size parameters. European Journal of 
Pharmaceutics and Biopharmaceutics, 2008;69:1-9 
T. Gorner, R. Gref, D. Michenot, F. Sommer, M. N. Tran and E. Dellacherie. 
Lidocaine-loaded biodegradable nanospheres. I. Optimization of the drug incorporation 
into the polymer matrix. Journal of Controlled Release, 1999;57:259-268 
T. Govender, S. Stolnik, M. C. Garnett, L. Illum and S. S. Davis. PLGA nanoparticles 
prepared by nanoprecipitation: drug loading and release studies of a water soluble 
drug. Journal of Controlled Release, 1999;57:171-185 
R. Gref, G. Miralles and É. Dellacherie. Polyoxyethylene-coated nanospheres: effect of 
coating on zeta potential and phagocytosis. Polymer International, 1999;48:251-256 
F. Hassouna, J.-M. Raquez, F. d. r. Addiego, P. Dubois, V. r. Toniazzo and D. Ruch. 
New approach on the development of plasticized polylactide (PLA): Grafting of 
 113 
poly(ethylene glycol) (PEG) via reactive extrusion. European Polymer Journal, 
2011;47:2134-2144 
A. Hawley, L. Illum and S. Davis. Preparation of Biodegradable, Surface Engineered 
PLGA Nanospheres with Enhanced Lymphatic Drainage and Lymph Node Uptake. 
Pharmaceutical Research, 1997;14:657-661 
E. D. Hugger, K. L. Audus and R. T. Borchardt. Effects of poly(ethylene glycol) on 
efflux transporter activity in Caco-2 cell monolayers. Journal of Pharmaceutical 
Sciences, 2002;91:1980-1990 
E. D. Hugger, C. J. Cole, T. J. Raub, P. S. Burton and R. T. Borchardt. Automated 
analysis of polyethylene glycol-induced inhibition of P-glycoprotein activity in vitro. 
Journal of Pharmaceutical Sciences, 2003;92:21-26 
E. D. Hugger, B. L. Novak, P. S. Burton, K. L. Audus and R. T. Borchardt. A 
comparison of commonly used polyethoxylated pharmaceutical excipients on their 
ability to inhibit P-glycoprotein activity in vitro. Journal of Pharmaceutical Sciences, 
2002;91:1991-2002 
A. C. Hunter, J. Elsom, P. P. Wibroe and S. M. Moghimi. Polymeric particulate 
technologies for oral drug delivery and targeting: a pathophysiological perspective. 
Nanomedicine: Nanotechnology, Biology and Medicine, 2012;8, Supplement 1:S5-S20 
J. Iqbal, J. Hombach, B. Matuszczak and A. Bernkop-Schnurch. Design and in vitro 
evaluation of a novel polymeric P-glycoprotein (P-gp) inhibitor. Journal of Controlled 
Release, 2010;147:62-69 
 114 
T. Jiang, N. Han, B. Zhao, Y. Xie and S. Wang. Enhanced dissolution rate and oral 
bioavailability of simvastatin nanocrystal prepared by sonoprecipitation. Drug 
Development and Industrial Pharmacy, 2012;38:1230-1239 
V. A. J-M. Rabanel1, and P. Hildgen1. Impact of Polymer Physico-chemical Properties 
on PEG-grafted-PLA Nanoparticles Structure. CRS  annual meeting, 2012;2012 CRS 
37th annual meeting: 
C. N. Kiho Lee, Kim L. R. Brouwer, and Dhiren R, Thanker. Secretory Transport of 
Rantidine and Famotidine across CaCo-2 cell Monolayers. The Journal of 
Pharmacology and Experimental Therapeutics, 2002;303:574-580 
H. Kin-Kai, D. H. Giesing, G. H. Hurst and US6451815. Aventis Pharmaceuticals, Inc. 
Method of enhancing bioavailability of fexofenadine and its derivatives. US6451815, 
2002; 
A. Lamprecht, N. Ubrich, M. Hombreiro Perez, C.-M. Lehr, M. Hoffman and P. 
Maincent. Influences of process parameters on nanoparticle preparation performed by a 
double emulsion pressure homogenization technique. International Journal of 
Pharmaceutics, 2000;196:177-182 
S.-D. Li and L. Huang. Pharmacokinetics and Biodistribution of Nanoparticles. 
Molecular Pharmaceutics, 2008;5:496-504 
S.-Y. Lin, W.-T. Cheng and S.-L. Wang. Thermodynamic and kinetic characterization 
of polymorphic transformation of famotidine during grinding. International Journal of 
Pharmaceutics, 2006;318:86-91 
 115 
P. Liu, X. Rong, J. Laru, B. van Veen, J. Kiesvaara, J. Hirvonen, T. Laaksonen and L. 
Peltonen. Nanosuspensions of poorly soluble drugs: Preparation and development by 
wet milling. International Journal of Pharmaceutics, 2011;411:215-222 
J. M. Rabanel, V. Aoun, I. Elkin, M. Mokhtar and P. Hildgen. Drug-Loaded 
Nanocarriers: Passive Targeting and Crossing of Biological Barriers. Current 
Medicinal Chemistry, 2012;19:3070-3102 
E. Merisko-Liversidge, G. G. Liversidge and E. R. Cooper. Nanosizing: a formulation 
approach for poorly-water-soluble compounds. European Journal of Pharmaceutical 
Sciences, 2003;18:113-120 
O. Mert, S. K. Lai, L. Ensign, M. Yang, Y.-Y. Wang, J. Wood and J. Hanes. A 
poly(ethylene glycol)-based surfactant for formulation of drug-loaded mucus 
penetrating particles. Journal of Controlled Release, 2012;157:455-460 
G. Mittal, D. K. Sahana, V. Bhardwaj and M. N. V. Ravi Kumar. Estradiol loaded 
PLGA nanoparticles for oral administration: Effect of polymer molecular weight and 
copolymer composition on release behavior in vitro and in vivo. Journal of Controlled 
Release, 2007;119:77-85 
S. Monjed, P. Gilles and F. Elias. Particle uptake by Peyer's patches: a pathway for 
drug and vaccine delivery. Expert Opinion on Drug Delivery, 2004;1:141-163 
B. Morakul, J. Suksiriworapong, J. Leanpolchareanchai and V. B. Junyaprasert. 
Precipitation-lyophilization-homogenization (PLH) for preparation of clarithromycin 
nanocrystals: Influencing factors on physicochemical properties and stability. 
International Journal of Pharmaceutics Special Section: Formulating Better Medicines 
for Children, 2013;457:187-196 
 116 
V. Nadeau, G. Leclair, S. Sant, J.-M. Rabanel, R. Quesnel and P. Hildgen. Synthesis of 
new versatile functionalized polyesters for biomedical applications. Polymer, 
2005;46:11263-11272 
D. E. Owens  and N. A. Peppas. Opsonization, biodistribution, and pharmacokinetics 
of polymeric nanoparticles. International Journal of Pharmaceutics, 2006;307:93-102 
A. Panoyan, R. Quesnel and P. Hildgen. Injectable nanospheres from a novel 
multiblock copolymer: Cytocompatibility, degradation and in vitro release studies. 
Journal of Microencapsulation, 2003;20:745-758 
V. B. Patravale, A. A. Date and R. M. Kulkarni. Nanosuspensions: a promising drug 
delivery strategy. Journal of Pharmacy and Pharmacology, 2004;56:827-840 
V. J. Pranav Shah, Tamishraha Bagchi, Ambianandan Misra. Role of Caco-2 Cell 
Monolayers in Prediction of Intestinal Drug Absorption. Biotechnology Progress, 
2006;22:186-198 
S. Ramachandran, S. Nandhakumar and M. D. Dhanaraju. Formulation and 
Characterization of Glutaraldehyde Cross-Linked Chitosan Biodegradable 
Microspheres Loaded with Famotidine. Tropical Journal of Pharmaceutical Research, 
2011;10:309-316 
H. M. Redhead, S. S. Davis and L. Illum. Drug delivery in poly(lactide-co-glycolide) 
nanoparticles surface modified with poloxamer 407 and poloxamine 908: in vitro 
characterisation and in vivo evaluation. Journal of Controlled Release, 2001;70:353-
363 
 117 
A. d. Rieux, V. Fievez, M. Garinot, Y.-J. Schneider and V. Preat. Nanoparticles as 
potential oral delivery systems of proteins and vaccines: A mechanistic approach. 
Journal of Controlled Release, 2006;116:1-27 
V. Rozehnal, D. Nakai, U. Hoepner, T. Fischer, E. Kamiyama, M. Takahashi, S. 
Yasuda and J. Mueller. Human small intestinal and colonic tissue mounted in the 
Ussing chamber as a tool for characterizing the intestinal absorption of drugs. 
European Journal of Pharmaceutical Sciences, 2012;46:367-373 
N. G. Sahoo, M. Kakran, L. A. Shaal, L. Li, R. H. Muller, M. Pal and L. P. Tan. 
Preparation and characterization of quercetin nanocrystals. Journal of Pharmaceutical 
Sciences, 2011;100:2379-2390 
S. K. Sahoo, J. Panyam, S. Prabha and V. Labhasetwar. Residual polyvinyl alcohol 
associated with poly (d,l-lactide-co-glycolide) nanoparticles affects their physical 
properties and cellular uptake. Journal of Controlled Release, 2002;82:105-114 
S. Sant, S. Poulin and P. Hildgen. Effect of polymer architecture on surface properties, 
plasma protein adsorption, and cellular interactions of pegylated nanoparticles. Journal 
of Biomedical Materials Research Part A, 2008;87A:885-895 
S. Sepassi, D. J. Goodwin, A. F. Drake, S. Holland, G. Leonard, L. Martini and M. J. 
Lawrence. Effect of polymer molecular weight on the production of drug 
nanoparticles. Journal of Pharmaceutical Sciences, 2007;96:2655-2666 
Q. Shen, Y. Lin, T. Handa, M. Doi, M. Sugie, K. Wakayama, N. Okada, T. Fujita, et al. 
Modulation of intestinal P-glycoprotein function by polyethylene glycols and their 
derivatives by in vitro transport and in situ absorption studies. International Journal of 
Pharmaceutics, 2006;313:49-56 
 118 
S. Shilpa, N. Ve´ronique and P. Hildgen. Effect of porosity on the release kinetics of 
propafenone-loaded PEG-g-PLA nanoparticles. Journal of Controlled Release, 
2005;107:203-214 
M. Shoaib, S. Al Sabah Siddiqi, R. Yousuf, K. Zaheer, M. Hanif, S. Rehana and S. 
Jabeen. Development and Evaluation of Hydrophilic Colloid Matrix of Famotidine 
Tablets. AAPS PharmSciTech, 2010;11:708-718 
K. S. Soppimath, T. M. Aminabhavi, A. R. Kulkarni and W. E. Rudzinski. 
Biodegradable polymeric nanoparticles as drug delivery devices. Journal of Controlled 
Release, 2001;70:1-20 
M. Tobio, R. Gref, A. Sanchez, R. Langer and M. J. Alonso. Stealth PLA-PEG 
Nanoparticles as Protein Carriers for Nasal Administration. Pharmaceutical Research, 
1998;15:270-275 
A. Vila, H. Gill, O. McCallion and M. Ì. a. J. Alonso. Transport of PLA-PEG particles 
across the nasal mucosa: effect of particle size and PEG coating density. Journal of 
Controlled Release, 2004;98:231-244 
K. Yoncheva, E. Lizarraga and J. M. Irache. Pegylated nanoparticles based on 
poly(methyl vinyl ether-co-maleic anhydride): preparation and evaluation of their 
bioadhesive properties. European Journal of Pharmaceutical Sciences, 2005;24:411-
419 
L. Yu. Amorphous pharmaceutical solids: preparation, characterization and 
stabilization. Advanced Drug Delivery Reviews Characterization of the Solid State, 
2001;48:27-42 
 
 119 
Page de liaison 
 
The results of the first article have demonstrated usefulness of synthesized grafted 
polymer (PLA-g-PEG) to prepare Famotidine loaded NPs to be used as P-gp efflux 
inhibitor of Famotidine. It was reported that PEG has an inhibition effect of P-gp 
efflux. The impact of PEG of two molecular weights (750 Da and 2000 Da) at two 
grafting ratios (1% and 5%) on P-gp efflux was evaluated. CaCo-2 cell monolayer in 
vitro model was used to evaluate the effect of different NPs formulations on P-gp. It 
was thought the NPs formulations that containing more PEG will have more inhibition 
effect on P-gp efflux, therefore  it was assumed that NPs having PEG 2000 Da at 5% 
grafting  ratio will have significant effect on P-gp efflux of Famotidine. Even though 
there is no a clear explanation for PEG mechanism by which it inhibits the P-gp 
function, PLA-g-5%PEG was found more effective irrespective to the tested PEG 
molecular weights. As mentioned in the hypothesis section increased PEG 
concentration improved the inhibition effect on P-gp. Thus, in continuation with the 
results obtained from the first study, further studies were planned to explore the 
applications of selected 5% grafted NPs formulations. In this second article, the 
development of a tablet formulations based on NPs was undertaken to evaluate their 
effect on P-gp compared to a reference commercial Famotidine tablet formulation. 
Thus, the work of the second article focuses on developing tablet formulation, 
evaluating transport study across Caco-2 and evaluating the impact of compressing 
forces on NPs properties.   
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Résumé : 
 
L’objectif de cette étude est d’évaluer les nanoparticules de famotidine inhibitrices de 
P-gp ((NPs) comme une partie de la formulation d’un dosage solide. Les 
nanoparticules de famotidine ont été préparées par évaporation d’émulsion de solvants 
en utilisant le polymère PLA-g-5%PEG de poids moléculaire de 750 et 2000 Da. Les 
comprimés renfermaient 40% de nanoparticules  famotidine, 52.5% de cellulose 
microcristalline, 7% d’amidon prégélatinisé comme agent liant/désintégrant et 0.5% 
stéarate de magnésium comme lubrifiant. Les comprimés contenant 1.6 mg de 
famotidine ont été préparés avec une moyenne de 500 mg, une épaisseur allant de 6.2 à 
6.5 mm, une dureté de 5 à 8 kp et un temps de désintégration de moins d’une minute. 
Les résultats obtenus suggèrent que les NPs contenant la famotidine peuvent être 
formulés comme une formulation orale solide toute en inhibant les P-gp quelque soit le 
poids moléculaire du PEG et peut alors améliorer la perméabilité orale ainsi que la 
biodisponibilité. 
 
 
 
 
 
 
 
 122 
4.1. Abstract 
 
The objective of this study was to evaluate the use of P-gp inhibiting Famotidine (P-gp 
substrate drug model) loaded nanoparticles (NPs) as a part of a suitable oral solid 
dosage form. Famotidine loaded NPs were prepared by solvent emulsion evaporation 
method using PLA-g-5%PEG grafted polymer using two PEG molecular weights 2000 
and 750 Da. Tablet formulation was composed of 40 % Famotidine loaded NPs, 52.5 
% microcrystalline cellulose as filler, 7 % pregelatinazed starch as binder/disintegrant 
and 0.5 % magnesium stearate as lubricant. Tablet containing 1.6 mg of Famotidine 
were prepared at an average  weight of  500 mg, thickness of 6.2 to 6.5mm,  hardness 
of  5 to 8 kp and disintegration time was less than one minute. The obtained results 
suggest that NPs from grafted PEG-g-PLA polymers loaded with Famotidine can be 
formulated as an oral solid dosage form while effectively inhibit P-gp efflux 
irrespective to PEG molecular weights and therefore could represent a formulation 
alternative to enhance oral permeability and oral bioavailability of P-gp substrate. 
 
4.2. Introduction 
 
Bioavailability is defined as the fraction of dose which could reach the systemic 
circulation. Generally, orally administrated drug could be affected by many factors 
such as drug solubility, absorption, permeability and gut wall metabolism(1). The 
most studied transporter protein responsible for efflux drug from cells is permeability 
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glycoprotein P-gp(2-4). P-gp acts as a pump to lower drug intracellular concentration 
by secretion of drug molecules from intracellular to lumen side so it reduces 
permeability and bioavailability of drug (P-gp efflux)(3, 4). Famotidine is a histamine 
H2-receptor antagonist used to treat peptic ulcer; gastroesophageal reflux; and 
Zollinger-Ellison syndrome(5). Although Famotidine was reported to be more potent 
that Ranitidine and Cimetidine, its oral bioavailability is low due mainly to P-gp 
efflux(6, 7). Poly lactic acid (PLA) and Polyethylene glycol (PEG) are used as drug 
delivery pharmaceutical excipients in a wide range of pharmaceutical 
formulations(8). PEG is also used to modify nanoparticles (NPs), dendrimers and 
excipients  surface to avoid cell recognition and to inhibit P-gp efflux(9-11). 
Nanoparticles (NPs) generally are used to protect and stabilize drug molecules in 
GIT(12). To overcome P-gp efflux of Famotidine, dispersion within pegylated 
(PEG5%-g-PLA) nanoparticles (NPs) can be used to protect, stabilize and block P-gp 
pump activity(13). CaCo-2  as in vitro model was used to evaluate NPs ability to 
inhibit P-gp efflux. The aim of the study was to develop a tablet formulation based on 
those Famotidine loaded NPs and to evaluate its inhibition function on P-gp efflux. 
Dry granulation was used to improve NPs flow properties therefore it was necessary 
to find suitable excipients with good compactability and disintegrating ability. 
Tablets were assessed for in vitro evaluation of Famotidine permeability and 
compared to commercial Famotidine (Pepcid®). 
 
 
 124 
4.3. Materials and Methods 
4.3.1. Materials 
Famotidine (lot no: 02-0024), microcrystalline cellulose 200 (Blanver lot 
no:12122/10), starch pregelatinazed (Starch 1500, Colorcon) and magnesium stearate 
(Ligamed MF-2-V, Peter Greven,) were obtained from Corealis Pharma Inc (Montreal, 
Canada). Commercial Famotidine tablet 10 mg (Pepcid®) was purchased from 
Pharmaprix (Montreal, Canada). All other materials and solvents were purchased from 
Laboratoire MAT (Montreal, Canada) and Sigma-Aldrich (St-Louis, USA) and used 
without further purification. All materials for cell culture were purchased from 
Invitrogen (Burlington, Canada).   
 
4.3.2. Polymer Synthesis and Characterization 
  
 
Poly(ethylene glycol) (PEG) grafted randomly on poly (D,L)-Lactide were synthesized 
in the laboratory and details procedure is described in the previous work(14-16). PEG 
grafting of two molecular weights (750 and 2000 Da) was performed at 5 % density 
ratio (mol/mol of lactic acid). In brief, the homopolymer ploy (D, L)-lactide was 
synthesized by ring-opening polymerization of dilactide under argon at 180 °C for 6 h 
using tetraphenyltin as catalyst. The synthesized polymer with allyl group was oxidized 
to hydroxyl group by hydroboration then to carboxylic acid groups by Jones reagent. 
Finally, methoxy poly (ethylene glycol) (MePEG) was grafted onto the polymer. 1H 
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NMR spectra were recorded using a Bruker ARX 400 spectrometer (Germany). 10 to 
20 mg samples of each polymer were dissolved in CDCl3 and Chemical shift (d) was 
measured in ppm using tetramethylsilane (TMS) as an internal reference. The number 
(Mn) and the weight average molecular weights (Mw) of synthesized polymers were 
determined by gel permeation chromatography (GPC). Waters associate 
chromatography system model 717 (Waters, USA) equipped with a refractive index 
detector model 410 and a Phenogel 5 µm column (Phenomenex, USA) was used. 
Polystyrene standards were used for calibration with chloroform as a mobile phase at a 
flow rate of 0.6 mL/min. Fourier transform infrared (FTIR) spectroscopy was used to 
characterize the functional groups of PLA and PEG of PLA-g-PEG polymers. The 
spectra of polymers were recorded using a Nicolet iS10spectrometer (Madison, WI). 
All spectra were recorded at ambient temperature at a resolution of 2 cm−1 and 64 
times scanning for each measurement to obtain an adequate signal-to-noise ratio. The 
IR spectra were recorded in transmission mode with dry powder of polymers, which 
were spread on a sample holder stage and scanned from 4000 cm-1 to 400 cm-1. 
 
4.3.3. Nanoparticles Preparation and Characterization 
 
NPs preparation is described in previous work (13). Briefly, NPs were prepared by 
dissolving the drug and PEG-g-PLA polymer in solvents (DCM/DMF) and 0.5% of 
PVA was used to produce stable emulsion droplets. NPs were prepared by (oil/water) 
emulsion-solvent evaporation method using high-pressure homogenizer (HPH) 
Emulsiflex C30 (Avestin, ON, Canada). The emulsion was collected then solvents 
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were evaporated under vacuum pressure. Suspensions were centrifuged then 
lyophilized to obtain dry NPs. Same process was used for blank NPs except for the 
addition of Famotidine. 
  
4.3.3.1. Particle Size and Size Distribution 
Loaded NPs before, after  compression and placebo blend (same excipients without 
NPs) were measured to evaluate the impact of tablet compressing on NPs. NPs size and 
size distribution were measured by dynamic light scattering (DLS) using a ZetaSizer 
Nanoseries ZS (Malvern instrument, Worcester, UK). NPs were resuspended in Milli-
Q water (0.01%w/v) and ultrasonicated for three minutes prior to measurement in order 
to break aggregates. Three runs and three measurements of particle size analysis were 
performed at 25°C.  
 
4.3.3.2. Surface Charge (Zeta Potential) 
Surface charges of NPs were measured in triplicate using a Zeta Sizer Nanoseries ZS 
(Malvern instrument, Worcester, UK). NPs were suspended in 10 mM sodium chloride 
aqueous solutions and measurements were carried out at 25°C. The mean value and 
standard deviation were calculated from triplicate measurements of each sample.  
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4.3.3.3. Drug Loading and Encapsulation Efficiency  
Encapsulation efficiency NPs was determined by adding 10 mL of 1N NaOH aqueous 
solution to 10 mg of NPs under stirring for 30 min. Sample analysis were performed in 
triplicate using  high performance liquid chromatography (Shimadzu LC-2010HT, 
Kyoto, Japan) with SPD-20A UV/vis detector, and a Hyperclone 5 microns packing 
130 A pore size BDS C18 column (Phenomenex, CA,USA). The mobile phase used 
was composed of a mixture of phosphate buffer solution pH 6.0 and methanol (10/90 
%v/v) at a flow rate of 1 mL/min and Famotidine was measured at 267 nm. 
Encapsulation efficiency (EE) was calculated as the percentage of drug entrapped in 
NPs compared to the initial amount of drug in the solvent phase using the following 
Equation 4.1  
Equation 4.1 
ܧܧ% = Amount	of	drug	entrapped	in	NPsInitial	amount	of	drug	added	into	the	solvent	phase x100					 
Drug loading (DL) of NPs was calculated as percentage of drug entrapped in NPs 
compared to the total weight of NPs using the following Equation 4.2: 
Equation 4.2  
ܦܮ% = ܣݏݏܽݕ	݋݂	ܨܽ݉݋ݐ݅݀݅݊݁	݁݊ݐݎܽ݌݌݁݀	݅݊	ܰܲݏܶ݋ݐ݈ܽ	ݓ݁݅݃ℎݐ		݋݂	ܰܲݏ 	ܺ	100 
 
4.3.4. Tablet formulation 
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4.3.4.1. Excipients Selection  
Tablet dosage form was chosen in this study because of it represents the most popular 
route amongst other dosage forms and also to ease comparison with commercial 
Famotidine tablet formulation(17). Generally the pharmaceutical excipients are added 
to aid the formulation manufacture, facilitate the preparation and ensure active 
ingredient uniformity, stability,  patient compliance and proper drug delivery. 
Therefore the excipients in this study were selected to develop an oral formulation 
based on their known compatibility with the drug and in order to ensure immediate 
release of Famotidine. Microcrystalline cellulose (MCC) was chosen as diluent 
because of its good compressibility. Pregelatinized starch was used as disintegrant and 
magnesium stearate as a lubricant. Those inactive ingredients are used in Famotidine 
commercial tablet Pepcid®. 
 
4.3.4.2. Tablet Formulation 
 
Two tablet formulations based on Famotidine loaded NPs loaded were prepared. First 
formulation (F1) was composed of NPs prepared from PLA-g-5%PEG2000Da and 
second formulation (F2) was composed of NPs prepared from PLA-g-5%PEG750Da. 
Formulation composition consists of 40 % Famotidine loaded NPs with a weights of 
200 mg (containing 1.6 mg Famotidine), 52.5% of micro crystalline cellulose (MCC) 
(262 mg) as a diluents, 7% of pregelatinized starch or 35 mg and 0.5% magnesium 
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stearate as lubricant (2.5 mg). The tablets contained high quantity of NPs due to low 
encapsulation efficiency of prepared Famotidine loaded NPs.  
 
4.3.4.3. Dry Granulation 
NPs had very poor flow properties and low density values as per small particle size. 
Therefore dry granulation technique was chosen to improve those properties(18, 19). 
NPs, MCC and starch were sieved over 30 mesh, weighed then mixed in V-shape 
blender Blend master Lab Patterson-Kelley (East Stroudsburg, PA, USA) for 5 minutes 
at 25 rpm. Single station carver press (Carver Laboratory Press, MN, USA) was used 
to fabricate slugs after weighing. Slugs were directly compressed at a constant 
compression force (300 lbs). 
 
4.3.4.4. Tablet Compression 
Compressed slugs from dry granulation technique were gently crushed in the mortar 
and sieved with 35 mesh screen. Mg stearate was added to powder blend and mixed 
using the same V-shape blender for 2 minutes. Finally powder blend was compressed 
using a Carver type single punch tablet press at 500 Lbf force to fabricate 500 mg 
standard concave 12 mm diameter tablets (Sami Precision Machining tooling, Canada).  
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4.3.4.5. Tablet Formulation Characterization  
 
4.3.4.5.1. Bulk & Tapped Density, Powder Flow  
 
Powder flow is a very critical parameter in tablets and capsules production to obtain a 
uniform feed, reproducible matrix filling and tablet weight. Carr’s index and Hausner’s 
ratios were characterized in order to evaluate the flow properties of powder blends 
containing NPs to be compressed into tablets. Density measurements were done with a 
Vankel tap density tester model 10700 (Edison, NJ, USA) according to USP(20). To 
carry out bulk density, fixed weights of powder were placed in a 50 mL graduated 
cylinder and the volume occupied was measured. For tapped density, graduated 
cylinder was then tapped at a constant velocity until a constant volume is obtained. 
Carr’s compressibility index and Hausner’s ratio were calculated for NPs powder and 
formulation blend powders before and after dry granulation. The Carr’s 
compressibility index was calculated by following Equation 4.3: 
Equation 4.3  
Carr's Index  =       ୘ୟ୮୮ୣୢ	ୢୣ୬ୱ୧୲୷ି୆୳୪୩	ୢୣ୬ୱ୧୲୷୘ୟ୮୮ୣୢ	ୢୣ୬ୱ୧୲୷  
and Hausner’s ratio was calculated by the following Equation 4.4 : 
Equation 4.4  
Hausner ratio =           ୘ୟ୮୮ୣୢ	ୢୣ୬ୱ୧୲୷୆୳୪୩	ୢୣ୬ୱ୧୲୷  
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4.3.4.5.2. Particle Size and Size Distribution of Powder Blends 
 
The size and particles size distribution (PSD) of the blend powder before and after dry 
granulation of F1 and F2 were determined in dry-dispersion mode using a Malvern 
Mastersizer 2000 equipped with a Scirocco 2000 module (measuring range of 0.02 to 
2000μm). The measurement parameters of this method are air pressure (4 bar), feed 
rate (50 %), sample tray and sample mass (100 mg). The size and particle size 
distribution are reported in term of volume.  
 
 
 
4.3.4.5.3. Tablet Weight, Thickness and Hardness  
 
Tablet weights were measured using a precision balance (Mettler Toledo AG104, 
Switzerland). The thickness of tablets were measured  using a Mitutoyo micrometer 
(Kanagawa, Japan). The crushing strength of the tablets were measured using a Vander 
Kamp tablet hardness tester model VK 200 (Edison, NJ, USA). The mean and the 
relative standard deviation values of tablets produced were calculated. 
 
4.3.4.5.4. Tablet Disintegration 
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Tablet disintegration was measured by QC-21 disintegration test system Hanson  
Research (Chatsworth, CA, USA) as directed by USP(20). A tablet was placed in each 
six tubes of the basket apparatus in 900 mL of water at 37 ± 2°C as immersion fluid. 
The time was monitored for complete disintegration of all tablets with no palpable 
mass remaining in the apparatus.   
 
4.3.4.5.5. Thermal Properties by Differential Scanning Calorimetry 
(DSC) 
 
Thermal characterizations were carried out using a TA Universal analysis Q20 (TA 
instruments, DE, USA). Samples of approximately 8 mg of polymers, NPs, two NPs 
based crushed tablets formulations (F1&F2) and commercial Famotidine were sealed 
in flat bottom aluminum pans with lids. Samples were analyzed in triplicate at a 
temperature range from -35 to 200°C at a heating rate of 10°C /min under a nitrogen 
purge of 50 mL/min. Indium was used as the calibration standard. 
4.3.4.5.6. Crystallinity of Famotidine in Tablets Formulations by 
XRPD 
 
The crystal structure was studied by X-ray powder diffractometry using Bruker X-ray 
diffractometer model D2 phaser (Karlsrushe, Germany), with a CuKα radiation source 
(ʎ= 1.59A°) at 30 kv and 10 mA equipped with LynxEye detector angular opening 
2.49239°. The opening slit, scatter plate and detector windows were 0.6 mm, 1.0 mm 
and 3 mm, respectively. The measurements were made over a range of 4 to 40° 2θ at 
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an increment of 0.02°, and the time per step 0.5s at a scanning speed of 3.4o  per min. 
Samples of two NPs based powder blends and crushed commercial Famotidine tablets 
were analyzed using a low volume sample holder. 
 
 
 
4.3.4.6. Drug Release 
 
In vitro Famotidine release from  two NPs, two NPs based tablet formulations and 
commercial Famotidine were evaluated by dialysis bag diffusion technique described 
in details  in previous work(13). Tablets were gently crushed in mortar with pestle 
then, known amount of samples were  evaluated to quantify Famotidine at 
predetermined time intervals (5, 15, 30, 60, 120 and 240 min). HPLC method 
described earlier in encapsulation efficiency section was used to quantify Famotidine 
released from NPs.  
4.3.4.6.1. Tablet Release Stability  
 
Tablets of the two formulations (F1 and F2) in HDPE bottles closed with induction seal 
PP caps were subjected to 4 weeks accelerated stability study by exposing the samples 
at 40 ± 2° C and relative humidity of 75 ± 5 % in programmable test chamber (Thermo 
Scientific forma environmental chamber model 39-40). Thermal analysis and drug 
release were evaluated after the storage period. 
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4.3.4.7. Drug Dissolution 
The in vitro dissolution studies were carried out and the dissolution rates of 
Famotidine from NPs tablets and commercial tablet formulations were determined 
using USP dissolution test apparatus type II rotating paddle (Distek 2100 C, USA). 
The apparatus containing 900 ml of pH 4.5 (0.1 M phosphate buffer 13.6g/L of 
monobasic potassium phosphate) at 37 ± 0.5 °C(20). Six tablets of each formula were 
placed in individual 900 ml vessels. The paddle rotated at 50 rpm, then, 3 ml from the 
dissolution medium were withdrawn at predetermined time intervals(5, 10, 15, 30, 45 
and 60 min).  Samples were filtered through 0.45 µm and analyzed by HPLC 
described in section 1.3.3.3.  
 
4.3.4.8. In-Vitro Permeability Evaluation of Oral Tablet 
Formulations 
 
 
 
4.3.4.8.1. Cell Culture  
 
Caco-2 cells were cultured at 37°C in DMEM as described in details in previous work 
(13). Culture medium was changed in both compartments the day after seeding and 
every successive day (Apical volume 0.5 ml, Basolateral volume 1.5 ml). Caco-2 cells 
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monolayer were used 21-28 days postseeding. The integrity of the cell monolayers 
during the growth phase was monitored by TEER reading using an EVOM™ epithelail 
Tissue voltohmmter and a Millipore Corp Endohm-12 electrode (Sarasota, USA). 
 
 
 
 
4.3.4.8.2. Transport Study 
 
Transport study was done to evaluate the effect of tablet formulations on the 
Famotidine P-gp efflux across CaCo-2 in vitro model compared to commercial 
formulation. Transport study was carried out for five different formulations, first 
formulation (F1) loaded NPs prepared from PLA-g-5%PEG2000Da, second 
formulation (F2) loaded NPs PLA-g-5%PEG750Da, first physical mixtures 
formulation (PM1) blank NPs of PLA-g-5%PEG2000Da with Famotidine, second 
physical mixture formulation (PM2) blank NPs of PLA-g-5%PEG750Da with 
Famotidine and commercial Famotidine. Physical mixtures were prepared with the 
same excipients used in F1 and F2 with respect to the quantity of NPs and Famotidine. 
Gently crushed tablets using mortar and pestle  were used  in the transport study.  Cell 
monolayers were pre-incubated for 30 minutes at 37º C in transport Hanks Buffer 
supplement solution (HBSS). Basolateral to apical and apical to basolateral transport 
experiments were performed by adding 1.5 and 0.4 mL of solutions, respectively, 
containing 80 μg/mL Famotidine or its corresponding quantities of different 
combinations. Transport study was carried out in triplicate for each formulation. High 
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performance liquid chromatography method described in section 4.3.3.3 was used to 
quantify Famotidine in basolateral and apical compartments over four hours. From 
these results, calculations allowed to obtain the apparent permeability coefficients in 
both directions as well as the asymmetry index of the transport. The apparent 
permeability coefficient is determined from the amount of Famotidine diffused with 
time. Papp is calculated according to the following Equation 4.5:  
    Equation 4.5  
ܲܽ݌݌	(ܿ݉	ݏିଵ) = (݀ܳ ݀ݐ)	(1 (ܣܥ଴⁄⁄ )) 
 
Where dQ/dt is the rate of permeation, C0 is the initial concentration of Famotidine in 
the donor cell (either basal or apical compartment), and A is the area of the cells 
monolayer. The asymmetry index allows identification of potential P-gp substrates. 
Indeed, this efflux ratio is determined by dividing the Papp value in the BL-AP 
direction by the corresponding value in AP-BL direction. An index greater than 1.0 
indicates predominance of secretory transport suggesting the presence and action of an 
efflux transporter such as P-gp.   
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4.3.4.9. Data Analysis 
All the experiments were conducted at least in triplicate (n=3) and results were 
expressed  as mean ± standard deviation unless otherwise noted. Statistical 
significance was evaluated by one-way analysis of variance(ANOVA) using 
SigmaStat software version 3.1. The effect of PEG from all formulations on the P-gp 
efflux of Famotidine from transport study was evaluated using one-way analysis of 
variance (ANOVA) with the Holm-Sidak comparisons versus control (Pure 
Famotidine). The significant effect of treatment/level of statistical significance was 
judged as being p < 0.05, with a confidence limit of 95%.  
 
 
4.4. Results and Discussion 
 
4.4.1. Polymer Characterization 
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1H NMR spectrums (Figure 4.1) of grafted polymers (PLA-g-PEG) showed the two 
main peaks of PLA. First PLA peak at 5.2 pmm (1) corresponding to the tertiary PLA 
proton (m, –CH), and another peak at 1.5 ppm (3) for the pendant methyl group of the 
PLA chain (m, –CH3). Moreover, spectrum showed PEG peak at 3.6 pmm (2) for the 
protons of the repeating units in the PEG chain (m, OCH2–CH2O). 1H NMR spectrums 
for grafted polymers was consistent with previous  findings(13, 14). GPC analysis 
(Table 4.1) showed consistency with PEG molecular weight grafting ratio used. 
Indeed, average molecular weights were 16621 and 12905  Da and the average number 
molecular weight were 21137 and 17330 Da, respectively, for PLA-g-5%PEG750Da 
and PLA-g-5%PEG2000Da grafted polymers. Polydispersity index (PDI) results 
(Table 4.1) were similar for both polymers and  showed narrow molecular weights 
distribution. FTIR scans were done for pure PLA, pure PEG and the two grafted PEG-
g-PLA polymers. The characteristic stretch bands of PLA and PEG, at 1747 cm-1 and at 
2883 cm-1 respectively, were used as a reference to be compared to the spectrum from 
PLA-g-5%PEG grafted polymers(21, 22). FTIR scans of the two synthesized polymers 
from Figure 4.2 showed that both characteristic peaks of PLA and PEG were detected. 
DSC results (Table 4.1) showed only PLA glass transition temperature (Tg) for PLA-g-
5%PEG750Da was detected at 29.68°C, while PLA Tg could not be measured due to 
the interference with PEG melting point at 53.42oC for PLA-g-5%PEG2000Da 
polymer.  More details on polymer synthesis and characterization can be found in 
previous work(13) 
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Figure 4.1 NMR for grafted PLA-g-5%PEG2000Da polymer 
 
 
Polymer Composition Mw (Da) Mn (Da) PDI 
PEG m.p 
(oC) 
PLA Tg (oC) 
PLA-g-5%PEG750Da 16621 12905 1.29 N/D 29.68 ± 1.87 
PLA-g-5%PEG2000Da 21137 17330 1.22 53.42 ± 0.39 N/D 
m.p=melting point, Tg= glass transition temperature, N/D Not detected,     (n=3) 
 
Table 4.1 Molecular weights, PDI and DSC results for PEG-PLA  grafted polymers 
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Figure 4.2 FTIR Spectrum of pure PLA, PEG and two grafted polymers 
 
4.4.2. Nanoparticles Characterization 
 
Particle size and size distribution obtained by dynamic light scattering of two NPs 
formulations are shown in Table 4.2. PLA-g-5%PEG750Da and PLA-g-
5%PEG2000Da NPs had similar mean particle size of  211 and 217 nm, respectively. 
The  polydispersity index (PI)  values were 0.11 for NPs prepared from PLA-g-
5%PEG750Da and 0.05 for NPs prepared from PLA-g-5%PEG2000Da. NPs had low 
PI value (homogenous samples) which demonstrated a unimodal size distribution(23). 
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Table 4.2 showed that zeta potential of loaded NPs prepared from PLA-g-
5%PEG750Da and PLA-g-5%PEG2000Da were -4.6 and  -7.7 mV, respectively. The 
observed  low zeta potential values of  NPs were attributed mainly due to the residual 
PVA amount associated with NPs preparation(24, 25). Low zeta potential values of 
NPs in agreement with reported results for similar polymers(26). Table 4.2 also shows 
that NPs formulations had low encapsulation efficiency at approximately 15% and 
drug loading at 0.8 %. The hydrophilic nature of drug model Famotidine might 
resulted in significant loss of drug during NPs preparation involving solvents. 
Improving encapsulation efficiency and/or drug loading of NPs is an approach to 
improve tableting process.  
 
 
NPs formulation NP Size mean ± SD PI ± SD 
Zeta 
potential 
(mV) ± SD 
EE (%) ± 
SD 
DL (%) ± 
SD 
PLA-g-5%PEG750Da 211 ± 18 0.11±0.03 -4.6 ± 0.4 14.5 ± 3.6 0.8 ± 0.2 
PLA-g-5%PEG2000Da 217 ± 14 0.05±0.03 -7.7 ± 1.0 15.3 ± 2.5 0.8 ± 0.3 
 PI=polydispersity Index, EE=Encapsulation Efficiency, DL=Drug Loading 
 
Table 4.2 The mean particles size, PI, Zeta Potential and Drug Loading of Two NPs 
Formulations (n=3) 
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4.4.3. Tablet Formulation  
 
A pharmaceutical dosage form typically consists of active pharmaceutical ingredient 
and excipients. The excipients are added to aid the formulation stability, manufacture, 
facilitate the preparation, patient acceptability and drug delivery(8). Some properties of 
final dosage form, such as bioavailability and stability, are dependent on the excipients 
chosen, concentrations and interactions with each other and the active ingredients (27). 
Therefore the excipients in this study were selected to develop an oral solid dosage 
formulation, based on their known compatibility(20). The formulation of a tablet based 
on Famotidine loaded PLA-g-PEG NPs is the aim of the study. A tablet formulation 
was developed to be composed of 40 % of loaded NPs (corresponding to 1.6 mg of 
Famotidine per tablet), 52.5% of microcrystalline cellulose (MCC), 7% of 
pregelatinized starch and 0.5 % of magnesium stearate.  MCC was added to the 
formulation as diluent and to improve flow property and also as a binder(28).  
Pregelatinized starch was added to the formulation as a binder (to facilitate the 
agglomeration of powder), as a tablet disintegrant and also to improve powder flow.  
Magnesium stearate was added as a lubricant, which is usually used to reduce the 
frictional forces between particles and between particles and metal contact surface of 
tablet punches and dies(29).  High quantity of NPs with very poor flow powder was 
needed to compensate the low drug loading of 0.8%.. This was considered as an 
obstacle in developing a tablet formulation. Improving NPs drug loading would be 
effective approach  to reduce NPs quantity then improve blend powder flow properties 
and decrease tablet weight. Both tablets formulations PLA-g-5%PEG2000Da (F1) and 
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PLA-g-5%PEG750Da (F2) were prepared by dry granulation in order to densify NPs 
with poor density and flow properties. Commercial Famotidine (Pepcid® 10 mg) was 
used as a comparator with NPs based tablets. 
 
4.4.4. Dry Granulation 
Dry granulation process is preferably used to prepare granules and to densify the 
powder blend, for proper flow and compressibility properties. Dry granulation process 
involves compaction and densification of powders, using a roller compactor or tablet 
press that is employed as a slugging tool for powders that may not have a sufficiently 
uniform stream in the die cavity. In this study, slugging was chosen to perform dry 
granulation. Dry granulation consists in compacting powder to form a slug with a 
heavy duty, rotary tablet press or a solid strip, using a roller compactor and then 
reducing its size by milling or screening to achieve a desired granule(18, 30). NPs have 
a very poor flowability, therefore dry granulation was chosen to improve NPs powder 
blend flow. The fine particles (<100 um) tend to be more cohesive and less flowing, 
while large dense particles tend to be free flowing(31, 32).  
 
4.4.5. Formulation Characterization 
4.4.5.1.  Bulk, Tapped Density and  Powder Flow 
 
Powder flowability is a very important property in tablets-production process and for 
product uniformity. The dosage and pharmacological effect of the products depends on 
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powder flow(19, 30, 33-35). Powder flowability is influenced by factors such as 
particle size, size distribution and shape. Some characterizations of particle properties 
such as flowability and compactibility are very crucial to achieve a successful tablet 
compression(30, 33, 34, 36, 37). Consequently, powder flow properties was evaluated 
as part of the formulation development. Tapping test, a common and easy method, is 
widely used in pharmaceutical industry to measure flowability. It also provides Carr's 
index of the powder bed(35). The bulk and tapped density were measured for NPs 
powder, powder blend before and after dry granulation for two NPs formulations 
(F1&F2). Table 4.3 shows results of bulk/tapped density, Hausner ratio and Carr's 
index of two NPs powders formulations with very poor flowability. Table 4.4 presents 
qualitative interpretation of Hausner ratio and Carr's index results(20). Poor flow of 
NPs was expected, due to small particles size. Table 4.3 shows that both NPs PEG5%-
g-PLA had similar and very low bulk density values of 0.02 g/mL and tapped density 
of 0.05 g/mL, which indicate a very poor powder flow based on calculated Carr's index 
57-59 (Hausner ratio above 1.9), which is related to inter particles fraction (20). The 
formulated blend powder density slightly increased but still a very poor powder flow 
was observed after adding the excipients to NPs powder, probably because of high 
proportion of NPs within the formulations. Following dry granulation process, the 
blend powder showed a significant increase in bulk density of 0.33-0.34g/mL and 
tapped density of 0.46-0.48 g/mL and the calculated Carr's index was 28-32 (Hausner 
ratio was 2), not optimal but passable powder flow. Both NPs formulations had similar 
values of bulk and tapped density before and after dry granulation process. Even 
thought Carr’s index values after dry granulation showed powder flow properties for 
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both NPs formulations had a qualitative very poor flow, powder blends were 
practically sufficiently dense to be properly compressed. The very poor flow of powder 
blend even after dry granulation due to high proportion of NPs within tablet 
formulation drive to find another approach to improve powder flow. For instance, 
increase drug loading of NPs could be one approach in order to reduce NPs quantity 
per tablet and  therefore improve powder flow. 
 
 
 
 
 
 
Bulk 
Density(g/ml) 
Tapped 
Density(g/ml) Carr's  index Hausner Ratio 
F1 based on PLA-g-5%PEG2000Da NPs 
NPs 0.02 ± 0.01 0.05 ± 0.01 59 ± 3.0 2.46 ± 0.16 
Blend powder 0.08 ± 0.07 0.16 ± 0.01 48 ± 7.3 2 ± 0.16 
Dry-granulated 0.33 ± 0.01 0.48 ± 0.05 32 ± 8.5 2 ± 0.22 
F2 based on PLA-g-%%PEG750Da NPs 
NPs 0.02 ± 0.01 0.05 ± 0.01 57 ± 2.08 1.89 ± 0.19 
Blend powder 0.08 ± 0.07 0.17 ± 0.01 52 ± 7.60 2.13 ± 0.12 
Dry-granulated 0.34 ± 0.02 0.46 ± 0.05 28 ± 3.21 2.00 ± 0.19 
Table 4.3 Powder flow characterization of NPs, powder blend and dry granulated powder 
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Carrʼs Index Flow character Hausner ratio
1 to 10 Excellent 1.00 to 1.11 
11 to 15 Good  1.12 to 1.18 
16 to 20 Fair  1.19 to 1.25 
21 to 25 Passable  1.26 to 1.34 
26 to 31 Poor  1.35 to 1.45 
32 to 37 Very poor 1.46 to 1.59 
> 38 Very, very poor > 1.6 
 
Table 4.4 Hausner ratio and Carr's index interpretation(20) 
 
4.4.5.2. Particle Size and Size Distribution of Powder blends 
 
The particles size and size distribution (PSD) were evaluated for NPs formulations F1 
and F2 after dry granulation and the placebo blend powder (only excipients, no NPs). 
Particles sizing of the powder blends was evaluated by laser diffraction. The test was 
carried out at high pressure (4) bars to break down any agglomerates and at 50% feed 
rate. The particles size and size distribution are reported in terms of volume. Volume-
based methods are very sensitive to the appearance of a few large particles. Figure 4.3 
shows results obtained for F1, F2 and placebo blend formulations. They respectively 
showed a Gaussian-like distribution of the particles size. Results (Figure 4.3) clearly 
showed that the average particle size of NPs tablet formulations is in the same range as 
standard pharmaceutical excipients. F1 particles were sized between 156 and 440 μm 
with a mean of 284 μm. For F2, results showed d(0.1) is 105 and d(0.9) is 440 μm with 
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mean of 265 μm. While for placebo formulation composed of standard excipients, 
similar particles sizes between 112 and 405 μm with a mean of 242 μm were observed. 
PSD results of powder blend after dry granulation of both NPs tablet formulations with 
placebo were found similar, suggesting a proper formulation and densification process. 
 
 
Figure 4.3 Particle size distribution of F1,F2 and Placebo formulations 
 
 
   
4.4.6. Tablets Characterization 
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F1 and F2 tablets were characterized for their tablet thickness, weight, hardness and 
tablet disintegration, and compared with commercial Famotidine formulation (Table 
4.5). Finally powder blend was compressed at 500 Lbf force to fabricate 500 mg tablets 
with 12mm. NPs Tablet formulations (F1&F2) possessed good mechanical strength 
with sufficient hardness. Table 4.5 showed that tablets prepared from PLA-g-
5%PEG750Da NPs (F2) had average thickness of 6.46 ± 0.11 mm, tablet average 
weight of 504 ± 3.25 mg and hardness of 8 ± 0.2 kp. On the other hand, tablets of the 
F1 formulation had average thickness of 6.33 ± 0.12 mm, average weight of 503 ± 3.48 
mg and a hardness of 5.2 ± 0.26 kp. Tablet hardness and thickness for F2 NPs PLA-g-
5%PEG750Da were statistically significant difference (p=<0.001) from F1 PLA-g-
5%PEG2000Da. Table 4.5 shows disintegration time for NPs formulations of less than 
one minute (20 seconds average) typical of immediate release dosage forms and 2.2 
minutes for commercial Famotidine at a increased hardness of 20.95 kp for the latter.  
Formulation Compositions Weight (mg) 
FMT 
Dosage 
(mg) 
Thickness 
(mm) 
Hardness  
(Kp) 
Disintegration   
( min) 
Commercial Famotidine (n=10) 208 ± 2.81 10 4.19 ± 0.05 20.9 ± 1.05 2.17 ± 0.017 
F1 Tablets NPs (PLA-g-5%PEG2000Da) 503 ± 3.48 (n=30) 1.6 
6.33 ± 0.12 
(n=30) 
5.2 ± 0.26 
(n=6) 
17 ± 1.0 
(n=6) 
F2 Tablets NPs (PLA-g-5%PEG750Da) 
x 
504 ± 3.25 
(n=30) 1.6 
6.46 ± 0.11 
(n=30) 
8.0 ± 0.29 
(n=6) 
18 ± 1.6 
(n=6) 
 
 
Table 4.5 Tablets characterization of Commercial Famotidine, F1 and F2 NPs formulations 
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4.4.7. NPs Size Analysis Before and After Tablet Compression  
 
The mean particle size of powder blends and after tablet compressing were 
characterized to examine the influence of compressing force on NPs. The average of 
the mean particle size of NPs formulations after tablet compressing showed that PLA-
g-5%PEG750Da had mean particle size at 201 nm and PLA-g-5%PEG2000Da had 
215nm. Results (Table 4.6) of NPs size showed there was no significant different, 
therefore the compression force used had no influence on NPs. 
Tablet Formulations  Mean of NP size (nm) ± SD 
NPs(PLA-g-5%PEG750Da) 211 ± 18.7 
after compressing 201 ± 3.5 
NPs(PLA-g-5%PEG2000Da) 217 ± 14.3 
after compressing 215 ± 19.3 
Placebo ( excipients without NPs) 1613 ± 125.0 
 
Table 4.6 The mean particles size values of NPs tablet formulations before and after tablet 
manufacturing (n=3) 
 
4.4.8. Thermal Properties by Differential Scanning Calorimetry (DSC) 
 
Based on the literature review, Famotidine exists in two crystal forms (A and B) and 
the form B is the metastable, kinetically favored form (38). Melting points of different 
crystals of Famotidine are 171.43 and 164.4°C, respectively, for forms A and B. 
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Famotidine loaded NPs formulations had Tg value at 43 and 48°C, respectively, for 
PLA-g-5%PEG750Da and PLA-g-5%PEG2000Da. Tablet formulations of NPs (F1 
and F2) and commercial Famotidine were characterized by DSC. Figure 4.4 and Table 
4.7 shows a163°C melting point that was detected for commercial Famotidine while 
For NPs formulations (F1) Famotidine, it was detected at 188°C and 186°C for (F2). 
F1 and F2 had sharp melting point of Famotidine and the peak had shifted from the 
original position to a higher melting temperature. It could be possibly due to solvents 
impact on Famotidine crystals form or presence of other functional groups of 
polymers. Further investigation need to be carried out  to verify the reasons whereas it 
so not the main focus of the study. 
 
 
 
Table 4.7 DSC characterization of Tablet formulations (n=3) 
 
Formulation Composition Glass transition temperature (°C) 
Famotidine melting 
point (°C) 
F1 Tablet NPs (PLA-g-5%PEG2000Da) 48 ± 2.0 188 ± 1.9 
F1 after Stability study 49 ± 1.3 188 ± 1.0 
F2 Tablet NPs (PLA-g-5%PEG750Da) 43 ± 0.6 186 ± 3.1 
F2 after Stability study 44 ± 2.6 188 ± 0.6 
Commercial Famotidine tablet NA 166 ± 1.5 
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Figure 4.4 Thermograms of Famotidine from different tablet formulations 
 
4.4.9. Crystallinity of Famotidine in Tablets Formulations by X-Ray Powder 
Diffraction (XRPD) 
 
X-ray powder diffraction technique was used to identify Famotidine crystal state after 
encapsulation in NPs. Famotidine form B used in this study has  distinct major 
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characteristic peaks at 5.96, 11.5, 15.7, 17.5 19.5, 20.5, 22.5 and 24.5° 2Ɵ (39, 40). X-
ray diffraction patterns scans revealed that pure Famotidine was clearly in crystalline 
state, since it showed sharp, distinct peaks. XRPD scans of Famotidine loaded NPs 
(Figure 4.5) showed two Famotidine minor peaks at 21.50 and 23.50° 2Ɵ.  
 
 
 
 
Figure 4.5 X-ray Diffractograms of Famotidine from different tablet formulations 
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Commercial Famotidine ablets  showed a peak at 23° 2Ɵ with very low intensity 
compared to pure Famotidine peak. Such low intensity and decrease number of peaks it 
might be attributed to change in Famotidine from crystal to amorphous state or that 
XRPD could not detect all Famotidine peaks (41-45). But based on the DSC 
characterization where Famotidine melting peak were detected,  such absence might be 
due to the limit of detection of the machine used for this low drug loading. 
 
4.4.10. Drug Release 
 
The purpose of studying kinetic release of Famotidine from two NPs tablet 
formulations and comparing it with commercial Famotidine formulation was to 
evaluate the effect of NPs matrix and compressing force on Famotidine release. The 
kinetic release of Famotidine from different tablet formulations was carried out at same 
conditions as kinetic release of Famotidine from corresponding 
unformulated/uncompressed NPs formulations. It was found that Famotidine showed a 
total fast release profile  from all tablets formulations in  pH 7.4 medium, consistent 
with NPs results and reported results (46-48). Famotidine release profile showed a 
biphasic release behavior as previously  reported(49), the first phase up to 30 min 
where 35 to 40 % of drug was released followed by a slower release from 30 min and 
up to 4 h. Figure 4.6 showed that there is no difference of Famotidine release rate 
amongst different formulations. It was found that 75 % of Famotidine was released 
within 2 h. Famotidine released from NPs tablet formulation prepared by dry 
granulation and commercial Famotidine showed no differences in dissolution profiles, 
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suggesting that the tablet manufacturing technique had no effect on Famotidine drug 
release(48). NPs tablet formulations demonstrated that they provide an immediate 
release of Famotidine that is comparable with commercial Famotidine formulations. 
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Figure 4.6 Percentage of Famotidine Released at pH 7.4 from different tablet formulations 
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4.4.11. Stability Study 
Results from DSC and drug release results (Figure 4.6 and Table 4.7) from NPs based 
tablet formulations (F1 and F2) showed no change neither for Famotidine melting 
point, Tg and Famotidine release in pH 7.4 PBS medium over 4 weeks storage under 
accelerated conditions. 
4.4.12. Drug Dissolution 
 
Famotidine release (Figure 4.7) from F1, F2 and commercial tablet formulations 
showed fast release from 0.1M phosphate buffer pH 4.5 (13.6g/L of monobasic 
potassium phosphate). All formulations achieved above 90 % of Famotidine 
dissolution after 5 min of dissolution. The percentage of Famotidine released showed 
no significant difference amongst all formulations except at five minutes sampling 
time. Indeed, at five minutes time points, commercial Famotidine had a significantly 
(p=0.034) higher release than NPs formulations, which might be attributed to short 
term entrapment of drug molecules within NPs polymeric matrix. The fast release 
was attributed to fast disintegration time for all tablet formulations that enhanced 
wetting of dissolution medium into the tablet and thus promoting Famotidine release. 
Complete Famotidine release from all tablet formulations occurred less than 30 min 
therefore NPs tablets formulations demonstrate an immediate release. Dissolution test 
clearly showed no impact of NPs on Famotidine release comparing to Famotidine 
commercial tablet formulation. The different in Famotidine release profiles from both 
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release study drug release pH 7.4 and dissolution study pH4.5 is due to different pH 
medium. 
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Figure 4.7 Famotidine Dissolution Profile from Different Tablet Formulations 
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4.4.13. Transport Study 
  
The transport experiments were conducted to evaluate permeability of Famotidine and 
to examine the potential effect of PEG on P-gp efflux of Famotidine loaded NPs tablets 
formulations  across CaCo-2 cells in vitro model. A total of five formulations were 
used in this study to examine these effects on Famotidine permeability across CaCo-2. 
Gently crushed tablets loaded with NPs formulations were prepared from PLA-g-
5%PEG2000Da (F1) and PLA-g-5%PEG750Da (F2), two formulations of physical 
mixtures (PM1&PM2) of blank NPs formulations (corresponding to loaded 
formulations) with Famotidine and commercial Famotidine formulation were used. 
The transport results from commercial Famotidine and pure Famotidine (no PEG) were 
used as references to evaluate the effect of PEG to inhibit or decrease P-gp efflux on 
Famotidine. Transport experiments in bidirectional sides were carried out in triplicate 
for all formulations and average results were reported. CaCo-2 well is divided into 
upper part, the apical (serosal) side representing the lumen side, and a lower part, the 
basolateral (mucosal) side. In the mucosal intestine, lower part in CaCo-2 model, 
where secretory transport of Famotidine occurs, the effect of PEG as P-gp inhibitor 
would be expected either by decreasing or inhibition of P-gp function. Asymmetry 
index (AI) is the ratio of secretory (BL-to-AP) side to absorptive (AP-to-BL) which 
reflects P-gp efflux on Famotidine. AI also showed PEG inhibition on P-gp efflux of 
Famotidine. Our study (Table 4.8) showed an asymmetric index value of 1.01 for pure 
Famotidine had which means the secretion level (BL-to-AP) slightly higher but mostly 
similar than absorption level (AP-to-BL) as reported(50). Results (Table 4.8) showed 
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that the AI value of tablets loaded NPs of PLA-g-5%PEG2000Da (F1) and PLA-g-
PEG750Da (F2) were 0.07 and 0.43, respectively, while the AI value for commercial 
Famotidine was 1.02. Both tablets loaded NPs showed inhibition effect of P-gp efflux 
of Famotidine compared to commercial and pure Famotidine, F1 being the most 
effective formulation.  AI results of 0.06 and 0 for physical mixtures formulations 
(PM1&PM2) showed also an inhibition of P-gp efflux of Famotidine which it can be 
attributed to PEG content. The secretory results (BL-to-AP) demonstrated that all 
formulations containing PEG showed a decrease of P-gp efflux of Famotidine back to 
apical side, compared to commercial and pure Famotidine. Tablet formulations 
containing NPs prepared from polymer grafted with PEG 2000Da either in loaded or 
blank NPs were found to be more effective to inhibit P-gp efflux of Famotidine than 
corresponding formulations containing PEG 750Da. Even if tablet formulations 
containing blank NPs showed good transport results, loaded NPs have advantages over 
blank NPs such as protecting drug from harsh environment, improving  drug 
absorption and  altering drug release(12). Those results confirmed our hypothesis that 
loaded NPs formulated as tablets can inhibit P-gp Famotidine efflux. In this study the 
presence of hydrophilic polymers (PEG) on the surface of NPs grafted at 5 % PEG, 
irrespective to molecular weights, provided an effective way to control the interface 
between NPs and the biological systems (P-gp in this case) as they are designed to 
interact with. To summarize transport results, it was observed that P-gp efflux 
inhibition of Famotidine is attributed to PEG content. Indeed, as PEG increased, the 
inhibition effect increased which is consistent with the hypothesis of the study(9, 51-
55). The studies presented herein suggest that commonly used pharmaceutical 
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excipients such as PEG (750 Da and 2000 Da) are capable of inhibiting efflux 
transporter (P-gp) activity. Even though PEG’s mechanism inhibits P-gp efflux still not 
clear, PEG has demonstrated its capability to inhibit the P-gp efflux mechanism. PEG 
might interfere with interaction between Famotidine molecules and drug substrate 
binding site of P-gp occurs principally in the trans-membrane domain(amino acid 
residues). 
 
 
Formulation and Combination AP-BL (x10-6cm/sec) 
BL-AP 
(x10-6cm/sec) AI 
Pure Famotidine 10.3 ± 0.7 10.4 ± 0.6 1.01 ± 0.6 
Commercial Famotidine 4.9 ± 1.4 5.0 ± 0.3 1.02 ± 0.05 
loaded NPs PLA-g-5%PEG750Da 1.7 ± 0.1 0.7 ± 0.6 0.43 ± 0.3 
Blank NPs PLA-g-5%PEG750Da 6.3 ± 0.2 0.4 ± 0.2 0.06 ± 0.004 
Loaded NPs PLA-g-5%PEG2000Da 4.1 ± 0.8 0.3 ± 0.2 0.07 ± 0.01 
Blank NPs PLA-g-5%PEG2000Da 4.0 ± 0.1 0 0.000 
AI=Asymmetric Index, AP=apical, BL=basolateral 
 
Table 4.8 Bidirectional results from Marketed Famotidine,F1&F2 NPs tablets formulations, 
pure Famotidine and tablet physical mixtures across CaCo-2 monolayer cells 
 
4.5. Conclusion 
Grafted PLA-g-5%PEG polymers were synthesized and loaded NPs were prepared. 
The mean average size of prepared loaded NPs were 211 and 217 nm and demonstrated 
a unimodal size distribution with low negative surface charge values ranging from -4.6 
 160 
and -7.7mV. Dry granulation achieved improvement of powder blend flow properties 
due to the intrinsic poor properties of NPs. Prepared tablets had adequate physical 
properties typical of an immediate release dosage form. Particle size, drug release and 
drug transport  results of NP based tablet formulations showed that the manufacturing 
process did not influence NPs properties. Famotidine released from NPs and from 
tablets made of NPs showed a similar biphasic release behavior with no significant 
difference of compressed NPs on Famotidine release compared to commercial 
formulation at pH 7.4. Transport study results of all tablet formulations containing 
PEG showed their capability to inhibit the P-gp efflux of Famotidine. The permeability 
results demonstrated the concept of connecting hydrophilic Me.PEG with hydrophobic 
PLA capable to inhibit P-gp efflux. Generally in  addition to PEG’s inhibitory effect, 
drug loaded within PEGylated NPs could offer a protection from stomach harsh 
environments. Thus, NPs prepared from PLA-g-5%PEG could be an effective 
formulation tool to enhance drug permeability through inhibit P-gp efflux then improve 
oral bioavailability. 
 
 
 
 
 
 161 
4.6. References 
 
 
1. Aulton ME. Aulton's pharmaceutics : the design and manufacture of medicines. 
3rd ed. Edinburgh ; New York: Churchill Livingstone; 2007. 
2. Hediger MA, Romero MF, Peng JB, Rolfs A, Takanaga H, Bruford EA. The 
ABCs of solute carriers: physiological, pathological and therapeutic implications of 
human membrane transport proteins - Introduction. Pflugers Archiv-European Journal 
of Physiology 2004;447(5):465-468. 
3. Akhtar N, Ahad A, Khar RK, Jaggi M, Aqil M, Iqbal Z, et al. The emerging 
role of P-glycoprotein inhibitors in drug delivery: a patent review. Expert Opinion on 
Therapeutic Patents 2011;21(4):561-576. 
4. Estudante M, Morais JG, Soveral G, Benet LZ. Intestinal drug transporters: An 
overview. Advanced Drug Delivery Reviews 2013;65(10):1340-1356. 
5. McNally GP, Roche EJ. Stabilized composition of famotidine and sucralfate for 
treatment of gastrointestinal disorders. In: Google Patents; 1997. 
6. Thakker KLaDR. Saturable Transport of H2-Antagonists Ranitidine and 
Famotidine Across Caco-2 Cell Monolayers. Journal of Pharmaceutical Sciences 
1999;88(7):680-687. 
7. Bourdet D, Thakker D. Saturable Absorptive Transport of the Hydrophilic 
Organic Cation Ranitidine in Caco-2 Cells: Role of pH-Dependent Organic Cation 
Uptake System and P-Glycoprotein. Pharmaceutical Research 2006;23(6):1165-1177. 
 162 
8. Rowe RC, Sheskey PJ, Quinn ME. Handbook of pharmaceutical excipients. In. 
6th ed. London ; Chicago, Washington,DC: Pharmaceutical Press ;American 
Pharmacists association; 2009. 
9. Hugger ED, Novak BL, Burton PS, Audus KL, Borchardt RT. A comparison of 
commonly used polyethoxylated pharmaceutical excipients on their ability to inhibit P-
glycoprotein activity in vitro. Journal of Pharmaceutical Sciences 2002;91(9):1991-
2002. 
10. Gref R, L M, Quellec P, Marchand M, Dellacherie E, Harnisch S, et al. Stealth 
corona-core nanoparticles surface modified by polyethylene glycol (PEG): influences 
of the corona (PEG chain length and surface density) and of the core composition on 
phagocytic uptake and plasma protein adsorption. Colloids and Surfaces B: 
Biointerfaces 2000;18(3-4):301-313. 
11. Liu Y, Chiu GNC. Dual-Functionalized PAMAM Dendrimers with Improved 
P-Glycoprotein Inhibition and Tight Junction Modulating Effect. Biomacromolecules 
2013;14(12):4226-4235. 
12. Wehrung D, Geldenhuys WJ, Oyewumi MO. Effects of gelucire content on 
stability, macrophage interaction and blood circulation of nanoparticles engineered 
from nanoemulsions. Colloids and Surfaces B: Biointerfaces 2012;94(0):259-265. 
13. Mokhtar M, Gosselin P, Lacasse F-X, and Hildgen P. Design of PEG-grafted-
PLA nanoparticles as oral permeability enhancer for P-gp substrate drug model 
Famotidine. Journal of Microencapsulation 2014. 
 163 
14. Nadeau V, Leclair G, Sant S, Rabanel J-M, Quesnel R, Hildgen P. Synthesis of 
new versatile functionalized polyesters for biomedical applications. Polymer 
2005;46(25):11263-11272. 
15. Essa S, Rabanel JM, Hildgen P. Effect of polyethylene glycol (PEG) chain 
organization on the physicochemical properties of poly(d, l-lactide) (PLA) based 
nanoparticles. European Journal of Pharmaceutics and Biopharmaceutics 
2010;75(2):96-106. 
16. Shilpa S, Ve´ronique N, Hildgen P. Effect of porosity on the release kinetics of 
propafenone-loaded PEG-g-PLA nanoparticles. Journal of Controlled Release 
2005;107:203-214. 
17. Abebe A, Akseli I, Sprockel O, Kottala N, Cuitino AM. Review of bilayer 
tablet technology. International Journal of Pharmaceutics 2014;461(1-2):549-558. 
18. Kleinebudde P. Roll compaction/dry granulation: pharmaceutical applications. 
European Journal of Pharmaceutics and Biopharmaceutics 2004;58(2):317-326. 
19. Leuenberger H, Lanz M. Pharmaceutical powder technology from art to 
science: the challenge of the FDA's Process Analytical Technology initiative. 
Advanced Powder Technology 2005;16(1):3-25. 
20. USP. United States Pharmacopeia and National Formulary (USP-NF). 
Rockville, MD, USA,; 2014. 
21. Choi K-m, Choi M-C, Han D-H, Park T-S, Ha C-S. Plasticization of poly(lactic 
acid) (PLA) through chemical grafting of poly(ethylene glycol) (PEG) via in situ 
reactive blending. European Polymer Journal 2013;49(8):2356-2364. 
 164 
22. Elmowafy E, Awad G, Mansour S, El-Shamy A. Release Mechanisms Behind 
Polysaccharides-Based Famotidine Controlled Release Matrix Tablets. Aaps 
Pharmscitech 2008;9(4):1230-1239. 
23. Patravale VB, Date AA, Kulkarni RM. Nanosuspensions: a promising drug 
delivery strategy. Journal of Pharmacy and Pharmacology 2004;56(7):827-840. 
24. Yoncheva K, Lizarraga E, Irache JM. Pegylated nanoparticles based on 
poly(methyl vinyl ether-co-maleic anhydride): preparation and evaluation of their 
bioadhesive properties. European Journal of Pharmaceutical Sciences 2005;24(5):411-
419. 
25. Vila A, Gill H, McCallion O, Alonso MÌaJ. Transport of PLA-PEG particles 
across the nasal mucosa: effect of particle size and PEG coating density. Journal of 
Controlled Release 2004;98(2):231-244. 
26. Sant S, Poulin S, Hildgen P. Effect of polymer architecture on surface 
properties, plasma protein adsorption, and cellular interactions of pegylated 
nanoparticles. Journal of Biomedical Materials Research Part A 2008;87A(4):885-895. 
27. Panakanti R, Narang AS. Impact of Excipient Interactions on Drug 
Bioavailability from Solid Dosage Forms. Pharmaceutical Research 2012;29(10):2639-
2659. 
28. Li Q, Rudolph V, Weigl B, Earl A. Interparticle van der Waals force in powder 
flowability and compactibility. International Journal of Pharmaceutics 2004;280(1-
2):77-93. 
 165 
29. Sepassi S, Goodwin DJ, Drake AF, Holland S, Leonard G, Martini L, et al. 
Effect of polymer molecular weight on the production of drug nanoparticles. Journal of 
Pharmaceutical Sciences 2007;96(10):2655-2666. 
30. Parrott EL. Densification of powders by concavo-convex roller compactor. 
Journal of Pharmaceutical Sciences 1981;70(3):288-291. 
31. Mckenna A, Mccafferty DF. Effect of particle size on the compaction 
mechanism and tensile strength of tablets. Journal of Pharmacy and Pharmacology 
1982;34(6):347-351. 
32. Dolenc A, Kristl J, Baumgartner S, Planinsek O. Advantages of celecoxib 
nanosuspension formulation and transformation into tablets. International Journal of 
Pharmaceutics 2009;376(1-2):204-212. 
33. Teng Y, Qiu Z, Wen H. Systematical approach of formulation and process 
development using roller compaction. European Journal of Pharmaceutics and 
Biopharmaceutics 2009;73(2):219-229. 
34. Sandler N, Lammens RF. Pneumatic dry granulation: potential to improve roller 
compaction technology in drug manufacture. Expert Opinion on Drug Delivery 
2011;8(2):225-236. 
35. Camboìn A, Brea J, Loza MI, Alvarez-Lorenzo C, Concheiro A, Barbosa S, et 
al. Cytocompatibility and P-glycoprotein Inhibition of Block Copolymers: Structure-
Activity Relationship. Molecular Pharmaceutics 2013. 
36. More PK, Khomane KS, Bansal AK. Flow and compaction behaviour of 
ultrafine coated ibuprofen. International Journal of Pharmaceutics 2013;441(1-2):527-
534. 
 166 
37. Sáska Z, Dredán J, Luhn O, Balogh E, Shafir G, Antal I. Evaluation of the 
impact of mixing speed on the compressibility and compactibility of paracetamol-
isomalt containing granules with factorial design. Powder Technology 2011;213(1-
3):132-140. 
38. Hassouna F, Raquez J-M, Addiego Fdr, Dubois P, Toniazzo Vr, Ruch D. New 
approach on the development of plasticized polylactide (PLA): Grafting of 
poly(ethylene glycol) (PEG) via reactive extrusion. European Polymer Journal 
2011;47(11):2134-2144. 
39. McDevitt CA, Callaghan R. How can we best use structural information on P-
glycoprotein to design inhibitors? Pharmacology & Therapeutics 2007;113(2):429-441. 
40. Ferenczy GG, Parkanyi L, Angyan JG, Kalman A, Hegedus B. Crystal and 
electronic structure of two polymorphic modifications of famotidine. An experimental 
and theoretical study. Journal of Molecular Structure: (Theochem) 2000;503(1-2):73-
79. 
41. Sahoo NG, Kakran M, Shaal LA, Li L, Muller RH, Pal M, et al. Preparation and 
characterization of quercetin nanocrystals. Journal of Pharmaceutical Sciences 
2011;100(6):2379-2390. 
42. Morakul B, Suksiriworapong J, Leanpolchareanchai J, Junyaprasert VB. 
Precipitation-lyophilization-homogenization (PLH) for preparation of clarithromycin 
nanocrystals: Influencing factors on physicochemical properties and stability. 
International Journal of Pharmaceutics Special Section: Formulating Better Medicines 
for Children 2013;457(1):187-196. 
 167 
43. Liu P, Rong X, Laru J, van Veen B, Kiesvaara J, Hirvonen J, et al. 
Nanosuspensions of poorly soluble drugs: Preparation and development by wet 
milling. International Journal of Pharmaceutics 2011;411(1-2):215-222. 
44. Jiang T, Han N, Zhao B, Xie Y, Wang S. Enhanced dissolution rate and oral 
bioavailability of simvastatin nanocrystal prepared by sonoprecipitation. Drug 
Development and Industrial Pharmacy 2012;38(10):1230-1239. 
45. Hecq J, Deleers M, Fanara D, Vranckx H, Amighi K. Preparation and 
characterization of nanocrystals for solubility and dissolution rate enhancement of 
nifedipine. International Journal of Pharmaceutics 2005;299(1-2):167-177. 
46. Shoaib M, Al Sabah Siddiqi S, Yousuf R, Zaheer K, Hanif M, Rehana S, et al. 
Development and Evaluation of Hydrophilic Colloid Matrix of Famotidine Tablets. 
AAPS PharmSciTech 2010;11(2):708-718. 
47. Mady FM, Abou-Taleb AE, Khaled KA, Yamasaki K, Iohara D, Ishiguro T, et 
al. Enhancement of the aqueous solubility and masking the bitter taste of famotidine 
using drug//SBE-b-CyD//povidone K30 complexation approach. Journal of 
Pharmaceutical Sciences 2010;99(10):4285-4294. 
48. Baseer AB, Abdul), Hassan FH, Fouzia), Hassan SH, Syed Muhammad 
Fareed), Jabeen SJ, Sabahat), Israr FI, Fozia), Murtaza GM, Ghulam), et al. Physico-
chemical comparison of famotidine tablets prepared via dry granulation and direct 
compression techniques. Pakistan Journal of  Pharmaceutical Sciences 2013;26(3):439-
443. 
49. Avgoustakis K, Beletsi A, Panagi Z, Klepetsanis P, Karydas AG, Ithakissios 
DS. PLGA-mPEG nanoparticles of cisplatin: in vitro nanoparticle degradation, in vitro 
 168 
drug release and in vivo drug residence in blood properties. Journal of Controlled 
Release 2002;79(1-3):123-135. 
50. Rozehnal V, Nakai D, Hoepner U, Fischer T, Kamiyama E, Takahashi M, et al. 
Human small intestinal and colonic tissue mounted in the Ussing chamber as a tool for 
characterizing the intestinal absorption of drugs. European Journal of Pharmaceutical 
Sciences 2012;46(5):367-373. 
51. Hugger ED, Cole CJ, Raub TJ, Burton PS, Borchardt RT. Automated analysis 
of polyethylene glycol-induced inhibition of P-glycoprotein activity in vitro. Journal of 
Pharmaceutical Sciences 2003;92(1):21-26. 
52. Shen Q, Lin Y, Handa T, Doi M, Sugie M, Wakayama K, et al. Modulation of 
intestinal P-glycoprotein function by polyethylene glycols and their derivatives by in 
vitro transport and in situ absorption studies. International Journal of Pharmaceutics 
2006;313(1-2):49-56. 
53. Iqbal J, Hombach J, Matuszczak B, Bernkop-Schnurch A. Design and in vitro 
evaluation of a novel polymeric P-glycoprotein (P-gp) inhibitor. Journal of Controlled 
Release 2010;147(1):62-69. 
54. Brendan M. Johnson, William N. Charman, Porter CJH. An In Vitro 
Examination of the Impact of Polyethylene Glycol 400, Pluronic P85, and Vitamin E 
d-a-Tocopheryl Polyethylene Glycol 1000 Succinate on PGlycoprotein Efflux and 
Enterocyte-Based Metabolism in Excised Rat Intestine. AAPS Pharmscitech 
2002;4(4):13. 
55. Kin-Kai H, Giesing DH, Hurst GH. Aventis Pharmaceuticals, Inc. Method of 
enhancing bioavailability of fexofenadine and its derivatives. US6451815 2002. 
 169 
56. Mundargi RC, Babu VR, Rangaswamy V, Patel P, Aminabhavi TM. 
Nano/micro technologies for delivering macromolecular therapeutics using poly(d,l-
lactide-co-glycolide) and its derivatives. Journal of Controlled Release 
2008;125(3):193-209. 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 170 
Chapter Five 
General Discussion, Conclusion and Perspectives
  
 
 
5.1. General Discussion 
 
 
The choice of PEG grafting ratio (1% and 5%) was based on previous works(1-4). 
GPC results of grafted polymers showed that average molecular weight of grafted 
PEG750Da1%-g-PLA polymer has the lowest molecular weight while 
PEG2000Da5%-g-PLA has the largest molecular weight (in consistency with PEG 
molecular weight and grafting ratio used). The actual grafting % obtained for PEG 750 
grafting was lower than theoretical ones, whereas PEG 2000Da grafting was higher 
than expected. The better obtained results was using PEG 2000 Da compared to PEG 
750 Da, it might be explained by reactivity of the different PEG with pendant 
carboxylic compared to ended carboxylic group. Mechanistic study could demonstrate 
the following hypothesis, PEG 750 Da reacts with lactic carboxylic group at the end of 
polymer backbone while PEG 2000 Da reacts more with pendant carboxylic group. 
PEG750Da1%-g-PLA thermograms (Table 3.1) show Tg at -1.77 °C but pure PEG 
have Tg at - 21°C, PLA at 50 °C and PLA-g-PEG at 29.68 °C, this results could be due 
to a low grafting efficiency of PEG as pendant group. The large amount of unreacted 
PEG could also plasticizes the polymer but PEG is very soluble in aqueous washing 
phase and it does not appear in GPC distribution. PEG molecular weight of 750 Da and 
2000 Da were chosen for optimal biocompatibility. PEG with higher molecular weight 
become too big to be eliminated. A lower grafted % of PEG molecular weight smaller 
than 750 Da is possibly not enough to increase the hydrophilicity of the NPs surface. 
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1H NMR spectrum and FTIR scans for the four synthesized grafted polymers PEG-g-
PLA were obtained and the grafted polymers were used to prepare different NPs 
formulations. The average particle size is consistent by measurement using two 
different methods and with previous work(1-4). It does not seem that the amount of 
PEG nor Famotidine change the size of NPs. Chemical surface studies would be 
helpful to quantify the amount of PEG and to determine this self organized structure. 
Residual PVA was observed in many studies but the actual influence of this surfactant 
is not clearly demonstrated(2, 5). Our previous works do not show significant 
difference in size with NPs made by a method without any surfactant 
(nanoprecipitation)(6, 7). The advantage of emulsion/solvent evaporation method is an 
easy scalling up comparing to nanoprecipitation. Changing to another surfactant FDA 
approved should be done in future development. Nanoprecipitation do not allow to 
prepare enough NPs for tablet preparation. Famotidine is hydrophilic drug since the 
octanol/water partition coefficient is log P = -0.64 and it has ionisable guanidine basic 
group (pKa= 8.44). Famotidine is very hydrophilic at working pH (7.4) since 
calculated log D = -3,0 and actual water solubility is 1 g/l ; that could explain low drug 
loading. Polymorphic crystal form B of Famotidine is used in the commercial tablet 
form. DSC results of different loaded NPs formulations showed a shift of melting point 
of Famotidine to a higher temperature (180 °C). This suggests the presence of a 
crystalline form however no polymeric form at this melting point has been described in 
literature. The possible explanation is an interaction between the drug molecules and 
the polymer yielding a complex. For NPs as well as tablet with low loading, no melting 
point can be detected, then Famotidine could be molecularly dispersed as well as in 
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amorphous or nanocrystalline state. The XRPD scans of loaded NPs showed two 
pattern types that varied more with grafting ratios rather than with PEG molecular 
weight. XRPD scans of NPs prepared from PEG1% showed Famotidine form B 
characteristic peaks. While for PEG5%, Famotidine exhibited only two minor peaks at 
21.50° and at 23.50° 2Ɵ, suggesting that Famotidine exists below XRPD limit of 
detection(8-11). Famotidine from NPs formulations showed fast release profiles which 
might be attributed to the hydrophilic nature of Famotidine(12, 13). Famotidine 
released profile did not show significant influence of polymer molecular weights, PEG 
molecular weights, PEG grafting ratios, particle size, and PVA on Famotidine released 
from different NPs formulations. Polymers and NPs characterizations results of 
different loaded NPs formulations showed Famotidine was encapsulated for the four 
different grafted polymers. The asymmetry index, namely the ratio of secretory 
(basolateral-to-apical) to absorptive (apical-to-basolateral) transport, reflects the 
overall effect of P-gp. For P-gp function inhibition it will be expected from the 
formulation that has lower AI value. Asymmetry index (AI) results from transport 
experiments of loaded NPs showed that NPs of PLA-g-5%PEG2000Da had the lowest 
AI value (0.007), followed by NPs prepared from PLA-g-5%PEG750Da (0.01), then 
PLA-g-1%PEG750Da (0.58). It can be noticed from asymmetry index results that 
increased P-gp inhibition were obtained from formulations containing PEG 5%, 
irrespective to molecular weights which is consistent with other findings(14-16). 
Therefore the two Famotidine loaded NPs formulations prepared from PEG-g-PLA 
grafted at 5% were selected to develop two NPs based tablet formulation. The tablet 
formulation was developed to be composed of 40 % of loaded NPs (corresponding to 
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1.6 mg of Famotidine per tablet), 52.5% of microcrystalline cellulose (MCC), 7% of 
pregelatinized starch and 0.5 % of magnesium stearate. The reason why tablets based 
on NPs (F1 and F2) had a weight of 500 mg is that they contained high quantity of NPs 
(40%) due to NPs low drug loading (0.8%). Therefore, high quantities of NPs with 
very poor powder flow quality were needed to compensate the low drug loading. Rapid 
partition of Famotidine into external phase during NPs preparations, therefore 
decreased Famotidine entrapment into NPs during polymer deposition(17). This was 
considered an obstacle in developing a tablet formulation for this study. Moreover high 
quantity of NPs was used to obtain detectable Famotidine concentration from drug 
transport study and for tablet characterization tests. Improving NPs drug loading would 
be effective approach to reduce NPs quantity then improve blend powder flow 
properties and decrease tablet weight. Famotidine is very hydrophilic therefore 
famotidine partition from oil into the aqueous phase, that could explain low drug 
loading. To avoid or minimize such partitioning of drug between two immiscible 
phases, w/o/w double-emulsion method would be preferred in producing NPs loaded to 
encapsulate hydrophilic drug(18).  Both tablets formulations PLA-g-5%PEG2000Da 
(F1) and PLA-g-5%PEG750Da F2) were prepared by dry granulation in order to 
densify NPs powder with poor flow property. The bulk and tapped density were 
measured for NPs powder, powder blend before and after dry granulation for two NPs 
formulations (F1&F2). Results of bulk, tapped density, Hausner ratio and Carr's index 
of two NPs powder formulations showed very poor flowability. By comparing the 
results of Carr's index of  NPs powder versus dry granulated ones, a significant 
improvement in powder flow was noticed. Even thought Carr’s index values after dry 
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granulation showed powder flow properties for both NPs formulations had a very poor 
flow, powder blends were practically sufficiently dense to be properly compressed. 
The size and particles size distribution (PSD) results obtained for F1, F2 and placebo 
blend formulations showed a Gaussian-like distribution of the particle size. PSD results 
of powder blend after dry granulation of both NPs tablet formulations with placebo 
were found similar, suggesting a proper densification process. Commercial Famotidine 
(Pepcid® 10 mg) was used as a comparator with NPs formulations. Tablet formulations 
(F1&F2) possessed good mechanical strength with sufficient hardness. Disintegration 
time for NPs tablet formulations (F1&F2) was less than one minute (20 seconds 
average) and 2.2 minutes for commercial Famotidine. NPs based tablet formulations 
had rapid disintegration time probably attributed to the dry granulation and the lower 
compression force. The mean particle size of NPs after tablet compressing were 
characterized to examine the influence of compressing force on NPs and results of NPs 
size showed that tablet compression process does not affect morphology of NPs. 
Despite the large amount of NPs, the size was not modified during compression. To 
obtained enough Famotidine in the tablet with NPs, large amount of NPs modified the 
properties of the powder and making tablet. Moreover, kinetic release of Famotidine 
from  tablet formulations was studied to evaluate the effect of NPs matrix and 
compressing force. Comparing Famotidine released from NPs tablet formulation 
prepared by dry granulation and commercial Famotidine showed no differences, 
suggesting that the tablet manufacturing technique had no effect on Famotidine drug 
release. Stability results of tablet formulations (F1 and F2) showed no change neither 
for Famotidine melting point, Tg and Famotidine release in pH 7.4 PBS medium. Drug 
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dissolution Famotidine from F1, F2 and commercial tablet formulations showed fast 
released from 0.1 M phosphate buffer pH 4.5. The fast release was attributed to fast 
disintegration time for all tablet formulations that enhance penetrating of dissolution 
medium into the tablet and thus promote Famotidine release. There no modification of 
dissolution profile which are all immediate release. The transport study results  (AI) of 
tablet formulations showed that the AI value of tablet of loaded NPs of PLA-g-
5%PEG2000Da (F1) and PLA-g-5%PEG750Da (F2) were 0.07 and 0.43, respectively, 
while the AI value for commercial Famotidine was 1.02. F1 showed the most effective 
formulations (0.07) to inhibit P-gp function. Commercial Famotidine (no PEG) was 
used as a reference to evaluate the effect of PEG to inhibit or decrease P-gp efflux on 
Famotidine. Transport results of NP-based tablet formulations showed no impact of 
tabletting process on NPs to inhibit P-gp efflux. Transport results of tablet formulations 
containing NPs prepared from polymer grafted demonstrate that PEG 2000Da to be 
more effective to inhibit P-gp efflux of Famotidine than formulations containing PEG 
750Da. There are three possible mechanisms for P-gp inhibition(19, 20). Even though 
pegylated NPs mechanism inhibits P-gp efflux is not clear, free PEG inhibits P-gp 
function(14).  Aoun et al demonstrated also an inhibition of P-gp on fungus cells when 
using similar polymer as nanocarrier(4). To summarize transport results, it was 
observed that P-gp efflux inhibition of Famotidine is attributed to PEG content and 
results of loaded NPs and tablet formulations showed that P-gp efflux inhibition of 
Famotidine can be attributed to PEG content. Indeed, as PEG content increased, the 
inhibition effect increased which is consistent with the general hypothesis of the 
study(15, 21-23). The studies presented herein suggest that commonly used 
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pharmaceutical excipients such as PEG (750 Da and 2000 Da) are capable to inhibit 
efflux transporter (P-gp) activity. Those results confirmed our hypothesis that 
inhibition of P-gp Famotidine efflux by loaded NPs formulated as tablets is efficient 
and open a way to increase the bioavailability of drugs that are P-gp substrate. It has 
been reported that NPs transported via transcellular transport in which NPs up taken by 
endocytic process takes place at cell apical membrane intracellular trafficking toward 
exocytic release at basolateral compartment(24-26). Tablet made with NPs containing 
P-gp inhibitor allow formulator to use of less drug. 
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5.2. Conclusion and Perspective 
 
The PLA-g-PEG polymers with different grafting ratios 1 and 5 % were synthesized 
with molecular weights consistent with PEG molecular weight of 750 and 2000Da. The 
grafting of PEG on PLA was confirmed with 1H NMR, FTIR and DSC results. NPs 
characterization results demonstrate that NPs formulations were prepared with mean 
particle size ranged from 156 to 211nm and a unimodal size distribution. NPs had zeta 
potential values ranging from -4.6 to -9.9 mV. Dry granulation was used to improve 
the powder blend flow properties due to the intrinsic poor flow properties of NPs. 
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Prepared tablets had adequate physical properties typical of an immediate release 
dosage form. NPs tablets formulation demonstrated that they provide an immediate 
release of Famotidine comparable to commercial Famotidine. Particle size, drug 
release and drug transport results of NP based tablet formulations showed that dry 
granulation and tabletting processes did not influence NPs properties. Transport study 
results showed that loaded NPs and tablet formulations prepared from PLA-g-5%PEG, 
irrespective of PEG molecular weights, are able to inhibit the P-gp efflux of 
Famotidine. Therefore, NPs prepared from PLA-g-5%PEG could be a promising oral 
solid formulation strategy to improve oral bioavailability of P-gp substrate. The 
permeability results of demonstrate the concept of connecting hydrophilic Me.PEG 
with hydrophobic PLA capable to inhibit P-gp efflux. Generally in addition to PEG 
inhibitory effect, drug loaded within PEGylated NPs could offer a protection from 
stomach harsh environment, increase drug dissolution and drug absorption. Thus, NPs 
prepared from PLA-g-5%PEG could be an effective formulation tool to enhance drug 
permeability by inhibition of P-gp efflux then improve oral bioavailability. 
  
 
Encapsulation efficiency of NPs will be improved in order to decrease the quantity of 
NPs in the formulation due to poor flow of NPs. Results from PLA-g-5%PEG NPs 
formulations may or may not be relevant to in vivo situations such as pharmacokinetic 
studies on human formulations containing PEG or exploratory formulations containing 
PEG. Further studies (e.g. gut perfusion studies and pharmacokinetic studies in animal 
models) should be conducted to establish a possible in vitro/in vivo correlation. For a 
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broader use of PLA-g-PEG copolymers as delivery systems, we may try to encapsulate 
other drugs (e.g. anticancer drugs) into those types of particles. Long term chemical 
and physical stability will be carried out for NPs based tablet formulations. 
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